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Structured Abstract  
 
Objectives.  To systematically identify quality measures and the evidence for them⎯ to 
support quality assessment and improvement in the palliative care of patients with cancer in the 
areas of pain, dyspnea, depression, and advance care planning (ACP), and to identify important 
gaps in related research. 
 
Data Sources.  MEDLINE®, CINAHL©, and PsycINFO© in English 1995-2005.  We also 
conducted an extensive Internet search of professional organizations seeking guidelines and 
other grey literature (i.e., not published in peer-reviewed journals) using similar terms and 
attempted to contact all measure developers.  
 
Review Methods.  We searched using terms for each domain for patients (adults and children) 
with a cancer diagnosis throughout the continuum of care (e.g., diagnosis to death).  Pain and 
depression searches were limited to cancer, but we searched broadly for dyspnea and ACP, 
because the evidence base for dyspnea is more limited and experts advised that ACP measures 
would be generalizable to cancer.  Measures were included if they expressed a normative 
relationship to quality and included a measurable numerator and denominator.  Citations and 
articles were each reviewed/abstracted by two of six palliative care researcher/clinicians who 
described populations, testing, and attributes for each measure. 
 
Results.  The literature search identified 5,187 titles, of which 4,650 were excluded at abstract 
review.  Of 537 articles, only 25 contained measures: 21 on ACP, 4 on depression, 2 on dyspnea, 
and 12 on pain.  Ten relevant measure sets were identified: ACOVE, QA Tools, Cancer Care 
Ontario, Cancer Care Nova Scotia, Dana-Farber, Georgia Cancer Coalition, University Health 
Consortium, NHPCO, VHA, and ASCO.  We identified a total of 40 operationalized and 19 non-
operationalized measures.  The most measures were available for pain (12) and ACP (21), 
compared with only 4 for depression and 2 for dyspnea.  Few of the measures were published, 
and few had been specifically tested in a cancer population.  
 
Conclusions.  A large number of measures are available for addressing palliative cancer care, 
but testing them in relevant populations is urgently needed.  No measures or indicators were 
available to evaluate the quality of supportive pediatric cancer care.  Basic research is urgently 
needed to address measurement in populations with impaired self-report.  Funding field testing 
of highest quality measures should be an urgent patient and family-centered priority to meet the 
needs of patients with cancer. 
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Executive Summary 
 
Overview 
 
Cancer is a common, costly problem that affects many Americans and their families. 
Approximately 9.6 million Americans who were alive in January 2000 were estimated to be 
living with a previous diagnosis of cancer, and approximately 1.4 million cases of cancer were 
diagnosed in 2004.  Direct medical expenditures on cancer exceeded $180 billion in 2000.  The 
most common malignancies include lung, breast, colorectal, and prostate, for which 2003 
estimates of 5-year survival rates varied from 15% (lung) to 99% (prostate).  
Cancer imposes its burdens from diagnosis to death, and even survivors live with substantial 
impairments; therefore, supportive care is an important consideration of all phases of 
management.  Supportive care addresses the direct and treatment-related impacts of cancer 
including, pain, and symptom management; the psychosocial context, including spirituality; and 
caregiving.  Supportive approaches focus on assisting patients and caregivers to maximize well-
being and can ameliorate many of the debilitating consequences of living with a cancer 
diagnosis, regardless of cancer stage.  As early diagnosis and more effective treatment extend the 
experience of living with cancer, seamless integration of supportive principles and approaches 
becomes even more imperative.  
In spite of the prevalence of cancer and its enormous costs, little effort has been made to 
systematize the assessment of the quality of palliative cancer care.  AHRQ and a collaborative of 
Federal Partners, including the Centers for Disease Control and Prevention (CDC), the Centers 
for Medicare & Medicaid Services (CMS), and the National Cancer Institute (NCI), requested a 
systematic review of quality measures for supportive cancer care.  This report, prepared by the 
Southern California Evidence-Based Practice Center, is intended to assist the National Quality 
Forum (NQF) by describing quality measures in the areas of pain, dyspnea, depression, and 
advance care planning (ACP) and to identify priorities for a quality measurement research 
agenda. 
 
Reporting the Evidence 
   
This report addressed the following questions: 
 
1. What quality-of-care measures are available and what evidence supports those 
measures to assess pain, depression, dyspnea, and advance care planning for 
patients with cancer, including: 
a. Patient assessment,  
b. Intervention and appropriate management, and  
c. Timeliness and effectiveness of intervention. 
 
2. What gaps in knowledge about quality measurement are evident from the currently 
available literature, including absence of measures or measures lacking evidence of 
their scientific soundness, whether for the population of cancer patients as a whole 
or for specific subpopulations? 
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Methodology 
 
In consultation with the AHRQ Task Order Officer (TOO) and the NQF, we created a 
Technical Expert Panel (TEP) of leading scientists and clinicians with expertise in oncology and 
palliative medicine and a broad knowledge of research and policy issues in the field of oncology 
and palliative care in the United States to guide the evidence report.  Project staff worked closely 
with AHRQ, NQF, and the TEP to refine the research questions and focus on the relevant 
outcomes.  Drs. Karl Lorenz and Joanne Lynn met with the NQF and members of their Steering 
Committee in December 2004 to discuss the task order question and plans for the systematic 
review.  
Originally, Question 1 specified focusing on “measures to assess pain, depression, distress, 
and advance care planning.”  However, the Committee indicated that distress had been 
incorporated in order to address broad psychosocial and spiritual concerns.  However, the group 
expressed concerns relative to the feasibility of conducting a systematic review of distress.  They 
also agreed that the broader spiritual and psychosocial concerns could be taken into account in 
conducting the literature review of depression measures.  Because dyspnea is an important 
symptom among cancer patients and a recent systematic review found promising evidence 
related to its treatment, the Committee recommended that RAND should add dyspnea as a topic. 
After consulting with the AHRQ Task Order Officer, the review team agreed to focus on pain, 
depression, dyspnea, and advance care planning.  
The first of a series of calls was held on February 9, 2005 with our TOO and the TEP.  An 
important issue that arose for discussion during our initial conference call with the TOO and TEP 
in February 2005 was the extent to which searches should be restricted to cancer.  Limiting the 
search logic to cancer provided an extremely limited number of references, particularly for ACP 
and dyspnea quality measures.  Our TEP advised that measures that were applied to the care of 
symptoms and advance planning in other disease states would also be relevant to cancer; thus, 
for those two topics, we broadened the search to include conditions other than cancer.  However, 
because our initial searches indicated that the literature on pain and depression was extensive, we 
restricted our review of these citations to cancer only.  
 
Literature Search and Review  
 
We searched MEDLINE®, CINAHL©, and PsycINFO© for English language literature 
(January 1995 - February 2005) using terms for pain, dyspnea, depression, and ACP combined 
with terms for cancer, quality assessment or improvement, and palliative care.  Because our 
previous experience identified limitations in the indexing of quality measures in scientific 
databases, we used pre-specified terms to search the Internet for evidence-based standards or 
quality measures that had been developed by healthcare organizations or specialty societies. 
(February to March 2005).  We directly contacted developers of all measures or measure sets we 
identified and sought additional information using a ‘contact form.’  
 
Study Selection and Abstraction 
 
Six reviewers, with clinical backgrounds in internal medicine and nursing, and research 
careers in palliative care, organized into four teams by domain, each reviewed documents 
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independently, resolving disagreement by consensus.  We applied the following inclusion and 
exclusion criteria at both the title/abstract and article screening phases.  Study reports or other 
documents were accepted only if they contained either indicators or measures.  An indicator was 
defined as “a descriptive statement with a normative relationship to quality that includes a 
numerator and denominator and that is expressed as a measurable standard.”  A measure is an 
indicator fully specified for measurement, including data elements, the data collection approach, 
data sources, analysis, and presentation.  
 
Documents were excluded if they: 
 
• Were non-Western (i.e., not United States, Canada, Australia, New Zealand, Great 
Britain, or European),  
 
• Were published in a non-English language,  
 
• Focused exclusively on a disease other than cancer UNLESS they were on the topic of 
pain or depression, or 
 
• Focused on cancer but considered only a topic other than ACP, depression, dyspnea, or 
pain, 
 
• Addressed only specific types of cancer and/or processes of care that were not 
generalizable across the most common cancer conditions (e.g., particular pain syndromes 
for tumor subtypes), 
 
• Guidelines were excluded if they did not contain any description of their methods or how 
they were developed. 
 
For the domains of pain and depression, if a measure or indicator was developed for 
populations (e.g., hospice) that generally include cancer patients, but the development or field 
testing for the indicator did not explicitly include cancer patients, we did not exclude the 
document or citation.  
Articles accepted at the screening stage were subjected to full abstraction using standardized 
forms.  Some studies or documents described only indicator or measure development, whereas 
others described testing or use in an actual population.  Detailed information on the attributes of 
these tools was abstracted. 
 
The Report 
 
In general, the review was organized around fundamental domains of symptom 
management—assessment, treatment, and follow-up.  Assessment includes all activities related 
to evaluating the presence of a symptom.  Treatment includes all activities subsequent to 
identification related to mitigating the symptom.  Follow-up includes re-assessment and/or re-
treatment of the symptom.  For consistency, ACP was also organized around these domains since 
they are reasonably analogous, although for ACP, the task of ‘assessment’ is to evaluate goals 
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and preferences, ‘treatment’ is the application of advance care plans, and ‘follow-up’ refers to 
actual implementation.  
 
Peer Review 
 
We received comments from eight peer reviewers and eleven TEP members who reviewed 
our draft report.  We compiled the comments and made appropriate changes to the report. 
 
Findings 
 
Literature Review  
 
The literature search identified 4,580 titles.  We identified an additional 389 articles from the 
database we had assembled for a systematic review of research on End-of-Life Care and 
Outcomes.  Our web search identified 105 guidelines.  An additional 109 articles were suggested 
from by the project members.  Four additional articles were suggested by our TEP upon review 
of the draft version of this evidence report.  In total, the RAND reviewers examined 5,187 titles. 
Of the 5,187 possibly relevant titles, 4,599 were excluded at abstract review, leaving 588. 
Repeat review by one principal investigator (KL) excluded an additional 51 titles, leaving 537 
reports and guidelines.  
Of the 537 articles ordered, we retrieved 536 prior to the cut-off date (June 10, 2005). 
Screening resulted in the exclusion of 485 articles: 347 included no indicator; 113 had no domain 
of interest; 8 considered a disease other than cancer; 5 were guidelines with no methods; 6 
originated in a non-Western location; 2 presented duplicate data; 2 were duplicate articles; and 2 
were useful for background only.  
Of the remaining 51 articles, 25 that contained measures and/or indicators and described their 
methods were reviewed in detail.  Potential indicators were identified by each team based on 
their working knowledge of research literature and prioritized based on each team’s opinion of 
the most important gaps in measurement.  The remaining 26 articles contained only potential 
indicators.  As one article can report on multiple topics and may include multiple measures 
and/or indicators/potential indicators the numbers in the domain boxes in Figure 1 represent the 
numbers of measures, indicators or potential indicators that were abstracted into the Evidence 
Tables and not the actual number of articles. 
 
Pain - Measures and Indicators  
 
This category addressed the general conceptual areas of pain assessment (five measures, two 
indicators) with numeric or nonspecific scales; treatment (two measures, two indicators), 
including timely intervention; side effect/constipation prophylaxis; radiotherapy; and follow-up 
(four measures, one indicator) including timely relief, satisfaction, and degree of relief (Table 2). 
Assessment measures and indicators specifically focused on cancer addressed routine pain 
assessment using numeric or non-specific scales in inpatient, intensive care, outpatient, and 
unspecified settings. 
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Dyspnea - Measures and Indicators  
 
Dyspnea measures and indicators addressed the general conceptual areas of routine 
assessment (one measure) with a numeric scale; treatment (three indicators), which included any 
treatment, terminal treatment, and addressing hypoxia; and follow-up (one measure), addressing 
timely relief.  
 
Depression - Measures and Indicators  
 
Depression measures and indicators addressed the general conceptual areas of assessment 
(one measure, one indicator), including psychosocial, spiritual assessment, treatment (two 
measures) including regular assessment or treatment.  
 
ACP - Measures and Indicators  
 
ACP measures and indicators addressed the general conceptual areas of assessment (1 measures, 
4 indicators), including surrogate identification, preference evaluation, patient/family 
participation, and timely planning; ACP application (2 measures), addressing documentation 
across venues and evaluation of specific life sustaining preferences; and ACP follow-up (10 
measures, 1 indicators), which addressed preference-treatment consistency, hospice admission, 
late life utilization of hospital or intensive care settings, emergency care, and chemotherapy.  
 
Recommendations for Future Research 
 
We identified priorities for future research in a number of important areas: 
 
Field Testing in Relevant Populations  
 
Many of the measures may be useful now for local quality assessment and improvement, but 
most measures lack even basic published evidence of reliability and validity.  Before these 
measures are deployed at higher levels of the health care system, information about their ability 
to discriminate quality performance and responsiveness to change will be required.  Furthermore, 
health care systems must consider the cost and feasibility of data collection and must be assured 
that measures are at low risk for perverse incentives and that they can provide timely feedback.  
 
The Need for Measures To Address Impaired Self-Report  
 
None of the indicators address how to evaluate symptoms among individuals with impaired 
self-report, which can be due to either temporary (e.g., delirium) or durable factors (e.g., 
dementia, brain metastasis).  There is no doubt that delirium is common among cancer patients, 
although its incidence and prevalence are not well studied.  Some recent reports noted a 
prevalence of 18-50% among patients with cancer in general, and observed rates are even higher 
in certain treatment settings such as the intensive care unit or the nursing home, where almost 
60% of the population is also living with dementia.  
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The Lack of Pediatric Measures  
 
We noted the complete absence of pediatric measures or indicators.  Cancer represents the 
second leading cause of death among children ages 5 to 15 in the United States, and serious 
deficiencies in the care of pediatric cancer cases have been noted.  It is insufficient to propose 
that adult measures or indicators could simply be adopted for pediatric care, as the kinds of 
disease, challenges of symptom reporting and intervention, and basic approach to care differ so 
significantly between pediatric and adult oncology care.  
 
Defining the “End-of-Life”  
 
The lack of consensus on definitions of “end-of-life” presents what has been called the 
“denominator” problem.  Many of the indicators define end-of-life retrospectively (e.g., last six 
months of life).  This definition does not provide guidance on important clinical service, and 
retrospective analyses may introduce a number of biases, since the timing of death is often not 
predictable.  Prospective indicators would account for patient preferences but will require 
methodological work to define which cancer patients (those with certain types that are usually 
fatal, those at advanced stage) should be in the denominator. 
 
The Publication Gap for Quality Measurement 
 
An important finding of our report was that much of the evidence on the measures that we 
identified was unpublished.  Additional information that might be available to inform the 
evidence base for these measures was likely collected by non-academic organizations and is 
probably unpublished.  Much of the actual experience with measures and measurement has 
probably been reported in an anecdotal rather than an archival form.  Those who conduct future 
systematic reviews should be aware of this important issue and make an explicit effort to capture 
this unpublished information.  Methods for systematically compiling and analyzing this type of 
data might help to improve the evidence base for quality measurement.  
 
Strengthening Quality Measurement of Depression in Cancer  
 
Given the recognized prevalence of depression among cancer patients, surprisingly few 
indicators have been evaluated depression in cancer.  Indicators developed for other settings may 
be appropriate but have not been tested in this population.  For late-stage disease, more 
fundamental clinical research is needed, for example to assess the optimal approach to screening 
and the usefulness of short term treatment.  
 
Building an Evidence Base To Compare Population Subgroups  
 
We found insufficient evidence to comment on population differences.  An important priority 
for future research is evaluating measures in important sub-populations (e.g., those that differ by 
race/ethnicity, language, or gender).  It is also important to define subgroups of cancer by stage 
of illness and to understand the performance of indicators among major subgroups, including  
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disease type and settings of care.  Fewer indicators are available for outpatient than for inpatient 
care evaluation, even though the majority of patient care over time occurs in the outpatient 
setting. 
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Chapter 1. Introduction 
  
Cancer is a common and costly problem that affects many Americans, their families, and 
their caregivers, since many are affected by a cancer diagnosis.  Approximately 9.6 million 
Americans who were alive in January 2000 were living with a diagnosis of cancer, and 
approximately 1.4 million new cases of cancer were diagnosed in 2004.1  The most recent 
estimate of lifetime risk suggests that males have an approximately one in two risk and women a 
one in three risk of developing cancer.1  Direct medical expenditures on cancer exceeded $180 
billion in 2000.  The costs of care are concentrated in the time just following diagnosis and the 
last few months before death, with about one-third of expenditures in the final year.2  The most 
common malignancies include lung, breast, colorectal, and prostate, for which 2003 estimates of 
5-year survival rates varied from 15% (lung) to 99% (prostate).3  
In spite of the prevalence of cancer and its enormous personal and societal costs, little effort 
has been made to systematize the assessment of the quality of palliative cancer care.  In 2004, the 
Agency for Healthcare Research and Quality requested a systematic review of quality measures 
for supportive cancer care in the areas of pain, dyspnea, depression, and advance care planning 
(ACP).  AHRQ and a collaborative of Federal Partners, including the Centers for Disease 
Control and Prevention (CDC), the Centers for Medicare & Medicaid Services (CMS), and the 
National Cancer Institute (NCI), sponsored the report in order to assist the National Quality 
Forum (NQF) by identifying and describing quality measures for supportive cancer care 
including the evidence that they are ready or nearly ready for incorporation into routine clinical 
practice.  An additional purpose of this report was to identify gaps in measurement that could be 
the basis for a quality measurement research agenda, including areas in which no measures exist, 
or in which measures exist but for which additional evidence is needed. 
  
Supportive Care and the Cancer Continuum 
Cancer imposes its burdens on patients and caregivers from diagnosis to death, and even 
long-term survivors often live with substantial impairments.  Supportive care addresses the direct 
and treatment-related impacts of cancer, pain and symptom management and the psychosocial 
context, including spirituality and the challenges of caregiving; it is important in all phases of 
cancer care.  Symptoms may prompt (e.g., dyspnea) or be precipitated by (e.g., depression) the 
diagnosis of cancer, and treatment and progressive illness typically impose substantial 
symptomatic burdens.  Some common cancers are diagnosed at a late stage: Only 16% of lung 
cancer cases are localized at the time of diagnosis.1  Supportive approaches focus on assisting 
patients and caregivers to maximize well-being and can ameliorate many of the debilitating 
consequences of living with a cancer diagnosis, regardless of cancer stage.4-6  As early diagnosis 
and more effective treatment extend the experience of living with cancer, seamless integration of 
supportive principles and approaches becomes even more imperative.   
Pain is one of the most common symptoms in patients with cancer and is often inadequately 
treated when measured by patient or staff perceptions, particularly in vulnerable subgroups.7-9 
Cancer pain can result from direct primary or metastatic tumor involvement, including bone and 
neurologic pain; from diagnostic interventions; and as a side effect of chemotherapy or radiation 
therapy.7  One-third to one-half of patients in active treatment, and three quarters of patients with 
advanced cancer experience pain.10  Chronic pain also may be a component of cancer 
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survivorship, and many patients with cancer also have pain due to unrelated causes.  Many 
studies have documented that pain is often inadequately treated, and the quality of treatment 
varies widely among centers.8  Racial and ethnic disparities in pain assessment and management 
have been described.11 
Dyspnea is an unpleasant, distressing, and common experience among cancer patients: over 
half of cancer patients experience significant shortness of breath.12-18  In the final months and 
days of life with cancer, rates of dyspnea range from 60% to 90%, with the symptom especially 
prominent in those with lung cancer.13-16,19  For example, 87% of 673 patients with stage III or 
IV non-small cell lung cancer reported dyspnea.19  Numerous etiologies for dyspnea exist in 
cancer, including pulmonary or pleural metastasis, anemia, and muscular weakness.  Despite the 
prevalence of dyspnea among cancer patients, the majority of dyspnea research has been 
conducted in patients with chronic pulmonary conditions.13,20,21  However, a promising evidence 
base supports assessment and interventions to improve the experience of cancer patients with 
dyspnea.21 
Depression has received increasing attention as a cause of distress or suffering in patients 
living with cancer.10  Studies suggest that around one quarter of cancer patients experience 
depression during the course of their care.10  Depressive symptoms often accompany the 
diagnosis of cancer,22 and depression is strongly associated with other symptoms⎯ such as 
pain⎯ that may fluctuate in severity over the course of cancer treatment.10  Depressive 
symptoms accompany patient and caregiver experiences throughout all stages of cancer care, 
including wrestling with treatment disappointments, the complications of therapy and of cancer 
itself, and progressive illness.  Evidence has demonstrated an important relationship between 
depression and spiritual or existential well-being, especially related to how patients and 
caregivers maintain hope along the trajectory of the cancer experience.23-26 
Another important area of consideration regarding cancer care is ACP.  Early on, the 
emphasis in ACP was on legal initiatives, “living wills,” and other similar documentation; 
however, over time, the concept has broadened to emphasize a process of effective 
communication and planning ahead to shape an appropriate course of care.27  Now, high quality 
practice includes ACP for a number of reasons: to allow patients to shape care to their 
preferences, to avoid imposition of unwanted treatment in urgent situations, to relieve patient and 
family anxiety, and to ensure availability of the specific practical arrangements that will allow 
the patient to have optimal care, on his or her own terms.  Cancer treatment commonly requires 
potentially difficult interventions such as chemotherapy or surgery.  The utilization of high 
intensity care such as hospitalization, particularly in an ICU, varies significantly among elderly 
cancer patients, without a clear relationship to patient-centered outcomes.28-30  Because of the 
emphasis on documentation of choices among a narrow set of treatment preferences, research on 
this topic emphasizes outcomes related to health care utilization generally or the actual use of 
particular services.21  However, informed consent and self-determination are cardinal ethical 
principles, and self determination is endorsed by both patients and caregivers as an important 
value in late life care.31  Furthermore, planning ahead allows deliberate forgoing of undesired 
care.   
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Summary 
Supportive care emphasizes treatment to minimize symptoms and enhance patient and 
caregiver well-being and is relevant across the trajectory of cancer care, from diagnosis and 
initial treatment to chronic progressive illness and the end-of-life.  Palliative care is a term that is 
sometimes used interchangeably with the term supportive care, except that palliative care 
generally refers to a focus on care for patients in more-advanced stages of illness.  Pain, dyspnea, 
depression, and ACP are common, high impact concerns to be considered as targets for quality 
assessment and improvement.  All of these areas represent problems that affect many patients 
receiving care for common malignancies, although the importance of particular symptoms varies 
among major cancers and throughout the illness trajectory.  Pain, dyspnea, and depression, and 
ACP represent areas in which substantial initial research has begun to define the scope of the 
challenges and effective interventions for patients with cancer.  ACP is relevant to all phases of 
cancer, as potentially difficult treatments may be employed, and effective communication is 
always important to cancer patients and their caregivers.  
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Chapter 2. Methods 
Final Task Order Questions 
The Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and 
Prevention (CDC), Centers for Medicare & Medicaid Services (CMS), and the National Cancer 
Institute (NCI) requested this systematic review.  They also requested that the review be 
available in time for review by the National Quality Forum’s (NQF) Steering Committee in 
September 2005. The following key questions were addressed in the response to the Request for 
Task Order (RFTO): 
 
1. What quality-of-care measures are available and what evidence supports those 
measures to assess pain, dyspnea, depression, and advanced care planning for 
patients with cancer, including: 
a. Patient assessment,  
b. Intervention and appropriate management, and  
c. Timeliness and effectiveness of intervention. 
 
 
2. What gaps in knowledge about quality measurement are evident from the currently 
available literature, including absence of measures or measures lacking evidence of 
their scientific soundness whether for the population of cancer patients as a whole 
or for specific subpopulations?  
 
Overview 
In order to accomplish the tasks as directed, we assembled a team of clinical and 
methodological experts and staff who worked closely with the directors and staff of the Southern 
California Evidence Based Practice Center (SCEPC).  Dr. Karl Lorenz led the day-to-day work 
of the review and writing teams with the close assistance and regular involvement of Drs. Joanne 
Lynn, Paul Shekelle, and Sally Morton.  Our team included six literature reviewers (with Dr. 
Lorenz) with experience and expertise in palliative care and with diverse clinical training and 
experience, including an oncology nurse, one intensivist, and two general internist/palliative care 
physicians.  The reviewers were trained and experienced in the critical analysis of scientific 
literature and had conducted a systematic review of palliative care in December 2004.21 
The entire team met weekly to review and refine the methodology of the task order.  
Meetings and teleconferences of the SCEPC staff with the TEP helped specify issues central to 
this report within the framework of the key questions.  The SCEPC conducted a comprehensive 
search of the medical literature to identify studies that addressed the key questions.  Staff 
conducted an extensive search for grey (unpublished) literature, including a Web search; 
reviewed relevant articles; contacted quality-of-care measure developers; compiled tables of 
measures; appraised the methodological validity of studies and measures; and summarized the 
results.  
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Technical Expert Panel and Approach to the Report 
In consultation with the AHRQ Task Order Officer (TOO) and the NQF, we created a 
Technical Expert Panel (TEP) to guide the evidence report.  We invited a multidisciplinary group 
of leading scientists and clinicians with expertise in oncology and palliative medicine and a 
broad knowledge of research and policy issues in the field of oncology and palliative care in the 
United States to participate.  The list of potential technical experts and their curriculum vitae 
were submitted to the Task Order Officer for approval, and the final list of members is included 
in Appendix A*.  
Project staff worked closely with AHRQ, NQF, and the TEP to refine the research questions 
and focus on the relevant outcomes in the topic areas.  Drs. Karl Lorenz and Joanne Lynn met 
with the NQF and members of the NQF Steering in December 2004 to discuss the task order 
question and plans for the systematic review.  At that initial meeting, the specific domains that 
were the focus of the task order and the task order questions were discussed at length and 
finalized.  
The first of a series of teleconferences was held on February 9, 2005 with our TOO and the 
TEP.  In preparation for the call, we conducted a series of exploratory MESH-based literature 
searches for each of the domains.  We also conducted an initial Web-based search for grey 
literature, including important guidelines and recommendations of major specialty societies.  We 
solicited the TEP’s knowledge about the relative strengths and weaknesses of the evidence base 
for quality measures in the domains of interest and asked them to complete a worksheet listing 
existing measures and important sources, as well as priorities for improving quality measurement 
(Appendix B*).  
An important issue that arose for discussion with our TEP was the extent to which our 
searches should be restricted to cancer.  Although the purpose of the systematic review was to 
provide measures for improving palliative cancer care, restricting the search logic to cancer 
would severely limit the number of pertinent references, particularly for ACP and dyspnea 
quality measures.  Furthermore, our TEP advised that measures of the care of symptoms and 
advance planning in other disease states would also be applicable to patients with cancer and 
should be considered in the systematic review, as they would likely be useful to the NQF 
Committee.  
During the call, we reviewed terms, logic, and results of our initial searches.  We finalized 
our formal literature (Appendix C*) and Web searches and finalized the list of organizations from 
which we would attempt to retrieve guidelines and other relevant information.  Because our 
initial searches indicated that the literature on pain and depression was relatively extensive, we 
restricted our review of these citations to cancer only, because of resource limitations.  However, 
for the topics of dyspnea and ACP, we followed our TEP’s advice and in consultation with our 
TOO, broadened the search to include conditions other than cancer.  We limited our search to the 
past decade because our experience with this topic suggested that most of the relevant research 
would be relatively recent based on typical progress in medical knowledge.21  Although the task 
order specified limiting the review to US measures only, we decided to include all English-
language sources in the systematic review and to highlight the origin of particular measures in 
our report.  
 
                                                 
* Appendixes cited in this report are provided electronically at  
http://www.ahrq.gov/downloads/pub/evidence/pdf/eolcanqm/eolcanqm.pdf 
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Analytic Framework 
According to the model of Donabedian, the evaluation of quality of care includes structure, 
process, and outcomes.32  Structural measures focus on the capacity of the health care delivery 
system and depend upon demonstrating a relationship between structure and the health outcomes 
of interest, which is often difficult to establish.  Process-of-care measures evaluate whether 
providers deliver the appropriate service for the patient’s presenting condition.  Outcome 
measures directly assess relevant effects of care on the patient (or possibly, in the case of 
palliative care, the caregiver).  Focusing on either processes or outcomes alone has both 
advantages and disadvantages.  
Compared with outcomes, processes are more numerous (thus providing more measurement 
options), they are more directly attributable to the health care system rather than the patient, and 
the performance of some processes can be measured in routine health care records or data.  
When processes are selected for quality monitoring, they should exhibit a strong relationship to 
outcomes.  Even when outcomes are satisfactory, inadequate processes of care can reflect 
problems with health care provision.  
In contrast, outcomes provide direct insight into relevant effects of care, but they can be 
difficult to measure, especially in frail or very sick patients, they may not be routinely measured 
in health care encounters, and they are affected by the individual patient’s health status and 
comorbidities.  Thus, outcomes must typically be risk-adjusted, but adjusting for patient 
characteristics can be difficult.  In addition, the low frequency of serious adverse events requires 
large sample sizes.  The task order directed us to focus our attention on process measures, 
because they would be most relevant to NQF’s concerns.  Thus, our review and discussion 
emphasize process measures; however, for the sake of completeness, our report also includes 
outcome measures. 
 
Processes Relevant to Symptom Care and Advance Care 
Planning Quality Measurement 
 
We organized the review in general around three domains of care that are fundamental to 
symptom management – assessment, treatment, and follow-up (Table 1).  Assessment includes 
all activities related to measuring or evaluating the presence of a symptom in a patient. 
Treatment includes all activities (including distinct concurrent or stepwise activities such as 
medication and counseling) subsequent to identification that are related to mitigating the 
symptom.  Follow-up includes re-assessment and/or re-treatment of the initial symptom.  We 
organized our review of ACP around these same domains for clarity since they are reasonably 
analogous, although “assessment” becomes evaluation of goals and preferences, “treatment” is 
the application of advance care plans, and “follow-up” refers to actual implementation. 
Both symptom management and ACP fundamentally begin with the patient’s own symptom 
description.  Thus, assessing self-report ability is a fundamental process to be considered for 
quality measurement and has important implications for denominator determinations in these 
domains.  Patients who are impaired in this regard may need to “opt-out” of measures, or 
providers may need to seek alternative measures that are appropriate for them.  Symptoms are 
“subjective evidence of disease,”33 and ACP requires eliciting the patient’s values and care 
preferences.  Our review included both adults and children, and self-reports may be impossible 
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for very sick or very young individuals.  Pediatric assessment must be developmentally 
appropriate.34  Adults may experience a variety of sensory or expressive impairments, most 
commonly dementia in the elderly, that interfere with self-expression.  Surrogate reporting is 
essential for symptom assessment in young children and adults with impairments; and 
designation of a surrogate for decision-making and care planning are critical for ACP.  
Symptom management begins with addressing the presence of the symptom, as well as 
frequency, severity, and bother or functional impact.35,36  Specific historical, physical 
examination, and technical diagnostic tests are employed in searching for specific etiologies.37 
Treatment must consider targeting specific etiologies as well as relieving symptoms alone. 
Pursuing specific symptom etiologies involves tradeoffs in the burden for patients, even when 
those etiologies are identified.  Therefore, measuring the quality of symptom care may need to 
include patients’ right to “opt-out” among care preferences as well as considering the 
contraindications for certain supportive care diagnostic or treatment algorithms.38  Some 
treatments for dyspnea such as supplemental oxygen, may be relatively easy to arrange and 
tolerate, but others such as pulmonary stenting are more challenging.  For that reason, the phase 
of illness and preferences may moderate decisions about appropriate diagnostic testing or the 
specific etiologic treatment.39  
Differences in the time course of symptom occurrence and treatment, as well as the side 
effect profile of therapies, offer considerations for quality measurement.  Some symptoms 
fluctuate over brief intervals, and the reliability and validity of measurement vary with patients’ 
cognitive ability and the length of the retrospective lookback.40  Chronologic considerations also 
affect appropriate follow-up intervals.  For example, pain and dyspnea may fluctuate over short 
periods; whereas, depression is typically a more durable symptom.  However, depression also 
varies with other physical symptoms (e.g., pain), and transient mood states are common in 
cancer.7,41  The frequency with which these effects influence measurement varies with the 
treatment setting.  Although follow-up of the symptom depends on both chronological variability 
in the symptom and expected timing of responses to treatment, the side effects of treatment may 
be experienced before the benefits.  High quality care includes prophylaxis for some side effects 
(e.g., constipation with opioids); whereas, other effects (e.g., sedation with opioids) require 
timely monitoring and supportive care until they abate.  
Measures of ACP as a component of quality care may reflect a variety of processes or steps 
that are necessary in focusing on the most crucial medical decisions that are likely to confront the 
patient and the process of considering alternative care approaches.  Measurement may need to 
account for the patient’s changing clinical status, because preferences about treatments fluctuate 
over time.42, 43  An important consideration for culturally sensitive care is whether or not care 
planning begins with an assessment of informational preferences and how others should 
participate in decisions.  Elements of care planning include prediction of the clinical situation or 
prognostication, awareness of alternative treatment plans, eliciting preferences through clear 
communication, including key decisionmakers, and synthesizing preferences and alternatives. 
Advance care plans must be available to medical providers when patients need them and through 
important transitions in care.  Ultimately, care plans should be reflected in the actual medical 
treatment a patient receives. 
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Table 1: Processes potentially relevant to symptom care and advance care planning 
 
 Symptom Management Advance Care Planning 
Assessment 
      Evaluation of self-report 
capacity; determination of 
severity, frequency, 
bother/functional impact; 
history, physical 
examination, and diagnostic 
testing; preferences for 
evaluation and treatment 
including desired level of 
relief; consideration of 
specific etiologies. 
Evaluation of self-report 
capacity; evaluation of 
information preferences and 
caregiver(s) involvement. 
Treatment (or “Application” of Advance Care Planning) 
 Specific etiologic 
treatment(s); symptom-
guided treatment; patient 
education including 
information about side 
effects; prophylaxis of side 
effects. 
Clear communication; 
prognostication of patient’s 
clinical situation and 
potential clinical scenarios; 
provision of information 
about alternative choices; 
elicitation of patient and/or 
surrogate values and 
preferences; appropriate 
documentation. 
Follow-up 
 Timely follow-up of 
symptom changes and side 
effect manifestations; 
treatment adjustment; 
appropriate care for 
complications of therapy. 
Availability of preferences 
to other providers, and 
across settings; 
implementation of 
preferences to actual care 
delivered; re-assessment 
with notable changes in 
clinical context. 
 
 
Evidence Sources and Searches 
Literature Searches 
Sources for our review included MEDLINE®, the Cumulative Index to Nursing & Allied 
Health Literature (CINAHL©) database, and PsycINFO.©  The RAND Library staff performed 
the searches.  Members of the project team worked closely with the TEP and the librarians to 
refine the search strategy.  We limited the searches to articles published in the English language, 
appearing in journals between the years 1995 and 2005, involving human subjects, and excluding 
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individual case reports.  We limited our search to the past decade because our prior experience 
demonstrated that most of the progress in the science of supportive or palliative care was limited 
to that period.  
The main search strategy included an extensive list of terms intended to identify all research 
publications associated with all of the following: 
 
• Each of the domains of interest (pain, dyspnea, depression, and advance care planning) 
 
• Quality assessment or improvement 
 
• Quality measurement  
 
As described above, searches for pain and depression were limited with terms related to 
cancer.  Searches for dyspnea and ACP were not limited with cancer-specific terms.  We 
searched both the adult and pediatric cancer literature.  We also searched “related articles” (e.g., 
using similar articles linked by MEDLINE®) for citations that described using measures within 
the Assessing Care of the Vulnerable Elders (ACOVE) measure set that were likely to meet our 
criteria.  All of these searches were conducted during February 2005. The search strategies can 
be found in Appendix C*.  
 
Grey Literature - Internet Search 
 
 Because of limitations in the indexing of quality measures in traditional scientific databases, we 
employed a number of additional search strategies.  We sought to identify guidelines that would 
point to recommended evidence-based standards of practice or specific quality measures that had 
been developed by health care organizations or specialty societies.  Most of these searches 
involved the Internet.  First, we used the National Guideline Clearinghouse 
(www.guidelines.gov) and the National Quality Measures Clearinghouse (http://www. 
qualitymeasures.ahrq.gov/) to identify guidelines and indicators that fit our criteria. In addition, 
we accessed the websites of specific professional societies, disease societies, medical 
organizations, medical associations, and patient advocacy groups to search for any relevant 
guidelines or measures, as follows: 
 
• ASCO (American Society of Clinical Oncology) - www.asco.org  
 
• European Society for Medical Oncolgy - www.esmo.org   
 
• Canadian Cancer Society - http://www.cancer.ca/ccs/internet/frontdoor/ 
0,,3172___langId-en,00.html  
 
• Canadian Association of Psychosocial Oncology - http://www.capo.ca/eng/index.asp  
 
• ONS (Oncology Nursing Society) - www.ons.org/evidence  
                                                 
* Appendixes cited in this report are provided electronically at  
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• Canadian Association of Nurses in Oncology - http://www.cos.ca/cano/web/en/ 
index.html  
 
• American Cancer Society - http://www.cancer.org/docroot/home/index.asp  
 
• AAHPM (American Academy of Hospice and Palliative Medicine) - www.aahpm.org  
 
• NHPCO (National Hospice and Palliative Care Organization) - www.nhpco.org  
 
• EAPC (European Association of Palliative Care) - www.eapcnet.org  
 
• PCA (Palliative Care Australia) - www.pallcare.org.au/  
 
• Canadian Palliative Care Association - http://www.chpca.net/  
 
• Growthhouse - www.growthhouse.org 
 
• Center to Advance Palliative Care (CAPC) - www.capc.org  
 
• Center for Palliative Care Studies - www.medicaring.org  
 
• Americans for Better Care of the Dying - www.abcd-caring.org  
 
• Innovations in End of Life Care (online journal) - http://www2.edc.org/lastacts/ 
 
• IHI (Institute for Healthcare Improvement) - www.ihi.org  
 
• Promoting Excellence in End of Life Care - www.promotingexcellence.org 
 
• Supportive Care of the Dying - www.careofdying.org  
 
• MacColl Institute for Healthcare Innovation - http://www.improvingchroniccare.org/  
 
• American Alliance of Cancer Pain Initiatives - http://www.aacpi.wisc.edu/ 
 
• American Pain Society - http://www.ampainsoc.org/  
 
• Pain and Policy Studies Group - http://www.medsch.wisc.edu/painpolicy/  
 
• American Thoracic Society - www.thoracic.org  
 
• The National Comprehensive Cancer Network - www.nccn.org. 
 
We also conducted Internet searches using Google™ and the following search terms: 
guideline, clinical practice guideline, indicator, measure, quality measure, performance measure,  
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cancer, metatstatic cancer, prostate cancer, breast cancer, lung cancer, colorectal cancer, 
depression, depressive symptoms, emotional depression, antidepressive agents, tricyclic 
antidepressants, selective serotonin re-uptake inhibitors, pain, morphine, opioids, nonsteroidal 
anti-inflammatory drugs, treatment of bone metastasis, radiation therapy, dyspnea, shortness of 
breath, anemia, erythropoeitin therapy, advance care planning, advance directives, goals of care, 
DNR, DNI, withholding or withdrawal of treatment. 
Finally, we searched the following published sources for relevant guidelines or indicators: 
Directory of Clinical Practice Guidelines, Guide to Clinical and Preventive Services, Health 
Plan Employer Data and Information Set (HEDIS©) 2005, The Medical Outcomes and 
Guidelines Sourcebook, Clinical Process and Outcomes Measurement Directory, and Behavioral 
Outcomes and Guidelines Sourcebook.44-49  Whenever possible, we downloaded publications 
from the Internet; otherwise, we ordered them from the UCLA Biomedical Library or directly 
from the publishing organizations.  All of these additional searches were conducted from January 
2005 through March 2005.  
 
Grey Literature - Measure Developers  
 
We sought supplemental information on measures that we identified by directly contacting 
developers of those measures or measure sets.  In our communications, we specified which 
additional types of information might be helpful for this report and used a “contact form” as a 
guide to solicit this additional information (Appendix D*). 
 
End-of-Life Care and Outcomes Literature Database 
 
We searched the reference database for the End-of-Life Care and Outcomes Project, a systematic 
review recently completed by this report’s authors, for articles coded as “cancer.”21  This search 
yielded 389 articles that met the criteria and were screened for relevance to this project. 
 
Title Screening, Article Review, and Selection  
of Individual Studies 
 
The literature review team described above selected studies for further review.  The six 
researchers formed four teams, organized by each domain of interest.  Each reviewer on each 
team independently reviewed the documents or studies, and the teams resolved disagreements by 
consensus.  Dual review was used at all stages of the project.  Any questions or needs for 
clarification that arose throughout the literature review were resolved by the principal 
investigators. 
We adopted the following inclusion and exclusion criteria that were applied at both the 
title/abstract and article screening phases.  
Published reports or Internet documents were accepted only if they contained either 
indicators or measures.  An indicator was defined as a descriptive statement with a normative 
relationship to quality that includes a numerator and denominator and that is expressed as a 
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measurable standard.  As specified by the task order, we also defined a measure as an indicator 
that is fully specified for measurement, including data elements, the data collection approach, 
data sources, analysis, and presentation.2  We generally defined any indicator that had been 
previously operationalized and used for quality assessment or improvement activities as a 
measure.  A potential indicator was defined as a statement of a normative standard for which 
there exists substantial evidence of a relationship to quality of care.  We also identified articles 
with potential indicators; however, potential indicators were not included or identified 
systematically.  Potential indicators were identified by each team based on their working 
knowledge of the research literature and prioritized based on each team’s opinion of the most 
important gaps in existing measurement.  Potential indicators are based on reasoned expert 
judgment and are intended only as suggestions for further expert discussion.  We did not attempt 
to express them as fully operationalized measures. 
 
Study reports or other documents were excluded if they: 
 
• Were non-Western (i.e., not United States, Canada, Australia, New Zealand, Great 
Britain, or European),  
 
• Were published in a language other than English,  
 
• Focused exclusively on a disease other than cancer UNLESS they were on the topic of 
pain or depression, or 
 
• Focused on cancer but considered only a topic other than ACP, depression, dyspnea, or 
pain, 
 
• Addressed only specific types of cancer and/or processes of care that were not 
generalizable across the most common cancer conditions. (e.g., particular pain syndromes 
for tumor subtypes).  
 
We also excluded documents or citations that addressed only specific types of cancer and/or 
processes of care that were not generalizable across the most common cancer conditions (e.g., 
particular pain syndromes for tumor subtypes).  For the domains of pain and depression, some 
measures or indicators were developed for populations (e.g., hospice) that generally include 
cancer patients, although the development or field testing of these indicators may not have 
explicitly included cancer.  We did not exclude these documents or citations.  Reviewers 
screened all titles identified through the formal literature review and all documents found 
through our Internet and other grey literature searches for pertinence to the key questions and 
therefore their relevance to this project.  Project staff entered data from screening into an 
electronic database and tracked all studies through the process.  Titles and abstracts were 
screened simultaneously at the first stage.  If a title and abstract were accepted, then the full 
document was ordered and subjected to screening using a standardized screening form 
(Appendix E*).  Internet documents were also screened using a standardized screening form. 
                                                 
* Appendixes cited in this report are provided electronically at  
http://www.ahrq.gov/downloads/pub/evidence/pdf/eolcanqm/eolcanqm.pdf 
24 
Articles accepted at the screening stage were subjected to full abstraction using standardized 
abstraction forms.  Some studies or documents described only indicator or measure development, 
whereas others described testing or use in an actual population.  To the extent possible, at this 
stage, the following data were extracted for indicators and measures: 
 
• A general indicator description and/or statement 
 
• Numerator and denominator 
 
• The disease for which the indicator or measure was specified 
 
• Patient/population characteristics (age, race/ethnicity, and gender) 
 
• Setting of care for the indicator or measure application 
 
• Phase of illness to which the indicator was intended to apply 
 
• Data source 
 
• Data about psychometric performance – specifically, reliability and validity 
 
For guideline statements that were abstracted, we rated the quality of the guideline reports 
using statements following the Appraisal of Guidelines Research and Evaluation (AGREE) and 
Shaneyfelt criteria.50,51 
 
Summarizing the Evidence for Key Questions 
We report the evidence in several forms.  First, the evidence tables (Appendix F*) offer a 
detailed description of the individual indicators and measures that we identified, addressing each 
of the topic areas and attributes of indicators or measures that were specified by the task order 
and are important to understanding the selection of indicators for a national measure set.2,52 
Narrative text summarizes each of the indicators and measures, including the specification of the 
indicator or measure, its use or application in actual practice, and evidence supporting its 
relationship to quality of care and its application.  We provide statistical information (e.g., 
background rates, reliability, validity, etc.) useful to evaluating the indicator or measure when we 
found that information.  In addition, we provide tables of potential indicators to highlight 
priorities for future research in measurement in each of the topic areas.  We organized the 
indicators according to whether they most applied to the assessment, treatment, or follow-up of a 
symptom, and applied an analogous approach to the advance care planning indicators.  Because 
the strength of evidence related to available indicators and measures varied across topic areas, 
the degree to which each topic emphasizes existing indicators or measures versus potential 
measures varies accordingly.  
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Peer Review Process 
We identified potential peer reviewers through project staff and in consultation with our 
TOO.  We attempted to include representation from organizations representing adult and 
pediatric oncology, and palliative medicine, as well as major stakeholders in health care quality 
measurement.  Based on these inquiries, we contacted 20 individuals with wide expertise in the 
field representing 17 organizations and with deep knowledge of the literature, 14 of whom 
agreed to participate.  The final list of peer reviewers and their affiliations can be found in 
Appendix A*.  We mailed a copy of the draft evidence report to the peer reviewers and TEP 
members, with a request for their comments.  Comments were compiled and addressed in 
Appendix G*. 
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Chapter 3. Results 
Overview 
This chapter reports the findings of our systematic review of the evidence supporting 
indicators and measures for the quality of care for pain, dyspnea, depression, and advance care 
planning in cancer care.  The chapter first describes the literature review flow and then provides 
additional information about the specific indicators and measures that are outlined in our 
evidence tables (Appendix F*).  As described below, we identified 10 measure or indicator sets 
that were the source of most individual indicators and measures that we identified within the 
topic areas of pain, dyspnea, depression, and advance care planning.  In general, these indicator 
sets were developed to comprehensively evaluate health (Quality Assurance (QA) Tools, 
Assessing the Care Of Vulnerable Elders (ACOVE)), overall cancer care (Georgia Cancer 
Coalition, Cancer Care Ontario), supportive cancer care, or palliative care (Dana-Farber Cancer 
Center, Cancer Care Nova Scotia, Veterans Health Administration (VHA), University Health 
Consortium, National Hospice and Palliative Care Organization).  We successfully contacted 9 
of the 10 developers of the measure or indicator sets that are described (the exception being 
Georgia Cancer Coalition).  In addition, we noted several widely recognized measurement sets 
that contain potentially relevant measures (e.g., Joint Commission of Accreditation of Healthcare 
Organizations (JCAHO), National Community for Quality Assurance (NCQA)), but we did not 
abstract these indicators as these measurement systems are already widely recognized.  Table 2 
summarizes basic information about each measure set.  The section that follows describes 
measures, indicators, and potential indicators (as defined in our Methods) for pain, dyspnea, 
depression, and advance care planning derived from these sets and other sources.  
 
Table 2. Overview of identified measure sets  
 
Indicators 
QA Tools RAND Health developed the QA Tools system as a comprehensive, clinically based 
system for assessing the overall quality of care for children and adults. Each QA Tools 
indicator is based on a focused review of the scientific literature and on the ratings of a 
panel of experts in the field (based on the “RAND appropriateness method”). The QA tools 
system includes 46 clinical areas and all four functions of medicine: screening, diagnosis, 
treatment, and follow-up. It also covers a variety of modes of providing care, including 
history, physical examination, laboratory study, medication, and other interventions and 
contacts.  
 
Relevant to supportive cancer care, QA Tools identified indicators for the following: 
 
1. Pain assessment 
 
ACOVE   Assessing the Care Of Vulnerable Elders (called ACOVE) was intended to 
comprehensively address quality measurement for this population because vulnerable 
elders are at risk for serious declines in health and function from poor quality care and use 
health care resources disproportionately. ACOVE developed a method of identifying a  
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Table 2. Overview of identified measure sets (continued) 
 
Indicators 
Dana-Farber cont’d. community-based sample of vulnerable elders, selected clinical conditions for quality 
measurement, and developed an evidence-based set of 236 ACOVE-1 quality-of-care  
   process indicators to evaluate the care provided to vulnerable elders. The indicators are 
categorized into 22 clinical conditions of importance to vulnerable elders. Most of these 
quality indicators require only data from medical record review, though some require 
interviews or administrative data only. Relevant to supportive cancer care, ACOVE 
indicators addressed the following: 
 
1. Pain assessment and management (although these indicators excluded patients with 
cancer and therefore were ineligible for the current review) 
2. Depression 
3. Advance care planning (as part of dementia and end-of-life care) 
4. End-of-life care in general (including dyspnea) 
 
Dana-Farber The Dana-Farber Cancer Institute at Harvard University has pursued an effort to develop 
a set of administrative data-based indicators for palliative cancer care as part of its recent 
research agenda.  
   These measures focus on utilization as an outcome and address the following general 
aspects of supportive cancer care: 
 
1. Utilization-based intensity of service use (late chemotherapy, emergency, 
hospital/ICU use, site of death) 
2. Use of hospice 
 
CCNS   Cancer Care Nova Scotia (CCNS) is a Canadian provincial organization established to 
improve the delivery of cancer services across Nova Scotia.  CCNS is actively refining a 
quality measure set for palliative cancer care with the aim of determining which quality 
indicators are measurable from administrative datasets. The project has two phases:  
 
 Qualitative – The project systematically reviewed end-of-life quality indicators for 
cancer (generic indicators) and breast cancer (unique indicators).  It also drew from a 
general literature review (project identified 90 potential indicators at this stage) and 
assessed the feasibility of measurement with administrative data (i.e., good 
communication, having advance directives – not measurable using local resources). 
In addition, the project conducted focus groups with patients living with metastatic 
cancer and bereaved caregivers, and expert panels (modified Delphi) with 
multidisciplinary providers. This process yielded a set of final indicators for testing. 
 
 Quantitative – The project has defined a cohort of all women whose cause of death 
was related to breast CA over five years (1998-2002f) in Nova Scotia and in Ontario, 
a true population-based cohort; linked all available datasets that describe this 
population where feasible; and programmed measurable indicators. The project plans 
to validate the final indicator set by a detailed review of 100 charts in both provinces, 
assessing reliability using a 2nd set of abstractions. 
  
   The project identified 19 palliative cancer indicators on these topics: 
 
1. Pain management 
2. Nausea and vomiting 
3. Advance directives 
4. Utilization-based intensity of service use (site of death, hospital/ICU care, 
emergency, late chemotherapy use, and others) 
5. Hospice and multidisciplinary service use 
6. Transitions and coordination among settings and providers of care 
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Table 2. Overview of identified measure sets (continued) 
 
Indicators 
CCO   Cancer Care Ontario (CCO) is a Canadian provincial organization whose primary mission 
includes the effort to drive system quality, availability, and innovation. CCO developed a 
set of quality measures for a range of uses organized around measures of access to care, 
outcomes, evidence-based practice, efficient practice, and the data gathering performance 
of the cancer care system. Within these areas, individual clinical indicators address 
aspects of prevention, early detection, treatment, and palliative care. Measures relevant to 
palliative cancer care include those that address the following: 
 
1. Pain management (satisfaction) 
2. Utilization-based intensity of service use (site of death, emergency, and home-based 
services)  
 
GCC The Georgia Cancer Coalition (GCC) was created in 2001 as a legacy of the tobacco 
industry’s Master Settlement Agreement with 50 states. GCC contracted with the Institute 
of Medicine (IOM) to develop a set of quality measures for evaluating and improving 
cancer care in Georgia. Efforts were guided by the principles and selection criteria of the 
National Quality Forum’s Strategic Framework Board in recommending a set of 52 cancer 
care measures. GCC focused its 2003 review on potential measures that could be used to 
evaluate care for the most common cancers in Georgia and the United States as a whole 
– breast, colorectal, prostate, and lung cancer. GCC used various sources for measures 
including accreditation organizations, Federal agencies, provider and professional groups, 
State cancer control programs, and other sources (RAND Health, FAACT, NQF). GCC 
appointed an expert panel using the RAND appropriateness method to winnow an initial 
pool of more than 80 candidate measures. The final set included four items addressing the 
following: 
1. Pain assessment and management 
2. Use of hospice care 
 
VHA   In 2001, VHA, Inc initiated a rapid-cycle quality improvement program, the Transforming 
the Intensive Care Unit (TICU) initiative.  Phase 1.0, which included 23 hospitals, focused 
on safety and 2 pain measures shown to be effective in pilot studies at Johns Hopkins.  At 
the request of the participating ICUs, a key portion of phase 3.0, to be implemented in the 
Fall 2005, will be a palliative care bundle, which includes the pain measures and eight 
additional performance measures.  
 
   The measure set was developed using information from the Critical Care Peer Workgroup 
of Promoting Excellence in End-of-Life Care, the National Consensus Project for Quality 
Palliative Care, JCAHO standards, and other evidence. The measure set is currently 
undergoing small-scale pilot testing.  It will be implemented and tested in the TICU ICUs.  
As with other TICU projects, outcomes will be defined and abstracted for evidence of 
impact from sources such as administrative data, chart review, and satisfaction surveys. 
 
The palliative care bundle measures are as follows: 
 
Day 1: 
o Identify decisionmaker 
o Address advance directive status 
o Address CPR status 
o Distribute information leaflet 
o Assess pain regularly 
o Manage pain optimally 
Day 3: 
o Offer social work 
support 
o Offer spiritual support 
 
 
Day 5: 
o Family meeting 
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Table 2. Overview of identified measure sets (continued) 
 
Indicators 
UHC   The University Health Consortium (UHC), formed in 1984, is an alliance of academic 
health centers situated in the United States. The 2004 Palliative Care Benchmarking 
Project was conducted within the Clinical Process Improvement (CPI) division of the 
benchmarking program. The Benchmarking program provides members with the unique 
opportunity to evaluate and compare their clinical and operational practices with the finest 
university hospitals in the country. The UHC staff conducted an extensive literature review 
and assembled an expert panel of constituent members to choose final indicators based 
on the review and expert opinion. UHC collected data on a set of palliative care quality 
indicators from December 2003-February 2004. UHC employed its members’ Clinical Data 
Base (CDB) to select a retrospective cohort defined on the basis of adult status, several 
serious chronic conditions (HIV, cancer, pulmonary disease, congestive heart failure), and 
mortality risk (e.g., multiple recent admissions). The charts of these patients were 
subjected to review (40 patient records/each of 35 participating sites). A total of 1,596 
charts were included in the evaluation. Quality measures included the following: 
 
1. Pain assessment and treatment 
2. Dyspnea assessment and treatment 
3. Psychosocial care 
4. Care coordination/discharge planning 
 
NHPCO  The National Hospice and Palliative Care Organization (NHPCO), founded in 1978, is the 
largest nonprofit membership organization that represents hospice and palliative care 
programs and professionals in the United States. NHPCO has developed standards for 
hospice care from its inception. In 1998, NHPCO began to develop the National Data Set 
(NDS) to establish national benchmarks for hospice practice. Development was led by an 
expert group that included hospice and State government representatives and 
researchers; this group decided to focus on outcome measures. The measurement set 
underwent two sets of pilot testing. Data submission is currently voluntary, but enough 
hospices have submitted data (78 hospices in 2002) that published benchmarks are 
available.53  
 
   Quality measures included the following: 54  
 
1. Comfortable dying  
2. Self-determined life closure  
3. Safe dying  
4. Effective grieving  
5. Family evaluation of hospice care  
 
 
Literature Flow 
The literature search identified 4,580 titles.  We identified an additional 389 potentially 
relevant articles from the database we had assembled for the End-of-Life Care and Outcomes 
review.  Our web search identified 105 guidelines.  An additional 109 articles were suggested 
from the personal libraries of the project members.  Four articles were suggested by our TEP 
upon review of the draft version of this evidence report. In total, the RAND reviewers examined 
5,187 titles. 
Of the 5,187 titles identified as possibly relevant to our topics, 4,599 were excluded at 
abstract review, leaving 588 that might be useful to this project.  Repeat review by one principal 
investigator (KL) excluded an additional 51 titles.  Thus, the project sought to review 537 
articles and guidelines. 
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Of the 537 articles ordered, we retrieved 536 prior to the cut-off date (June 10, 2005) 
Screening resulted in exclusion of 485 articles and guidelines: 347 had no indicator; 113 had no 
domain of interest; 8 covered a disease that was not cancer; 5 presented guidelines with no 
methods; 6 dealt with a non-Western location; 2 presented duplicate data; 2 represented duplicate 
articles; and 2 were useful for background only.  (For a list of excluded studies, please refer to 
Appendix H*). 
Of the remaining 51 articles, 25 contained measures and/or indicators that described their 
methods and were reviewed in detail.  Potential indicators were identified by each team based on 
their working knowledge of research literature and prioritized based on each team’s opinion of 
the most important gaps in existing measurement.  The remaining 26 articles contained only 
potential indicators.  Because one publication can report on multiple topics and may include 
multiple measures and/or indicators/potential indicators, the numbers in Figure 1 add up to more 
than the total number of articles considered for detailed review.   
                                                 
* Appendixes cited in this report are provided electronically at  
http://www.ahrq.gov/downloads/pub/evidence/pdf/eolcanqm/eolcanqm.pdf 
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Figure 1. Article flow 
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Pain 
Introduction 
For the review of pain measures, we reviewed all relevant clinical guidelines, indicator and 
measure sets, potential indicators, systematic reviews, and articles related to quality 
improvement initiatives and clinical trials, including one review of quality improvement 
initiatives for cancer pain.  Please refer to Evidence Table Appendix F1*.  Pain was among the 
topics most commonly addressed within existing measure sets (6/8 of the sets identified).  We 
designated most of the items we identified within these measure sets as quality measures since 
all of them have been operationalized and used for at least quality assessment.  The exception is 
a handful of indicators that are either under development (e.g., Cancer Care Nova Scotia) or for 
which we were unclear whether or not they had previously been used for actual measurement or 
we were unsuccessful in obtaining information about that experience (e.g., Georgia Cancer 
Coalition).  
The report of IOM’s Committee on Assessing Improvements in Cancer Care in Georgia 
(National Cancer Policy Board)55 (Chapter 6, Treating Cancer) has two indicators related to pain, 
one each for assessment and follow-up.   
The performance measurement framework for Cancer Care Ontario56 has a measure relevant 
to pain management, defined as patients’ self-reported pain and perception of pain management 
by providers; this measure was operationalized as an indicator as “satisfaction with pain 
management.”57   
ACOVE generally excluded cancer patients, so the ACOVE set of measures for chronic 
pain58 were not included in our review, although some of these measures may be appropriate for 
patients with cancer.  However, ACOVE measures related to the end –of life did not exclude 
cancer; thus, that set includes one measure relevant to pain assessment.59  This measure has also 
been adapted for nursing homes.60  
The VHA Transforming the Intensive Care Unit (TICU) initiative includes two measures for 
pain assessment and follow-up that are currently being used in 30 ICUs and have evidence for 
efficacy in a cancer ICU.61,62   
The University Health Consortium (UHC) included two measures for assessment, one for 
treatment, and one for follow-up.  QA Tools included three items relevant to pain, although only 
two were accepted by the expert panel. However, the indicator not accepted by the QA Tools 
panel has been proposed as part of Cancer Care Nova Scotia.   
The NHPCO set includes one outcome measure for pain.63  
A broader cancer quality measurement set, QOPI (The Quality Oncology Practice Initiative), 
includes one measure for assessment of pain at the end of life.  We also identified a treatment 
indicator in a guideline for radiation therapy.64  
 
                                                 
* Appendixes cited in this report are provided electronically at  
http://www.ahrq.gov/downloads/pub/evidence/pdf/eolcanqm/eolcanqm.pdf 
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Measures and Indicators 
Assessment.  We identified five measures and two indicators relevant to cancer pain assessment.   
 
Measure - Regular Assessment of Pain.  Quality Assurance Tools (QA Tools), proposed in 
2000,64 includes one measure relevant to pain assessment.  The numerator of this measure is 
“patients with the presence or absence of pain noted every six months,” and the denominator is 
“all patients with cancer metastatic to the bone.”  The measure was limited to patients with bone 
metastases because this group was felt to be well defined and to have the highest prevalence of 
cancer pain.  The prevalence of every six months was chosen as a minimum requirement, based 
on older versions of clinical practice guidelines from the early 1990s.  Although this measure 
was tested as part of the QA Tools evaluation in a VA- and community-based population,65,66 the 
numbers of patients eligible for this indicator was too small to provide any useful validity, 
reliability, or comparability information.  This measure is intended for use in patients with any 
type of cancer metastatic to the bone.  The measure is not in current use. 
 
Measure - Routine Inpatient Pain Assessment.  The University Health Consortium (UHC) 
Palliative Care Benchmarking Project67 included two measures relevant to pain assessment.  The 
numerator for the first measure is “persons with pain assessment within 48 hours of admission.”  
The denominator is “adults ≥18 years of age, with admission for CHF (DRG 127), Cancer (DRG 
82, 203, 172, 274, 346, 10) HIV (DRG 489) OR respiratory (DRG 475, 483) AND length of stay 
> 4 days AND 2 prior admissions for any cause in preceding 12 months.”  This denominator was 
developed by an expert panel to represent a potential palliative care population in hospitals.  A 
mean of 96% (median 98.5%, range 83-100%) of charts in the UHC cohort satisfied this 
indicator, including 98% of cancer patients, and little variability was seen among participating 
sites.  No reliability or validity information is available; however, the benchmarking project 
found that using a combination of all of the UHC measures in a “palliative care bundle” was 
associated with lower patient length of stay.  In addition, several elements of the bundle could be 
used to identify hospitals with “best practices” for palliative care.  Scores from the bundle were 
instrumental in achieving advances in palliative care at several hospitals, including justifying at 
least one new palliative care program.  The measure is intended for use as a tool for comparing 
performance in all hospitals.  However, it is very broad, does not include an element of 
timeliness (within 48 hours of admission is late for pain assessment to occur), and is not in 
current use. 
The numerator for the second UHC pain assessment indicator (routine inpatient pain 
assessment with a numeric scale) is “persons assessed with a numeric pain scale.”  The 
denominator is “adults ≥ 18 years of age, with admission for CHF (DRG 127), Cancer (DRG 82, 
203, 172, 274, 346, 10) HIV (DRG 489) OR respiratory (DRG 475, 483) AND length of stay > 4 
days AND 2 prior admissions for any cause in preceding 12 months in the hospital, AND 
reported pain within the first 48 hours of admission.”  A mean of only 76% (median 85%, range 
13-100%) of the charts reviewed in the UHC cohort met this criterion, including 77% of those of 
cancer patients.  Some variability was seen among sites; at ten low-performing sites, only 15 to 
70% of charts included this information.  Information is the same as for the first UHC indicator; 
no additional reliability or validity information is available. 
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Measure - Regular ICU Pain Assessment.  The VHA TICU project, initially proposed in 2002,61 
includes one pain assessment measure, which was modified for inclusion in the VHA TICU 
palliative care bundle in 2005 (Quality Indicator #5).68  The numerator is “the total number of 4-
hour intervals (within the first 24 hours following ICU admission) for which pain was assessed 
and documented, using an appropriate rating scale.”  The denominator is “the total number of 4-
hour intervals (within the first 24 hours following ICU admission) for patients with an ICU 
length of stay ≥ 24 hours.”  Documentation of pain assessment may include (1) a numeric value 
of 1 to 10, or (2) pain was assessed but the patient was unresponsive (e.g., heavily sedated, 
comatose).  A four-hour interval is defined as a four-hour interval of patient care (patient-nursing 
interval).  The four-hour intervals are set at 8 am; 12pm; 4 pm; 8 pm; 12 am; and 4 am.  An 
appropriate rating scale is defined as either a visual analogue scale (VAS with numeric 
translation of 1-10) or another numerical rating scale of 1-10.  Exclusion criteria include 
intervals for which a patient was not physically available in the ICU (e.g. patient expired; not yet 
admitted to the ICU; was discharged/transferred out of the ICU (for part of the day); went into 
the operating room or off the unit for a procedure); and intervals for which pain was assessed, 
but without the use of an appropriate rating scale as defined above.  This measure is supported by 
the JCAHO Hospital Standards RI.1.2.9, PE.1.4 and the National Consensus Project for Quality 
Palliative Care Clinical Practice Guideline, 2.1.69  Evidence of its validity includes a rapid-cycle 
quality-improvement intervention in two ICUs, including a surgical cancer ICU, demonstrating 
that its use as part of a rapid-cycle quality improvement intervention, in which the percent of 
nursing intervals where pain scores were measured using a VAS scale increased from 42 to 94%, 
contributed to a decrease in pain scores ≥3 from 41% to 6%.62  In addition, a similar rating scale 
was used in an RCT of interrupted sedation in the ICU.70  No reliability information is available. 
This measure is intended for use in all ICU populations.  As with other pain outcome 
measures, variability in the quality of pain assessment may limit its use for comparing 
performance.  In the ICU population, as at the end of life or in nursing homes, many patients 
may have difficulty or may be unable to verbalize a numerical pain score; depending on local 
standards of assessment, this outcome variable may therefore apply to very different proportions 
of the population in different ICUs or settings.  The measure also does not specify whether this 
score should represent minimum, maximum, or average pain.  Also, the measure applies only to 
the first 24 hours in the ICU.  This measure is currently being used as part of the VHA TICU 
initiative and is part of the VHA palliative care bundle, which will be initiated in September 
2005.   
 
Measure - Assessing Pain in Patients Close to Death.  QOPI (the Quality Oncology Practice 
Initiative) included one end-of-life pain assessment measure in their practice-based system of 
quality assessment.  The numerator of this measure is “medical records where there is an explicit 
practitioner’s notation quantifying their physical pain or lack thereof on their last visit to the 
office prior to death,” and the denominator is “recently deceased  patients from oncology 
practices.”71  QOPI was developed and sponsored by individual oncologists and ACSO (the 
American Society of Clinical Oncology).  QOPI selected and developed quality measures that 
were easily identifiable through outpatient medical record review.  The measures also had to 
relate to important issues, as defined by (1) consensus among QOPI participants, (2) evidence-
based standards, or (3) requirements from organizations such as JCAHO.  This measure was 
evaluated through review of 10 medical records of patients who had died in 41 oncology 
practices.  The initial round of assessment showed that 56% of medical records met this measure, 
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69% met the measure in a second round 6 months later, and there was substantial variation 
among practices (range, 30-90%).  No validity or reliability information is available. 
This measure is intended for use in self-assessment in outpatient oncology practices.  The 
retrospective nature of the measure is a drawback, since death is often not predictable, and 
improvements might be due to changes in documentation that do not necessarily reflect 
improvement in practice.  This measure will be part of a new voluntary quality improvement 
initiative for oncology practices sponsored by ASCO, NCI, and the National Health Council, to 
begin in 2005.  End-of-life will be the first initiative and will include this measure as well as 
whether the pain was quantified by either a numerical scale or another descriptor. 
 
Indicator - Routine Pain Assessment in Expected Dying.  The Assessing Care of the Vulnerable 
Elderly (ACOVE) end-of-life measure set59 includes one measure relevant to assessment for 
pain.  Its numerator is “the number of vulnerable elders with documentation of pain or lack of 
pain during the last three days of life.”  The denominator is “vulnerable elders who are conscious 
during the last three days of life and who died an expected death.”  Although the eight measures 
from the ACOVE end-of-life set were evaluated for reliability and validity72 as part of the 
ACOVE project, this measure was not included in the evaluation.  The denominator may be 
difficult to define, since “expected death” requires explicit documentation of that expectation in 
the medical record more than one day before death.  This measure is intended for use in all 
vulnerable elders.  An expert panel accepted a modified version of this indicator as part of a 
revised set for nursing homes.60  The nursing home indicator requires a denominator of all 
nursing home residents who died an expected death and were conscious at all during the last 
seven days of life.  
 
Indicator - Routine Assessment of Pain.  The IOM’s Committee on Assessing Improvements in 
Cancer Care in Georgia (National Cancer Policy Board) proposed an indicator set in 2005 with 
two indicators related to pain, one of which targeted regular assessment.55  The numerator for 
this indicator is “the number of cancer patient encounters where the patient was assessed for 
pain,” and the denominator is “the number of cancer patient encounters.”  Available information 
does not specify the appropriate frequency of cancer pain assessment (i.e., every encounter) or 
how pain should be measured.  The indicator is intended for use for all cancer patients, across the 
continuum of care and all health care settings.  This indicator is newly proposed and information 
on actual use is not available. 
 
Treatment.  We identified three measures and one indicator relevant to cancer pain treatment.   
 
Measure - Responsive Pain Treatment.  QA Tools includes one measure relevant to treatment of 
pain, proposed in 2000.64  The numerator is “patients offered a change in pain management 
within 24 hours of the pain complaint,” and the denominator is “all cancer patients whose pain is 
uncontrolled.”  As with the other QA tools indicators, although this measure was tested as part of 
the QA Tools evaluation in VA and community-based populations,65,66 the number of eligible 
patients was too small in these studies to determine validity or reliability.  This measure is 
intended for use in patients with any type of cancer across the continuum of care.  The measure 
is not in current use. 
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Measure - Regular Prophylaxis of Opioid-Induced Constipation.  The UHC Palliative Care 
Benchmarking Project also included one measure relevant to pain treatment that addresses safety 
or avoiding side effects that can be effectively prevented.  The numerator is “patients with a 
bowel regimen initiated within 24 hours of an opioid, and in whom a bowel regimen is not 
contraindicated.”  The denominator is “adults ≥ 18 years of age, with admission for CHF (DRG 
127), Cancer (DRG 82, 203, 172, 274, 346, 10) HIV (DRG 489) OR respiratory (DRG 475, 483) 
AND length of stay > 4 days AND 2 prior admissions for any cause in preceding 12 months in 
the hospital, AND treated with narcotics.”  The treatment of constipation as a side effect of 
opioid administration was addressed in a recent systematic review.73  The review found that 25-
50% of cancer patients have constipation and that it is the most frequently occurring adverse 
effect of opioid use in advanced cancer; however, the review of 17 studies found none that 
directly compared patients treated with an opioid regimen with those not treated.  A similar 
potential measure has also undergone some field testing in a population that included cancer 
patients as part of the JCAHO-AMA-NCQA pain management performance measure 
development project.74  A mean of only 59% (median 59%, range 20-93%) of the charts 
reviewed in the UHC cohort met this criterion, and the distribution of the outcome appears 
broadly normal.  Eighty-three percent of cancer patients met the indicator.  No validity or 
reliability information is available for this indicator; more details on the testing of the 
measurement set are described in the UHC pain assessment measures.  This measure is intended 
for use across all types of cancer.  The measure set is not in current use. 
 
Indicator - Minimizing Radiotherapy Burden.  Cancer Care Ontario’s Program in Evidence-
Based Care reported a clinical practice guideline in 2003, Radiotherapy Fractionation for the 
Palliation of Uncomplicated Painful Bone Metastases, Practice Guideline Report #13-2.  This 
report includes an indicator relevant to the choice of radiotherapy regimen in patients with 
advanced cancer.75  The numerator is “patients receiving single dose therapy as a single 8Gy 
treatment, prescribed to the appropriate target volume.”  The denominator is “all adult patients 
with single or multiple radiographically confirmed bone metastases of any histology 
corresponding to painful areas in previously nonirradiated areas without pathologic fractures or 
spinal cord/cauda equina compression.”  It does not apply to the management of malignant 
primary bone tumor and is intended for patients receiving radiotherapy where the objective or 
intent is pain relief.  The report, which was based on a systematic review, also includes a number 
of qualifying statements.  The evidence was reviewed by a four-member group and then 
approved by a multidisciplinary group.  External review was obtained through a mailed survey of 
Ontario practitioners.  The indicator is based on 2 systematic reviews and 16 RCTs.  A meta-
analysis of eight RCTs, conducted as part of the guideline process, found no significant 
difference in response rate between single-fraction and fractionated radiotherapy.  There were no 
differences in quality of life (for the few studies where this was assessed) or side effects.  
Observed re-irradiation rates were higher with single-fraction than with multiple-fraction 
therapy, but details were not described.  A separate systematic review and meta-analysis76 
derived the same conclusions about pain, but concluded that the pathologic fracture rate was 
significantly higher for single-fraction than for multiple-fraction treatment.  The indicator is 
intended for use in a mixed cancer population, for palliative treatment.  This indicator is relevant 
to the efficiency of care.  The indicator is not known to be in current use. 
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Indicator - Effective Treatment for Painful Bony Metastasis.  Cancer Care Nova Scotia77 has 
proposed a set of quality indicators for palliative cancer care that includes one pain treatment 
indicator, adapted from a proposed QA tools indicator that was not accepted by the QA Tools 
expert panel and was not part of the final set.64  The numerator of this indicator is “patients who 
are offered one of the following within one week of the notation of pain: radiation therapy to the 
sites of pain, or radioactive strontium therapy.”  The denominator of this indicator is “patients 
with cancer metastatic to the bone and pain uncontrolled by opioids.”  Although there is 
excellent meta-analysis evidence of the efficacy of radiation therapy for bone pain,76 another 
meta-analysis found that the evidence supporting the efficacy of radioisotopes such as strontium 
was inconclusive,78 and we did not identify any evidence that supports the use of radiation 
therapy only for pain uncontrolled by opioids or that supports the timing of radiation therapy.  
Although this indicator was proposed, based on feedback from CCNS expert panels and 
available datasources, the indicator will not be field tested at the current time because 
“uncontrolled pain” could not be operationalized.  The indicator is intended for use in patients 
with metastatic breast cancer and addresses both effectiveness and timeliness.  The indicator may 
be limited by the lack of definition of “pain uncontrolled by opioids.”  The indicator set is 
proposed and is not in current use. 
 
Follow-up.  We identified four measures and one indicator relevant to the follow-up of cancer 
pain treatment.   
 
Measure - Timely Treatment of Pain in Hospice.  The NHPCO indicator set for hospice,54,63,79 
includes one outcome measure for pain.  The numerator is “the proportion of patients between 48 
and 120 hours after admission who report ‘yes’ when asked, ‘Was your pain brought to an 
acceptable level within 48 hours of your admission to the hospice program?’”  The denominator 
is “patients admitted to hospice who answer ‘yes’ when asked, ‘Are you uncomfortable because 
of pain?”  The measure does not apply to patients in nursing facilities, children, non-English-
speaking patients, or others who cannot self-report, because of concerns about measurement.  It 
assumes that all patients are assessed for pain on admission to hospice, and detailed information 
on how to administer the measure is available.63  The NHPCO chose to focus only on outcome 
measures, and considered and rejected alternative data collection methods for pain outcomes, 
including chart audits and retrospective surveys.  They also chose not to use proxy reports 
because of issues with reliability and validity.54  This concern, as well as the difficulty in 
assessing pain in the last days of life, led to the timing for the indicator at hospice admission.  A 
non-numerical dichotomous rating was chosen because of concerns about the validity of 
numerical ratings.  For construct validity, in pilot testing, more people said that they were 
“uncomfortable” because of their pain than said their pain was “unacceptable,” so the word 
“uncomfortable” was chosen as more sensitive for the denominator.54  Results from the use of 
this measure as part of the measurement set have also been published.79  For the 78 agencies that 
submitted data in 2002, the mean was 87% (median, 90%; 25th & 75th percentiles, 79% & 100%).  
These data suggest that there may be sufficient variation among hospices for this measure to be 
useful for comparing performance or quality improvement.  No other reliability or validity 
information is available.  A previous review of the palliative care literature found that general 
measures of satisfaction or subjective ratings of health care were subject to a strong ceiling 
effect, and items or measures that addressed specific processes tended to exhibit better 
variability.21  This measure is intended for use in hospice care.  It is limited by the inability of 
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many hospice patients to report their pain.  In addition, as an outcome measure, it would require 
evaluation for whether there needs to be risk adjustment for variation among organizations.  
Population characteristics such as the percentage of patients who report pain on admission, 
patients who cannot self-report, and patients with a history of drug abuse may significantly 
influence results.  It is currently being used by some hospice programs for internal quality 
assurance purposes and voluntary, confidential reporting to NHPCO. 
 
Measure - Effective Treatment of Pain in the ICU.  This measure, initially evaluated in 2002,61 
was modified for inclusion in the VHA TICU palliative care bundle in 2005 as an outcome 
measure for pain (Quality Indicator #6).68  The numerator is “the total number of 4-hour intervals 
(within the first 24 hours following ICU admission) for which the documented pain score was 
<3.”  The denominator is “the total number of 4-hour intervals (within the first 24 hours 
following ICU admission) with numerical pain values of 1 to 10, for patients with an ICU length 
of stay ≥ 24 hours.”  Exclusion criteria include intervals for which a patient was not physically 
available in the ICU (e.g. patient expired; was not yet admitted to the ICU; was 
discharged/transferred out of the ICU [for part of the day]; went into the operating room or off 
the unit for a procedure); intervals for which a pain score was not documented; intervals for 
which pain was assessed, but the patient was unresponsive (e.g., heavily sedated; comatose); and 
intervals for which pain was assessed, but without the use of an appropriate rating scale as 
defined above.  This measure is based upon a rapid-cycle quality-improvement intervention in 
two ICUs, including a surgical cancer ICU, demonstrating its responsiveness to changes in care 
processes (including the other VHA measure listed under assessment as well as whether house 
staff documented the pain score).  It is also based on the JCAHO Hospital Standards RI.1.2.9., 
PE.1.4; and the National Consensus Project for Quality Palliative Care Clinical Practice 
Guideline, 2.1. No additional reliability or validity information is available. 
This measure is intended for use in all ICU populations.  As with other pain outcome 
measures, variability in the quality of pain assessment may limit its use for comparing 
performance.  In the ICU population, as at the end of life or in nursing homes, many patients find 
it difficult or may be unable to verbalize a numerical pain score; depending on local standards of 
assessment, this measure may therefore be applicable to very different proportions of the 
population in different ICUs.  The measure also does not specify whether this figure should be a 
minimum, maximum, or average pain score.  It is currently being used as part of the VHA TICU 
initiative and is part of the VHA palliative care bundle, which will be initiated in September 
2005.   
 
Measure - Satisfaction With Pain Treatment.  This measure is part of the indicator set proposed 
by Cancer Care Ontario in 2005.57  The numerator of this measure is reported in three categories: 
“Patients where the response to the question “Do you think staff did everything they could to 
control your pain or discomfort?” was (1) yes, completely; (2) yes, somewhat; or (3) no.”  The 
denominator is “outpatient cancer patients reporting mild to severe pain.”  The source of this 
indicator is patient surveys.  Information on reliability/validity as an indicator is not available.  In 
a survey of  more than 5,000 cancer outpatients in 2004, 70% of patients answered “yes, 
completely,” 25% answered “yes, somewhat,” and only 5% answered “no.”  Variability by 
center was not reported, and all four provinces where the survey was done apparently had similar 
results.57  The low number of “no” answers is consistent with previous studies of satisfaction for 
pain, which have found that overall satisfaction reports may not reliably correlate with actual 
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pain scores and may be difficult to use because of ceiling effects.21  The indicator is intended for 
use in ambulatory/outpatient care.  It may be affected by recall bias (used for care in the previous 
six months), low response rate among palliative care patients, and a requirement for a minimum 
denominator of 300 patients per participating center.  It is currently being used in Ontario and 
three other Canadian provinces.  
 
Measure - Timely Treatment of Inpatient Pain.  The UHC Palliative Care Benchmarking 
Project,67 introduced in 2004, includes one outcome measure for pain.  The numerator is 
“persons with pain relief or reduction within 48 hours of admission to ≤ 3 on a 0-10 scale.”  The 
denominator is “adults ≥18 years of age, with admission for CHF (DRG 127), Cancer (DRG 82, 
203, 172, 274, 346, 10) HIV (DRG 489) OR respiratory (DRG 475, 483) AND length of stay > 4 
days, 2 prior admissions for any cause in preceding 12 months in the hospital, AND reported 
pain within the 1st 48 hours of admission.”  A mean of 76% (median 78%, range 46-92%) of the 
UHC cohort met this indicator.  Only 70% of cancer patients met the indicator.  There was 
moderate variability in this measure; although the range of performance was somewhat 
restricted, the distribution of results appeared to be relatively normal.  As with the other UHC 
measures, no individual reliability or validity information is available. It is not known to be in 
current use. 
 
Indicator - Effective Treatment of Pain.  The IOM Committee on Assessing Improvements in 
Cancer Care in Georgia’s (National Cancer Policy Board) 2005 indicator set proposed an 
indicator relevant to the follow-up of pain treatment.55  The numerator is “the number of cancer 
patients who report being in more than minor pain.”  The denominator is “the number of cancer 
patients who are not comatose.”  This indicator is based on the 2004 cancer pain guideline from 
the National Comprehensive Cancer Network (NCCN),80 the 1996 cancer pain guideline from 
the World Health Organization,81 the cancer pain position statement from the Oncology Nursing 
Society (ONS),82 and the American Pain Society Quality Improvement Guidelines for the 
treatment of acute pain and cancer pain.83  Evidence is based on the AHRQ evidence report on 
treatment of cancer pain7 and NIH Consensus State of the Science Statement on symptom 
management in cancer.84  
The indicator is intended for use for all cancer patients, across the continuum of care and all 
health care settings.  A validated pain scale that defines “minor pain” must be used in each health 
care setting, and the threshold should be reported along with the indicator.  Poor medical record 
documentation may lead to low prevalence estimates.  Potential benchmark sources are baseline 
patient surveys and medical records.  Evidence suggests that members of ethnic minority groups, 
women, and elderly patients may be less likely to be adequately treated for pain (Chapter 6, p. 
23).55  This indicator is newly proposed and information on use is not available. 
 
Potential Indicators and Measurement Gaps 
We identified a large number of potential indicators in the substantial guideline, quality 
improvement, and research literature that we reviewed.  Many of these guideline statements and 
potential indicators address specific management issues, such as the treatment of neuropathic 
pain, or more details on the indicators we have identified, such as more-comprehensive 
assessment for pain or pain outcomes.74  We highlight here eight potential indicators with 
relatively strong supporting evidence and/or expert consensus, highlighting critical issues not 
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addressed by the indicators and measures listed above, that may have potential for demonstrating 
variability in quality and improving patient outcomes, and applicable to cancer patients across 
the continuum and to diverse populations. 
 
Assessment   
 
Physician Documentation of Pain Assessment.  The numerator is “patients where a pain 
assessment is documented in the physician note,” and the denominator is “all patients with 
cancer.”  This potential indicator was used as a part of the pain continuous quality improvement 
study that led to the VHA pain measures61 and is supported by evidence that pain assessment by 
nurses or aides often does not lead to documentation of pain by the physician.  Improvements in 
pain assessment by non-physician staff may not lead to improved outcomes because the 
physician may not attend to the report of pain.85  Another consideration with pain assessment 
indicators is the extent to which they might address aspects of assessment including specific 
symptom attributes (e.g., timing, duration, and functional impairment) and specific etiologies. 
 
Disparities in Pain Assessment.  The numerator is “non-white patients with cancer who are 
assessed for pain,” and the denominator is “all patients with cancer who are assessed for pain.”  
Ensuring that pain assessment is equitable across ethnic groups is important because large 
studies have demonstrated that members of minority groups with cancer have higher rates of 
inadequate pain assessment and treatment than others.86,87  A recent nonsystematic review of this 
topic found that this disparity persists for both assessment and treatment, across multiple settings 
and types of pain.88  Whenever possible, assessment of disparity by ethnicity should also include 
assessment of other contributing factors, such as socioeconomic status and access to care, since 
these are often the primary cause of perceived disparities by race. 
 
Assessment in Patients Who Have Difficulty Verbalizing Their Pain.  The numerator of this 
potential indicator is “patients who have difficulty verbalizing their pain but who are assessed for 
pain,“ and the denominator is “cancer patients who have difficulty verbalizing their pain.”  This 
potential indicator is important because many of the indicators and measures we identified 
exclude patients who are unable to verbalize their pain.  Many cancer patients at high risk for 
pain would therefore be excluded from many of these measures, including infants and small 
children, many seriously ill or perioperative cancer patients, cancer patients with severe 
dementia, and many patients in the last days of life, where a decreased level of consciousness is 
very common.  In addition, patients with some degree of cognitive impairment or sedation may 
also be excluded from the denominator even though many of these patients are able to report 
their pain.40  Variable exclusion of these patients limits the usefulness of pain assessment 
measures for comparisons between facilities or over time.  Recent systematic reviews have 
summarized the variety of tools available for assessing pain in older adults with cognitive 
impairment89 and in infants.90  In addition, some evidence exists that cognitively impaired adults 
receive less pain medication than those who are cognitively intact and that untreated pain may 
lead to higher rates of adverse outcomes, such as delirium.91 
 
Assessment for Depression in Patients With Pain.  The numerator is “patients assessed for 
depression,” and the denominator is “all cancer patients with pain.”  This potential indicator is 
supported by evidence that cancer patients with pain are more likely to be depressed than cancer 
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patients without pain.92  In addition, there is substantial descriptive evidence that the symptoms 
of depression and pain often occur together. 10 
 
Treatment   
 
Educating Patients About Pain Management.  The numerator is “patients who are educated about 
pain management,” and the denominator is “cancer patients with pain.”  This guidance is 
included in many cancer pain guidelines, some of which also include education of caregivers.  A 
related potential outcome measure, that patients should be adequately informed and 
knowledgeable about pain management, is included in the 2005 American Pain Society 
Recommendations for Improving the Quality of Acute and Cancer Pain Management,74 based on 
an expert review of the measurement tools used in 20 quality improvement studies in pain 
management.93  A systematic review of educational interventions for patients and family 
caregivers found eight studies, two of which were randomized, controlled trials; both of these 
and all of the nonrandomized studies where pain management education was measured found a 
significant impact of education on pain.94 
 
Use of Opioids for Severe, Persistent Pain.  The numerator of this potential indicator is “patients 
who are treated with opioids,” and the denominator is “cancer patients with severe, persistent 
pain.”  This potential indicator is supported by a number of clinical practice guidelines for pain, 
including the World Health Organization81 and NCCN.80  One of the pilot measures that was 
field-tested as part of the JCAHO-AMA-NCQA initiative also relates to this issue,74 but it needs 
further development before use as a measure.  A randomized trial in advanced cancer patients 
comparing the use of strong opioids to the WHO stepped-care approach where patients are 
started on non-opioids, then given weak opioid medications, found that patients treated with 
opioids had better pain outcomes.95 
 
Use of Long-Acting Pain Medications.  The numerator is “all adults who are prescribed long-
acting opioids,” and the denominator is “all adults with cancer who have persistent pain and are 
prescribed opioids.”  This expert guidance is in numerous pain guidelines, including the Agency 
for Health Care Policy and Research cancer pain guideline96 and  the American Geriatrics 
Society cancer pain guideline for older adults.97  A systematic review of the cancer pain literature 
found only two relevant trials, which showed no difference between long-acting and around-the-
clock short-acting formulations.7  However, the expert consultants for the Cancer Symptom 
Management State-of-the-Science Statement84 also included this recommendation because 
improved adherence with long-acting drugs in clinical practice may improve outcomes.  
 
Procedure-Related Pain in Children.  The numerator is “all children who receive appropriate 
preparation and/or anesthesia” and the denominator is “all children with cancer receiving painful 
procedures.”  We chose to highlight this potential indicator because it is emphasized in 
guidelines for cancer pain in children but is typically not mentioned in guidelines for adults.  The 
World Health Organization34 describes this area as important because the pain from procedures 
is often worse than that from the cancer and because inadequate pain control may lead to anxiety, 
reduced adherence, and poorer relationships with health care providers.   
In addition, many pharmacological and nonpharmacological approaches, including the 
presence of parents whenever possible, local anesthetics, and opioids when needed, can reduce 
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procedural pain.  An assessment tool for postoperative pain management in children has been 
developed and psychometrically tested in children as young as eight years old.98  Many 
randomized, controlled trials have demonstrated that use of pharmacologic measures such as 
topical anesthetics not only reduces pain, but reduces procedure time and improves procedure 
success rates.99  Such an indicator might also be reasonable to consider for adults. 
 
Dyspnea 
Introduction 
We failed to identify any quality measures that were developed specifically for dyspnea in 
cancer.  Please refer to the Evidence Table in Appendix F2*.  Two measures were developed and 
tested as part of the UHC Project on palliative care for dyspnea assessment and dyspnea 
reduction/relief within 48 hours of hospital admission.67  The UHC indicators were used in an 
adult population with cancers that included lung, gastrointestinal, breast, male reproductive, and 
nervous system neoplasms – approximately 25% of the UHC cohort had cancer.  
We identified two indicators for dyspnea applicable to the cancer population derived from 
the Assessing Care of Vulnerable Elders (ACOVE) project59 and one indicator developed for 
COPD from the RAND QA Tools project that is applicable to patients with cancer and 
hypoxia.65 
 
Measures and Indicators 
Assessment.  We identified one measure and zero indicators relevant to dyspnea assessment. 
 
Measure - Regular Assessment of Dyspnea.   The University Health System Consortium (UHC) 
Palliative Care Benchmarking Project used a performance measure across an alliance of 
academic health centers in the United States in 35 participating hospitals for dyspnea assessment 
within 48 hours of admission.67  The numerator is “persons with dyspnea assessment within 48 
hours of admission.”  The specific criteria for how dyspnea assessment was operationalized were 
not described in available reports (other than the use of a 10-point scale).  The denominator is 
“adults 18 years of age and older, with admission for congestive heart failure (DRG 127), cancer 
(DRG 82, 203, 172, 274, 346, 10), HIV (DRG 489), or respiratory illness (DRG 475, 483) and a 
length of stay more than 4 days and 2 prior hospital admissions for any cause in the preceding 12 
months.”  This denominator was developed by an expert panel to represent a potential palliative 
care population in hospitals.  No reliability or validity information is available; however, the 
benchmarking project found that a combination of use of all of the UHC measures in a 
“palliative care bundle” was associated with shorter patient length of stay.  In addition, several 
elements of the bundle could be used to identify hospitals with “best practices” for palliative 
care.  Scores from the bundle were instrumental in achieving advances in palliative care at 
several hospitals, including justifying at least one new palliative care program.  
                                                 
* Appendixes cited in this report are provided electronically at  
http://www.ahrq.gov/downloads/pub/evidence/pdf/eolcanqm/eolcanqm.pdf 
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The dyspnea assessment measure is intended for use as a tool for comparing performance in 
all hospitals.  The data for this measure come from billing, administrative, and clinical databases 
combined in the UHC data set.  The UHC report indicates that a mean of 91% (median 95%, 
range 53-100%) of patients was assessed for dyspnea within 48 hours with the average rate for 
cancer being 89.9%.  The measure criterion appears broad and does not include an element of 
timeliness (within 48 hours of admission may be too long for dyspnea assessment to occur).  
Further details about operationalization and details on psychometric testing are needed.  The 
measure is not known to be in use.  
Treatment.  We identified zero measures and three indicators relevant to dyspnea treatment. 
 
Indicator - Effective Dyspnea Treatment in Expected Dying When Forgoing Ventilator.  ACOVE 
describes a set of quality indicators for adults age 65 years and older in 2001.59  The numerator is 
“whether or not the patient received or had an order for an opioid, benzodiazepine, or barbiturate 
infusion to reduce dyspnea and the chart documented whether the patient has dyspnea.”  The 
denominator is “all non-comatose vulnerable elders who are not expected to survive or those for 
whom a mechanical ventilator is withdrawn or intubation is withheld.”  The indicator is designed 
to be evaluated by retrospective chart review and is most applicable to hospitalized patients; 
however, the indicator could be applied to any setting where ventilator withdrawal or 
withholding could occur.  The withdrawal and withholding for mechanical ventilation indicator 
is supported by documentation of variation and inadequate management of dyspnea,100,101 best-
practice recommendations,102,103 and statements from professional societies.59,104,105  
 
Indicator - Regular Treatment and Follow-up of Dyspnea in Expected Dying.  A second ACOVE 
indicator addresses the follow-up of dyspnea treatment at the end of life.59  The numerator is 
“whether or not the medical record documents how dyspnea was treated and followed up.”  The 
denominator is “all vulnerable elders who had dyspnea in the last seven days of life and died 
expected deaths.”  The indicator is designed to be evaluated by retrospective chart review and is 
applicable to any setting of care.  This indicator was based on the premise that symptoms such as 
dyspnea should be a focus of end-of-life care and consensus calling for improvement in the care 
and management of dyspnea.  In supporting documentation, the developers stated that dyspnea 
can be effectively treated with oxygen and pharmacologic agents.59  Like the withholding and 
withdrawal of ventilation indicator, this indicator was not evaluable in the community-based 
study of ACOVE measures.72  
 
Indicator - Treatment of Dyspnea Caused by Hypoxia.  QA Tools did not include indicators for 
dyspnea within its multiple cancer sets.64-66,106  However, within the category of chronic 
obstructive pulmonary disease (COPD), one indicator for hypoxia is applicable to cancer patients 
with dyspnea caused by hypoxia.65,66,107  The numerator is “whether home oxygen therapy was 
used.”  The denominator is “all patients with baseline room air oxygen saturation < 88% at rest.”  
The original indicator in the QA Tools project for patients with COPD read as follows: “COPD 
patients should receive home oxygen if their baseline room air oxygen saturation is <88% at rest 
(not during an exacerbation).”65  This indicator was based on multiple studies demonstrating 
benefit to both survival in hypoxic patients and subjective improvement of dyspnea symptoms 
through oxygen therapy.107  More recent data supporting use of oxygen for symptomatic 
improvement in hypoxic patients exists, including a recent review by a working group of the 
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scientific committee of the Association of Palliative Medicine.108  This review included primarily 
patients with COPD and demonstrated more consistent symptom improvement with oxygen for 
those with hypoxia. 
The indicator is designed to be evaluated by retrospective chart review.  This indicator was 
used in the COPD population for outpatient care during routine clinical interactions that did not 
occur during an exacerbation, however it may be pertinent to other settings such as physician 
offices, home health care, and home hospice.  The indicator was operationalized by looking at 
the lowest oxygen saturation at least two weeks before the close of the study and scored as 
meeting the criterion if an order, prescription, or discharge order for home oxygen was identified 
within two weeks of a saturation value less than 88% or a note that the patient was already on 
home oxygen that was not discontinued.  Reliability was based on a 4% duplicate abstraction 
from the medical record and demonstrated a kappa of 0.83 for agreement on the condition 
(COPD), a kappa of 0.76 for agreement on eligibility for the indicator, and a kappa of 0.80 for 
scoring.  To become a measure for cancer care, the numerator and denominator of this indicator 
would need to be explicitly operationalized and tested in cancer populations.  
Follow-up.  We found one measure and zero indicators related to follow-up for dyspnea.   
 
Measure - Timely Treatment of Inpatient Dyspnea.  The UHC Palliative Care Benchmarking 
Project used a second performance measure regarding dyspnea relief or reduction of dyspnea.67  
The numerator is “persons with dyspnea relief or reduction within 48 hours of admission.”  
Significant reduction was operationalized as a 3-or-more-point reduction in dyspnea on a 10-
point scale.  The denominator is “adults 18 years of age and older, with admission for congestive 
heart failure (DRG 127), cancer (DRG 82, 203, 172, 274, 346, 10), HIV (DRG 489), or 
respiratory illness (DRG 475, 483) and a length of stay more than 4 days and 2 prior admissions 
for any cause in the preceding 12 months and reported dyspnea within the first 48 hours of 
admission.”  No reliability or validity information is available.  Information is the same as for the 
other UHC dyspnea indicator.  The UHC report indicates that 62% of patients assessed had 
dyspnea within 48 hours after admission and that of these, 77% overall and 77% of cancer 
patients had relief or reduction of these symptoms.  There was substantial variation in results 
with a range of 37.5% to 96.6% criteria met across the 35 hospitals participating in the 
benchmarking project.  Further details about operationalization and details on psychometric 
testing are lacking. The indicator set is not known to be in use.  
 
Potential Indicators and Measurement Gaps 
Assessment.  We identified a large number of potential indicators in the substantial guideline, 
quality improvement, and research literature that we reviewed.  We highlight here six potential 
indicators with relatively strong supporting evidence and/or expert consensus, highlighting 
critical issues not addressed by the indicators and measures listed above.  These indicators have 
potential for demonstrating variability in quality and improving patient outcomes, and are 
applicable to cancer patients across the continuum and to diverse populations. 
Although guidelines and evidence support assessment of dyspnea,15,18,21,109 future research is 
needed to understand the most appropriate approach and instruments for assessment (i.e., 
provider observation, single-item symptom measures, or multi-item self-report effects of 
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dyspnea) in particular settings and diseasesi as well as operating characteristics as quality 
indicators.15,16,109  Subsequent research is indicated for indicators in dyspnea assessment.  In the 
interim, it would be reasonable to develop and use a general indicator that at least some form of 
dyspnea symptom assessment was performed for all cancer patients.  
 
Assessment for Treatable Causes of Dyspnea.  The numerator is “all patients who have been 
assessed for treatable causes of dyspnea.”  The denominator is “all cancer patients with 
dyspnea.”  We identified four reports on the assessment of underlying causes of dyspnea.14,109-111  
The American College of Chest Physicians (ACCP) and American Thoracic Society (ATS) have 
recommended specific assessment for potentially correctable causes of dyspnea in this 
setting.109,110  A prospective observational study demonstrated potentially correctable causes for 
dyspnea such as hypoxia (40%), anemia (20%), and bronchospasm (52%).14  Another report 
supports the use of spirometry to detect any airway obstruction in patients with dyspnea.111  A 
reasonable potential indicator would be to use medical record review to document that 
correctable conditions were sought in evaluation of dyspnea in cancer patients.  Some 
consideration of time windows for recent evaluation would be important in operationalizing this 
as a standard.  
 
Treatment.  We identified eight potential indicators related to the treatment of dyspnea, from 
seven reports.110,108,109,112-115  As with the general research gap in assessment of dyspnea, the 
operationalization of how much and when to assess for response to therapy requires future 
research and refinement of quality indicators.  
 
Treatment for Malignant Pleural Effusions.  The numerator is “patients who have had 
thoracentesis and appropriate subsequent therapy (pleurodesis or chemotherapy) as indicated.”  
The denominator is “cancer patients with dyspnea and malignant pleural effusions.”  Evidence-
based guidance from the ACCP Lung Cancer Guidelines, published by the American College of 
Chest Physicians includes (1) Patients with malignant pleural effusions that cause dyspnea 
initially should be drained by thoracentesis; (2) Patients with non-small cell lung cancer and 
better performance status and recurrent malignant pleural effusions, and whose lungs re-expand 
with initial thoracentesis or thoracoscopy, should be followed up by pleurodesis;110 and (3) 
Patients with small cell lung cancer receive systemic chemotherapy when malignant effusions 
are present to relieve the symptoms of dyspnea.110  Potential indicators for these specific 
conditions could be developed and tested.  This guidance is clinically applicable to managing 
dyspnea in other cancers that cause malignant pleural effusions (breast, gastrointestinal, prostate, 
melanoma, others). 
 
Bronchoscopic Therapy.  The numerator is “patients who are offered, or who have, 
bronchoscopic therapy.”  The denominator is “cancer patients with central airways obstruction.”  
                                                 
i Measures may include the Lung Cancer Symptom Scale, Oxygen Cost Diagram, Baseline Dyspnea Index, 
Transition Dyspnea Index, University of California Shortness of Breath Questionnaire, Borg or Modified Borg 
Dyspnea Scale, Visual Analogue Scale, Chronic Respiratory Disease Questionnaire, Saint George Respiratory 
Questionnaire, Pulmonary Functional Status Scale, Breathing Problems Questionnaire, Modified Medical Research 
Council [Dyspnea Scale], American Thoracic Shortness of Breath Scale, and many other candidates including single 
item symptom scales, severity of symptom tools, generic health-related quality of life instruments, dyspnea related 
quality of life instruments, generic palliative care and satisfaction measures, symptom specific treatment response 
measures, and quality of dying measures.15, 16, 109 
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The ACCP110 also present evidence based on a review of the literature that bronchoscopic 
therapy can reduce dyspnea in the presence of central airway obstruction, recommending that 
patients with central airway obstruction should have bronchoscopy and that in patients with 
central airway obstruction, rapid relief of dyspnea can be accomplished by removal of 
intraluminal tumor and/or by inserting a stent.  A potential indicator may be that if a patient has 
cancer and central airway obstruction, then bronchoscopy and bronchoscopic therapy should be 
considered.  This potential indicator is most applicable to lung cancer. 
 
Patient Education and Non-Pharmacologic Interventions.  The numerator is “patients who have 
received education about their dyspnea.”  The denominator is “all cancer patients with dyspnea.”  
Kvale and colleagues110 recommended that all lung cancer patients with dyspnea receive non-
pharmacologic, non-interventional treatments including patient education to reduce the dyspnea 
symptoms.  Patient education can encompass breathing control education, relaxation techniques, 
and psychosocial support.  The evidence for this potential indicator was poor based on their 
review of the literature, and these interventions were felt to have poor supporting evidence but 
moderate net benefit due to the lack of side effects.  This indicator could be broadly formulated 
based on clinical practice to all forms of malignancy with dyspnea.  
 
Palliative Radiation and Chemotherapy.113,114  The numerator is “patients who are offered or 
have received appropriate palliative chemotherapy or palliative radiation therapy.”  The 
denominator is “all patients with particular malignancies.”  The Lung Cancer Guidelines 
published by the American College of Chest Physicians114 present evidence that chemotherapy 
can reduce dyspnea symptoms among patients with Stage IV non-small cell lung cancer.  
Socinski et al., identified seven studies that explored the palliation of symptoms by 
chemotherapy; four of the seven reduced dyspnea symptoms in over half of the patients 
enrolled.114  Palliative chemotherapy should be considered for patients who are deemed suitable 
for treatment, including other malignancies.  
The American Society of Clinical Oncology published a guideline for the treatment of 
unresectable non-small cell lung cancer113 in 2003 in which they cite research that radiotherapy 
can provide relief from dyspnea symptoms.  However, the evidence cited in this report included 
only nonrandomized comparisons to conventional therapy.  This indicator may likely be 
operationalized only in retrospective medical record review with fulfillment of criteria as 
consideration for therapy. 
 
General Approaches.  The numerator is “patients who have had oxygen, bronchodilators, 
corticosteroids, opioids, or antibiotics attempted.  The denominator is “patients with cancer and 
dyspnea (and possibly co-morbid conditions such as COPD).”110  The evidence for the 
effectiveness of particular interventions is modest, but the net benefit may be moderate.110  The 
ATS endorsed oxygen therapy, opioids, anxiolytics, and bronchodilator trials to diminish 
dyspnea symptoms among terminally ill patients with lung disease.109  Several systematic 
reviews support the efficacy of opioids and oxygen in patients with advanced illness including 
cancer.21,112,116  A reasonable criterion may be to consider whether therapy was considered, 
offered, or tried.  The operationalization of this indicator would require further specification 
based on underlying disease, the physiologic mechanism of dyspnea, and particular therapeutic 
interventions (for example, specifying concomitant obstructive lung disease when evaluating use 
of bronchodilators). 
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Depression 
Introduction 
For the condition of depression, we searched for measures and indicators restricted to the 
condition of cancer.  We identified one measure and three indicators that were relevant.  Please 
refer to the Evidence Table in Appendix F3*.  
The UHC Palliative Benchmarking Project has evaluated one indicator related to formal 
psychosocial assessment in mixed hospitalized populations that include cancer patients.67   
ACOVE’s end-of-life indicators addressed spiritual assessment prior to death, which we 
considered broadly applicable.59  ACOVE also included measures and indicators for depression, 
as did QA Tools.65,72  Some of these may be regarded as relevant, although we included only two 
additional ACOVE indicators, because one explicitly addressed depression in the elderly in the 
context of a new cancer diagnosis, and the other addressed somatic symptoms in vulnerable 
elders that overlap with presenting symptoms of cancer.  QA Tools relied on AHCPR depression 
guidelines that emphasized cancer as an associated risk factor, although none of its indicators 
address this situation directly.  
 
Measures and Indicators 
Assessment.  We identified one measure and one indicator relevant to cancer and depression 
assessment. 
 
Measure - Regular Assessment for Psychosocial Well-Being.  The UHC Palliative Care 
Benchmarking Project67 included one measure relevant to depression assessment.  The numerator 
is “persons with a formal psychosocial assessment (usually an assessment by a social worker) up 
to one year prior to admission during a previous admission OR within four days of the index 
admission.”  The denominator is “adults ≥18 years of age, with admission for CHF (DRG 127), 
Cancer (DRG 82, 203, 172, 274, 346, 10) HIV (DRG 489) OR respiratory (DRG 475, 483) AND 
length of stay > 4 days AND 2 prior admissions for any cause in preceding 12 months.”  This 
denominator was developed by an expert panel to represent a potential palliative care population 
in hospitals.  Only a mean of 25% (median 17%, range 0-95%) of the UHC sample met the 
criteria for this indicator.  This indicator identified four high performing facilities where more 
than 60% of patients had been assessed in the prior year.  No reliability or validity information is 
available; however, the benchmarking project found that a combination of use of all of the UHC 
measures in a “palliative care bundle” was associated with lower patient length of stay.  In 
addition, several elements of the bundle could be used to identify hospitals with “best practices” 
for palliative care.  Scores from the bundle were instrumental in achieving advances in palliative 
care at several hospitals, including justifying at least one new palliative care program.  Finally, 
results for the “bundle” varied significantly among the 35 hospitals participating in the project.  
It is intended for use as a tool for comparing performance in all hospitals.  The measure is not 
known to be in current use.  
                                                 
* Appendixes cited in this report are provided electronically at  
http://www.ahrq.gov/downloads/pub/evidence/pdf/eolcanqm/eolcanqm.pdf 
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Indicator - Regular Spiritual Assessment in Expected Dying.  ACOVE identified one indicator 
relevant to depression assessment.  The numerator is “vulnerable elders with a documentation of 
a spiritual assessment in the medical record.”  The denominator is “vulnerable elders who were 
conscious during the last three days of life and who died an expected death.”  Although eight 
items from the ACOVE end-of-life set were evaluated for reliability and validity72 as part of the 
ACOVE project, this indicator was not included in the evaluation.  The denominator may be 
difficult to define, since “expected death” requires explicit medical record documentation more 
than one day before death that the patient is expected to die.  This measure is intended for use in 
all vulnerable elders.  An expert panel accepted a modified version of this indicator as part of a 
revised set for nursing homes.60  The nursing home indicator requires a denominator of “nursing 
home residents who died expected deaths and were conscious at all during the last seven days of 
life.”  The numerator for the adapted measure requires that pain, spirituality, and emotional 
distress all have been addressed.  Neither indicator is in current use. 
 
Treatment.  We identified two measures relevant to depression treatment among cancer patients. 
 
Measure - Regular Assessment or Treatment of Depression in Newly Diagnosed Cancer.  
ACOVE identified two indicators relevant to both depression assessment and treatment.117,60  For 
the first indicator, the numerator is “patients asked about or treated for depression, or referred to 
a mental health professional within two months of the diagnosis of a condition.”  The 
denominator includes “all persons diagnosed with stroke, myocardial infarction, dementia, 
malignancy (excluding skin cancer), chronic pain, alcohol or substance abuse or dependence, 
anxiety disorder, or personality disorder.”  These conditions were accepted for the indicator on 
the basis of their association with incident or prevalent depression.  Although 13 indicators from 
the ACOVE depression set were evaluated for reliability and validity in a community 
population,72 this indicator was not included, although it was operationalized for cancer patients.  
No information on reliability and validity is available for this indicator.  The indicator is not in 
use.  
A second ACOVE measure (routine assessment or treatment of depression in symptomatic 
patients) relevant to depression assessment and treatment addressed both affective and somatic 
symptoms among vulnerable elders.117,60  The numerator is “patients asked about or treated for 
depression, or referred to a mental health professional within two weeks of presentation.”  The 
denominator is “vulnerable elders with new onset of one of the following symptoms-sad mood, 
feeling down, insomnia or difficulties with sleep, apathy or loss of interest in pleasurable 
activities, reports of memory loss, unexplained weight loss of more than 5% of body weight in 
the past month or 10% over one year, or unexplained fatigue or low energy.”  This indicator was 
included in the 13 indicators from the ACOVE depression set, although ACOVE field evaluation 
excluded patients undergoing active cancer treatment.  Only 26 of the 34 quality indicators 
triggered were passed.72  No information on reliability or validity is available. This indicator is 
not in use.  
 
Follow-up.  We identified zero measures and zero indicators relevant to the follow-up of 
depression treatment in cancer patients. 
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Potential Indicators and Measurement Gaps 
Within the literature that we identified, only the ACOVE set provided measures and 
indicators for depression among a population that did not include cancer patients, per se or was 
not limited to cancer patients; thus we considered these as potential indicators.  Quite a number 
of other measurement sets address depression care in general.  ACOVE provides only a general 
example of that class of non-cancer depression indicators that might be considered.  However, 
many of these indicators may not be appropriate for hospice or similar settings, since some of 
them address issues such as follow-up within months of depression diagnosis, and life 
expectancy in such settings may be very short.  Nevertheless, within ACOVE, we identified the 
following additional potential indicators for cancer care. 
 
Assessment.  We identified three potential indicators relating to initial depression assessment.  
 
Appropriate Diagnosis.  Two ACOVE indicators are based on the assumption that depression 
diagnosis should document the presence or absence of major affective symptoms and suicidality.  
Both of these indicators use as a denominator population “all vulnerable elders with a new 
diagnosis of depression.”  The first addresses the need to distinguish between major depression 
and other affective syndromes and uses as a numerator “patients where the medical record 
documents at least three of nine DSM-IV target symptoms within the first month of diagnosis.”  
The second indicator addresses the need to evaluate suicidality and uses as a numerator “patients 
where the medical record on day of diagnosis documents the presence or absence of suicidal 
ideation and psychosis.”  These indicators are based on the findings that only patients with major 
depression are known to respond to medication117 and that evidence of psychosis and suicidality 
should be considered in the approach to treatment.117  The documentation of depressive 
symptoms may differ somewhat for cancer patients, especially late stage patients where fatigue 
and other manifestations of illness overlap with the “vegetative symptoms.”  
 
Evaluating Suicidality.  One ACOVE indicator addresses the need to evaluate and treat 
suicidality appropriately when it is present in a patient with newly diagnosed depression.  The 
numerator for this indicator is “patients where the medical record documents that the person has 
no immediate plans for suicide or that the patient was referred for evaluation for psychiatric 
hospitalization.”  Expert opinion supports this approach even though ethical considerations make 
studies of interventions difficult.  Suicide is a disproportionate concern among the elderly in 
general, and cancer patients in particular.117 
 
Treatment.  We identified 2 potential indicators that were related to initial treatment. 
 
Use of the Most Appropriate Anti-Depressants.  Two ACOVE indicators address the appropriate 
use of medication in patients newly treated for depression.  The denominator for both of these 
indicators is “vulnerable elders being treated for depression with antidepressants.”  The 
numerator for the first potential indicator is “patients where the following medications are not 
used as first or second-line therapy: tertiary amine tricyclics, monoamine oxidase inhibitors 
(unless atypical depression is present), benzodiazepines, or stimulants (except 
methylphenidate).”  This indicator is based on the fact that for the most part, antidepressants 
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have equal efficacy, although side-effect profiles differ and are generally worse for older 
antidepressants highlighted by the indicator.117  
 
Dose Titration.  The denominator for this indicator is “vulnerable elders being treated for 
depression with antidepressants.”  The numerator for the second potential indicator is “patients 
with antidepressants started at appropriate doses, and with an appropriate titration schedule to a 
therapeutic dose, therapeutic blood level, or remission of symptoms by 12 weeks.”  Many studies 
demonstrate that older patients do not receive appropriate follow-up including therapeutic doses 
of antidepressant medications.117  
 
Follow-up.  We identified four potential indicators that were related to follow-up of initial 
treatment.  
 
Addressing Non-Responders to Initial Treatment.  The numerator for this potential indicator is 
“patients with antidepressant treatment, psychotherapy, or electroconvulsive therapy (ECT) 
offered within two weeks after depression diagnosis unless there is documentation within that 
period that the patient has improved, or unless the patient has substance abuse or dependence, in 
which case treatment may wait until eight weeks after the patient is in a drug or alcohol free 
state.”  The denominator is “vulnerable elders with a new diagnosis of depression.”  This 
indicator addresses the fact that psychotherapy may be the initial treatment attempted in 
depression, and that although the time-course of response is unclear, other treatments should be 
started within weeks of diagnosis if it is ineffective.117 
 
Addressing Partial Responders to Treatment.  Two ACOVE indicators addressed the appropriate 
care for patients who were only partial responders to initial pharmacotherapy at 6 and 12 weeks.  
The denominators for those potential indicators are “vulnerable elders who have only had a 
partial response to therapy (at each time period).”  For the first indicator that addresses week-6 
nonresponders, the numerator is “patients with one of the following treatment options initiated 
by the eighth week of care: medication dose should be optimized or the patient should be 
referred to a psychiatrist (if initial treatment was medication); or medication should be initiated 
or referral to a psychiatrist should be offered (if initial treatment was psychotherapy alone).”  
The second indicator addresses partial responses at 12 weeks.  The numerator for this indicator is 
“patients with one of the following options instituted by the 16th week of treatment: switch to a 
different medication class or add a second medication to the first (if initial treatment includes 
medication); add psychotherapy (if the initial treatment was medication); try medication (if 
initial treatment was psychotherapy without medication); consider ECT; or refer to a 
psychiatrist.” 
 
Maintaining Effective Anti-Depressant Care.  This potential indicator addresses the need for 
maintenance therapy.  The denominator is “vulnerable elders who have responded successfully 
to antidepressant medication treatment.”  The numerator is “patients continued on the drug at the 
same dose for at least six months, and making at least one clinician contact (office visit or phone) 
during that period.”  This potential indicator acknowledges uncertainty in the exact amount of 
time that therapy should be continued in responders but upholds a lower limit of six months.117 
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Advance Care Planning 
Introduction 
The review of literature in the area of advance care planning was not limited only to cancer.  
We identified a total of 30 indicators concerning the identification and documentation in the 
patient’s medical record of advance directives, designation of a proxy decisionmaker, 
preferences for care in cognitively impaired elderly, referral to hospice, and utilization-based 
indicators of high intensity care.  Please refer to the Evidence Table in Appendix F4*.  We 
included utilization indicators because much of the literature on advance care planning has 
focused on avoiding (e.g., resuscitation) or facilitating (e.g., hospice referral) particular treatment 
or utilization outcomes.  However, we acknowledge that such indicators are limited as patient-
centered metrics and may inadequately account for patient preferences.  Furthermore, measures 
of particular types of utilization (e.g., hospitalization) may also reflect structural factors or the 
adequacy of alternative services.  For that reason, other investigators might have made a 
reasonable decision to exclude such outcomes from consideration, although we included them 
for completeness.  The indicators tended to overlap significantly and, where there was overlap, 
the primary differences were in care setting (e.g., ICU vs. nursing home, nursing home vs. 
hospital)68 or populations (e.g., dementia vs. incapacitated patients).118  In addition, the literature 
on advance directive/advance care planning overlaps with the literature on good end-of-
life/palliative care standards.  Where appropriate, these overlapping indicators will be discussed 
together.  Some items that did not clearly address “assessment,” “application,” or “follow-up” 
but crossed all domains are addressed separately.  Finally, indicators may identify potential 
standards for hospital, system,67 or regional55,119,120 performance. 
 
Measures and Indicators 
Assessment.  We identified eight measures and four indicators relevant to advance care planning 
assessment. 
 
Measure - Regular Identification of a Surrogate in Outpatient Setting.  ACOVE’s end-of-life 
indicators included one measure addressing the identification of a surrogate decisionmaker 
among outpatients.59,72  The numerator is “the number of vulnerable elderly patients with 
medical record documentation of their surrogate decisionmaker’s name and contact information, 
or of a discussion with the patient of who would be surrogate, or documentation of a search for a 
surrogate, or an indication that there is no identified surrogate.”  The denominator is “all 
vulnerable elderly outpatients.”  No clinical trials or observational studies have examined this 
issue, yet documentation is an important tool for clinician access to an incapacitated patient’s 
decisionmaker,21,121 and many consensus statements promote designation of a surrogate 
decisionmaker (e.g., AGS Ethics Committee, 1995).  One prospective study of physicians 
discussing advance directives with patients revealed that the physicians recognized the correct 
surrogate decisionmaker 89% of the time after such a discussion.122  Only 4% of 370 eligible 
                                                 
* Appendixes cited in this report are provided electronically at  
http://www.ahrq.gov/downloads/pub/evidence/pdf/eolcanqm/eolcanqm.pdf 
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charts in the 420-person ACOVE community-based sample passed this indicator.72  No 
reliability or validity information is available for the individual measure.  The measure is not in 
use. 
 
Measure - Regular Identification of a Surrogate Among Hospital Admissions With Impaired 
Cognitionii.  One ACOVE measure addresses surrogacy among patients admitted to the 
hospital.59,72  The numerator is “the number of vulnerable elders (among those with the 
denominator conditions) who have chart documentation within 48 hours of either an advance 
directive indicating the patient’s surrogate decisionmaker, a discussion about who would be a 
surrogate decision maker or a discussion about a search for a surrogate, or an indication that 
there is no identified surrogate.”  The denominator is “all vulnerable elders with dementia, coma, 
or altered mental status admitted to a hospital who survive 48 hours.”  This indicator has 
implications for cancer patients who may have temporary (e.g., delirium) or durable cognitive 
impairment.  Research has shown that the majority of patients admitted to the hospital have 
neither named a surrogate decision maker nor expressed their treatment preferences in a written 
document.123  However, observational data suggest that physician understanding of patient 
resuscitation preference (a component of advance directives) is associated with a better match 
between those preferences and resuscitation attempts and is associated with less end-of-life 
resource use.124-126  Only 25% of 20 eligible charts in ACOVE’s 420-person community-based 
sample passed this indicator.72  No reliability or validity data are available on this individual 
item. The measure is not in use. 
 
Measure - Regular Assessment of Preferences Among Inpatients With Dementia.  One ACOVE 
measure addresses documentation of preferences among inpatients with severe dementia.59,72  
The numerator is “the number of severely demented elders with documentation in their medical 
record that the patient’s prior preferences for care have been considered or that these preferences 
could not be elicited or are unknown.”  The denominator is “all vulnerable elderly patients with 
severe dementia admitted to the hospital who survive 48 hours.”  This indicator has implications 
for cancer patients who may develop cognitive impairment associated with their cancer (e.g., 
delirium).  Aggressive medical interventions and inadequate pain management are common in 
hospitalized dementia patients.127  This measure could be evaluated among only 2 of 420 cases in 
ACOVE’s community-based cohort.72  No reliability or validity information is available for the 
specific measure.  The measure is not in use.  
 
Measure - Regular Assessment of Preferences in an ICU.  This ACOVE measure addresses 
documentation of preferences in an ICU.59,72  The numerator for this indicator is “the number of 
vulnerable elders admitted directly to the intensive care unit from an outpatient or ER setting and 
surviving 48 hours with documentation in the medical record that the patient’s preferences for 
care have been considered or that these preferences could not be elicited or are unknown within 
48 hours of admission.”  The denominator for this indicator is “all vulnerable elderly patients 
admitted directly to the ICU from the outpatient setting or emergency department and who 
                                                 
ii Dementia and altered mental status were defined as: diagnosis of dementia OR MD or RN note on Day 1 or 2 of 
cognitive impairment (confused, disoriented, Ox2,Ox1, unable to follow commands) OR neurologic change 
(somnolent, lethargic, poorly arousable, semicomatose, stuporous, obtunded, comatose) OR inattentive, restless, 
agitated.  
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survive 48 hours.”  Only 6 of 420 patients in ACOVE’s community sample were eligible for this 
measure, and 17% passed.72  No reliability or validity data are available for this specific measure.  
The measure is not in use.  
 
Measure - Regular Assessment of Preferences in Hospice.  NHPCO54 measure addresses 
common decisions about activities of daily living, life closure, and care received by patients and 
family members facing a terminal illness.  The numerator for this indicator is “the number of 
hospice patients who received care (either hospitalization or resuscitation) consistent with their 
expressed preferences as assessed at the time of admission.”  The denominator is “all patients 
admitted to hospice.”  Experts identified a number of global categories of decisionmaking, such 
as determination of the degree of symptom management desired, setting goals in relation to 
sentinel events, expressing or not expressing religious and spiritual needs, determination of one’s 
wishes for the site of death, hospitalization, and CPR.63  The intent of this indicator is to assist 
hospice patients in identifying care preferences and then meeting these needs by conducting a 
comprehensive assessment, including physical, functional, emotional, and spiritual and 
preferences, and allowing full autonomy to the patient and family to make decisions about how 
the remainder of the patient’s life is to be spent upon admission.  Hospices report these data 
voluntarily to NHPCO.  In 2002, 120 agencies reported this measure, and the mean and median 
values were 97%.  No reliability or validity data are available.  This measure is in current use as 
a voluntary reporting standard. 
 
Measure - Regular Patient Participation in Decisions To Limit Treatment.  This ACOVE 
measure focuses on ensuring participation in decisions for the withdrawal or withholding of life-
sustaining treatments (LST), which is consistent with ethical and professional guidelines.59,72  
The numerator is “the number of vulnerable elderly patients with documentation in the medical 
record of participation in the decision or why the patient did not participate in a decision 
regarding LST.”  The denominator is “all vulnerable elderly patients in the hospital or nursing 
home with written orders to withdraw or withhold a LST.”  A small study comparing chart 
documentation to patient recall about life-sustaining treatment decisions showed that medical 
record documentation reflected patient understanding of these decisions.128  Ten of the 420 cases 
in ACOVE’s community-based sample met criteria for the measure, and 70% passed.72  No 
reliability or validity information is available on this specific measure.  The measure is not in 
use.  
 
Measure - Regular Family Meetings Among Hospitalized Patients.  The numerator for this UHC 
measure is “the number of adults admitted to the hospital with documentation in the medical 
record that the health care team conducted a patient/family meeting within one week of 
admission that included discussion of the patient’s treatment preferences and/or a plan for 
discharge disposition.”67  The denominator is adults ≥18 years of age, with admission for CHF 
(DRG 127), cancer (DRG 82, 203, 172, 274, 346, 10) HIV (DRG 489) OR respiratory (DRG 
475, 483) AND length of stay > 4 days AND 2 prior admissions for any cause in preceding 12 
months.”  This indicator is similar to the ACOVE measures59,72 that specify documentation of 
patient participation in decisionmaking (implying communication of some sort between the 
patient and provider team) and the VHA indicators68 that specify conducting an interdisciplinary 
team meeting with the family within 120 hours of ICU admission.  A mean of 39% (median 
41%, range 0-93%) of the UHC cohort met this indicator.  Only 55% of cancer patients met the 
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indicator.  The distribution of results appeared to be broadly normal.  As with the other UHC 
measures, no individual reliability or validity information is available.  It is not known to be in 
current use. 
 
Measure - Timely and Effective Discharge Planning.  The numerator for this UHC measure is the 
number of adults admitted to the hospital with documentation in the medical record of a plan for 
discharge disposition within four days of admission.”67  The denominator is “adults ≥18 years of 
age, with admission for CHF (DRG 127), cancer (DRG 82, 203, 172, 274, 346, 10) HIV (DRG 
489) OR respiratory (DRG 475, 483) AND length of stay > 4 days AND 2 prior admissions for 
any cause in preceding 12 months.”  This measure implies that all patients who enter the hospital 
and stay at least one week should receive a plan for discharge disposition within four days of 
admission.  Planning for discharge is usually not explicitly included in discussions of advance 
directives, although many critically ill patients frequently move in and out of the hospital and 
across a variety of health care settings as they progress on a downward trajectory toward death.  
This explicit recognition of the importance of planning for care after leaving the hospital is a 
contribution to the advance directives discussion.  A mean of 53% (median 53%, range 18-94%) 
of the UHC cohort met this indicator.  Only 62% of cancer patients met the indicator.  The 
distribution of results appeared to be broadly normal.  As with the other UHC measures, no 
individual reliability or validity information is available.  It is not known to be in current use. 
 
Indicator - Regular Identification of a Surrogate in the ICU.  This VHA indicator focuses on the 
identification of a medical decisionmaker (family member or other appropriate surrogate) and is 
similar to the ACOVE indicator68,72,129 identifying a surrogate/proxy for community-dwelling or 
hospitalized vulnerable elders.  Other than setting, the major difference with the ACOVE 
indicators is the timeframe identified for performance of the indicator (24 vs. 48 hours): The 
denominator is “the total number of ICU patients with a stay of > 24 hours.”  The numerator is 
“the number of patients who have documentation on the status of identification of a health care 
proxy (or other appropriate surrogate decisionmaker) within 24 hours.”  Support for this 
indicator is derived from JCAHO Hospital Standard RI.1.2.3, literature focusing on the 
withdrawal of life-support in the ICU,130 and practice guidelines.100  This measure is currently 
being used as part of the VHA TICU initiative and is part of the VHA palliative care bundle, 
which will be initiated in September 2005. 
 
Indicator - Regular Assessment of Advance Directives for ICU Patients.  This VHA indicator 
focuses on the specification and documentation of the patient’s advance directive if admitted to 
the ICU within 24 hours of admission.68  The numerator for this indicator is “the number of 
patients admitted to the ICU with documentation of the patient’s advance directive (written or 
oral instructions from the patient specifying the type of medical treatment that is desired if the 
patient becomes incapacitated, including a living will, durable power of attorney (note State-
specific status) or any document that State law recognizes as an “advance directive” entered in 
the medical record within 24 hours following admission.”  The denominator is “the total number 
of patients with an ICU length of stay greater than 24 hours.”  Support for this indicator is 
derived from JCAHO Hospital Standard RI.1.2.5; the National Consensus Project for Quality 
Palliative Care Clinical Practice Guideline 1.2, 8.169,131 and literature on decision making and 
medical outcomes.132,133  This measure is currently being used as part of the VHA TICU 
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initiative and is part of the VHA palliative care bundle, which will be initiated in September 
2005. 
 
Indicator - Regular Assessment of Specific Resuscitation Preferences in the ICU.  This VHA 
indicator focuses on the percent of patients with documentation in the medical record of 
resuscitation status within 24 hours following admission to the ICU.68  The numerator for this 
indicator is “the number of patients admitted to the ICU with documentation of the patient’s 
advance directive (written or oral instructions from the patient specifying the type of medical 
treatment that is desired if the patient becomes incapacitated, including a living will, durable 
power of attorney (note State-specific status) or any document that State law recognizes as an 
‘advance directive’) entered in the medical record within 24 hours following admission.”  The 
denominator is “the total number of patients with an ICU length of stay greater than 24 hours.”  
Support for this indicator is derived from the literature on decisionmaking and medical 
outcomes.132  This measure is currently being used as part of the VHA TICU initiative and is part 
of the VHA palliative care bundle, which will be initiated in September 2005. 
 
Indicator - Regular Clinician-Patient-Family Communication in the ICU.  This VHA indicator 
addresses inadequate communication among patients, family members, and health care providers 
in ICUs.68,134  The numerator for this indicator is “the number of patients admitted to the ICU 
who survive more than 5 days (120 hours) with documentation in the medical record that an 
interdisciplinary team meeting (with at least the attending physician (primary care or ICU 
attending) and a nurse) and the patient and/or family was conducted within 72 hours of ICU 
admission and involved a discussion addressing each of the following topics: the patient’s 
condition (diagnosis and prognosis), goals of treatment, the patient’s and family’s needs and 
preferences, and the patient’s and family’s understanding of the patient’s condition and goals of 
treatment at the conclusion of the meeting.”  The denominator is “total number of patients with 
an ICU length of stay more than 5 days (120 hours).”  Support for this indicator is derived from 
JCAHO Standards RI.1.2.2.-RI.1.2.8, RI.1.3.6; NCP_CPG 1.3.135,136  A joint meeting with the 
surrogate and family members and the health care team, labeled a “family conference,” should be 
used to answer any questions family members might have regarding the condition of the patients 
and to explore goals of care.  The literature identifies various elements of good communication 
as well as barriers to advance directive discussions.137-141  This measure is currently being used 
as part of the VHA TICU initiative and is part of the VHA palliative care bundle, which will be 
initiated in September 2005. 
 
Application.  We identified two measures and zero indicators addressing the application of 
existing care plans. 
 
Measure - Documentation of Care Preferences Across Venues.  Several ACOVE measures 
address advance directive continuity.59, 72  The goal of advance care planning is to ensure that 
patient’s preferences for care are identified and followed.  The denominator is “all vulnerable 
elderly with an advance directive in the outpatient, inpatient, or nursing home medical record or 
who report the existence of an advance directive in an interview, and are receiving care in 
another venue.” The numerator is “those cases with documentation in their medical record of the 
existing advance directive at the second venue or documentation acknowledging the existing 
advance directive, it contents, and the reason that it is not included in the medical record.”  Five 
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observational studies have documented that even when advance directives are completed, 
patients’ physicians often do not know that they exist,126,142,143 and the directives are not always 
documented in the patients’ charts144 or transferred from outpatient to inpatient settings.145  This 
measure passed in 25% of the 8 cases among 420 community-dwelling elderly in the ACOVE 
study.72  No reliability or validity information is available on the specific measure.  The measure 
is not in use.  
 
Measure - Documentation of Specific Life Sustaining Preferences.  This ACOVE measure 
addresses the need to document decisions a vulnerable elder makes concerning future health 
states.59, 72  The numerator is “patients with one of the following documented in the medical 
record: a discussion of life-sustaining treatment preferences, an advance directive, or that the 
patient discussed this topic with the physician or does not wish to discuss this topic.”  The 
denominator is “all vulnerable elderly patients who indicate (during an interview) that they 
would rather die than live permanently comatose, ventilated, or tube fed.”  Observational studies 
show that large proportions of patients would prefer to die than live permanently comatose, 
mechanically ventilated, or tube fed and that physicians and surrogate decision makers often do 
not know patients’ preferences about life-sustaining treatments.59  Consensus statements promote 
the documentation of these preferences (e.g., The American Geriatric Society Ethics Committee, 
1995).  Of the 238 of 420 eligible patients in ACOVE’s community-based sample, only 12% 
passed the measure.72  No reliability or validity information is available on this specific measure.  
The measure is not in use.   
 
Follow-up.  We identified 14 separate measures (covering 10 general categories) and 7 
indicators (covering 8 general categories) addressing follow-up.  Many of these administrative 
measures and indicators are closely related.  For example, Cancer Care Ontario119 and CCNS146 
are both using indicators and measures very similar to those developed by investigators at the 
Dana-Farber Cancer Institute.146  For that reason, these similar measures and indicators are 
discussed together whenever possible. 
 
Measure - Consistency of Preferences With Use of Ventilator Support.  This ACOVE measure 
focuses on consistency between use of ventilator support and documented preferences.59, 72  The 
numerator is “the number of records with documentation of the goals of care and the patient’s 
decision for mechanical ventilation or why this information is unavailable.”  The denominator is 
“all hospitalized vulnerable elders requiring mechanical ventilation (except short-term and post 
operative mechanical ventilation).”  This indicator is intended for use with all vulnerable elderly 
patients requiring mechanical ventilation, including cancer patients.  Practices concerning 
withdrawal of treatment for patients receiving mechanical ventilation vary widely.123,135,143,147,148  
Practices regarding withholding of specific treatments among surveyed physicians also varied 
greatly.100  The SUPPORT study found that a primary predictor of whether a ventilator was 
withdrawn was the existence of communication about care preferences.149  Only 2 of 420 persons 
in ACOVE’s community-based study met criteria for the measure.  No reliability or validity 
information is available on this specific measure.  The measure is not in use.  
 
Measure - Late Life Hospital Use.77,150  Several measures or indicators address late-life hospital 
use.  One measure was developed by Dana-Farber Cancer Institute146 investigators, and a closely 
related measure is in use by Cancer Care Ontario.119  A similar indicator is in the process of 
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being operationalized by CCNS.146  The numerator for the Dana-Farber measure is “the 
proportion of cancer decedents with more than one hospitalization or ER visit in the last month 
of life.  The denominator is “all cancer decedents.”  Support for its validity comes from literature 
reviews; focus groups of patients, caregivers, and providers; expert panel review; and 
quantitative analysis of the indicator in Medicare claims data.  This measure was evaluated in a 
Medicare-SEER database, and using the highest performing decile of this measure implied that 
in high performing health care service areas (HCSAs), fewer than 4% of cancer decedents would 
have more than one hospitalization or emergency room visit in the last month of life.  When a 
sample of 150 charts at Dana-Farber were abstracted as the gold standard against which the 
sensitivity and specificity of the measure would be determined, this measure was determined to 
have a sensitivity of 0.96, specificity of 1.00, and accuracy of 0.097.  As a measure of variability, 
investigators determined the 5th/95th percentile ratio (2.38) (range: 1.85-3.16).  The Cancer Care 
Ontario measure is “hospital use in days by stage of cancer.”  The populations for the “stage of 
cancer” consist of those in initial care (within six months of diagnosis), continuing care, and 
terminal care (within six months of death).  A separate category, investigative care, is defined as 
patients with a benign outcome.  Provincial resource use in 2002 indicated that as a proportion of 
total cost, the terminal phase of care used 29 to 42% of resources across Ontario.  The initial 
phase of care used 31 to 38% of total resources.120  A closely related indicator, hospital days near 
the end of life, is being operationalized by CCNS. 
 
Measure - Late Life ICU Use.77,146,150  Several measures or indicators address late-life ICU use.  
One measure was developed by Dana-Farber Cancer Institute.  A similar indicator is currently 
being operationalized by CCNS.  The numerator for the Dana-Farber measure is “the proportion 
of cancer decedents with admission to the ICU in the last month of life.”  The denominator is “all 
cancer decedents.”  Support for its validity comes from literature reviews; focus groups of 
patients, caregivers, and providers; expert panel review; and quantitative analysis of the indicator 
in Medicare claims data.  This measure was evaluated in a Medicare-SEER database and, using 
the highest performing decile of this measure, the data implied that in high performing HCSAs 
fewer than 4% of cancer decedents would have more than one ICU admission in the last month 
of life.  When a sample of 150 charts at Dana-Farber were abstracted as the gold standard against 
which the sensitivity and specificity of the measure was determine, this measure was determined 
to have a sensitivity of 0.87, specificity of 0.97, and accuracy of 0.095.  As a measure of 
variability, investigators determined the 5th/95th percentile ratio (3.28) (range: 2.38-4.67).  A 
closely related indicator, ICU days near the end of life is being operationalized by CCNS.  
Neither the measure nor the indicator are currently in use. 
 
Measure - Late Life Rate of Emergency Care.  This measure was developed by Dana-Farber 
Cancer Institute77,146,150 investigators, and a closely related measure is in use by Cancer Care 
Ontario.119  A similar indicator is currently being operationalized by CCNS.146  The numerator 
for the Dana-Farber measure is “the proportion of cancer decedents with more than one 
emergency room visit in the last month of life.”  The denominator is “all cancer decedents.”  
Support for its validity comes from literature reviews; focus groups of patients, caregivers, and 
providers; expert panel review; and quantitative analysis of the indicator in Medicare claims 
data.  This measure was evaluated in a Medicare-SEER database, and, using the highest 
performing decile of this measure, the data suggested that in high performing HCSAs, fewer than 
4% of cancer decedents would have more than one emergency room visit in the last month of 
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life.  When a sample of 150 charts at Dana-Farber were abstracted as the gold standard against 
which the sensitivity and specificity of the measure was determined, this measure was 
determined to have a sensitivity of 0.82, specificity of 0.96, and accuracy of 0.89.  As a measure 
of variability, investigators determined the 5th/95th percentile ratio (2.78) (range: 2.04-3.88).  The 
Cancer Care Ontario measure is “the rate of cancer patients utilizing an emergency room in the 
last two weeks of life.”  The denominator is “all cancer patients dying in a hospital.”  Provincial 
rates of this measure varied between about 20% and 25% in 2002.  A closely related indicator, 
the frequency of emergency visits, is being operationalized by CCNS. 
 
Measure - New Chemotherapy Regimen in Last 30 Days of Life.77,150  This measure was 
developed at the Dana-Farber Cancer Institute146 and a closely related indicator is being 
operationalized in ongoing work by CCNS.77  The numerator is “the number of dying cancer 
patients started on a new chemotherapy regimen in the last 30 days of life.”  The denominator is 
“all deceased cancer patients.”  A high proportion (more than 2%) of cancer patients receiving a 
new chemotherapy regimen in the last 30 days of life indicates poor quality care.120  Support 
comes from literature reviews; focus groups of patients, caregivers, and providers; expert panel 
review; and quantitative analysis of the indicator in Medicare claims data.  This measure was 
normed in a Medicare-SEER database and, using the highest performing decile of this measure, 
the data implied that in high performing HCSAs, fewer than 2% of patient would initiate new 
chemotherapy regimens in the last month of life.  A sample of 150 charts at Dana-Farber were 
abstracted as the gold standard against which the sensitivity and specificity of the measure was 
determined.  This measure was determined to have a sensitivity of 0.83, specificity of 0.94, and 
accuracy of 0.85.  As a measure of variability, investigators determined the 5th/95th percentile 
ratio (3.19) (range: 2.03-5.41). CCNS is operationalizing a closely related indicator – the interval 
between new chemotherapy and death.  This measure is not in use. 
 
Measure - Chemotherapy in Last 14 Days of Life.77,150  This measure is derived from the Dana-
Farber Cancer Institute146 measure set and a closely related indicator is being operationalized in 
ongoing work by CCNS.77,120  The numerator is “the number of dying cancer patients receiving 
chemotherapy in the last 14 days of life.”  The denominator is “all deceased cancer patients.”  A 
high proportion (more than 10 %) of cancer patients receiving chemotherapy in the last 14 days 
of life indicates poor quality care.  Support for this indicator comes from literature reviews; focus 
groups of patients, caregivers, and providers; expert panel review; and quantitative analysis of 
the indicator in Medicare claims data.  This indicator was normed in a Medicare-SEER database 
and, using the highest performing decile of this measure, the data suggest that in high performing 
HCSAs, fewer than 10% of patients would receive chemotherapy in the last 14 days of life.   
When a sample of 150 charts at Dana-Farber were abstracted as the gold standard against which 
the sensitivity and specificity of the measure was determined, this measure was determined to 
have a sensitivity of 0.92, specificity of 0.94, and accuracy of 0.92.  As a measure of variability, 
investigators determined the 5th/95th percentile ratio (2.24) (range: 1.74-2.97).  CCNS is 
evaluating a closely related indicator, using a “short” interval between the last chemotherapy and 
death.  This measure is not in use.  
 
Measure - Admission to Hospice.150  This measure was developed by investigators at the Dana-
Farber Cancer Institute146 and is currently being operationalized as an indicator by CCNS77,120 
and Cancer Care Ontario.77  A closely related measure was also selected for use by the Georgia 
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Cancer Coalition.55  The numerator is “the number of cancer patients not admitted to hospice.”  
The denominator is “all deceased cancer patients.”  Numerous observational studies as well as 
several recent methodologically rigorous systematic reviews qualitatively support the 
effectiveness of hospice and palliative care in addressing the full range of quality-of-care 
domains.4,21  Support for the validity of this item comes from literature reviews; focus groups of 
patients, caregivers, and providers; expert panel review; and quantitative analysis of the indicator 
in Medicare claims data.  This measure was normed in a Medicare-SEER database and, using the 
highest performing decile of this measure the data suggested that in high performing HCSAs, 
fewer than 45% of patients would die without being admitted to hospice.  When a sample of 150 
charts at Dana-Farber were abstracted as the gold standard against which the sensitivity and 
specificity of the measure was determined, this measure was determined to have a sensitivity of 
0.24, specificity of 0.96, and accuracy of 0.88.  As a measure of variability, investigators 
determined the 5th/95th percentile ratio (5.00) (range: 3.76-6.89).  Several closely related 
indicators are being evaluated and operationalized by CCNS, including enrollment in hospice, 
access to palliative care or palliative physician assessment, and periodic palliative care.  The 
Georgia Cancer Coalition has operationalized this item as “the rate of cancer deaths in hospice.”  
Using a SEER-Medicare dataset, the proposed numerator is “the number of adults with cancer 
discharged due to death” and the denominator is “the number of adults with cancer (ICD-10 
codes C00-C97, ICD-9 140-208).”55  No reliability or validity information is available other than 
from the Dana-Farber experience.  This item is not known to be in current use as a measure.  
 
Measure - Late Referral to Hospice.77,150  This measure was developed by investigators at the 
Dana-Farber Cancer146 and is very similar to a measure developed by CCNS146 and the Georgia 
Cancer Coalition.55  The numerator is “the number of dying cancer patients referred to hospice or 
palliative care less than three days before death.”  The denominator is “all deceased cancer 
patients.”  A high proportion (more than 8 %) of dying cancer patient being referred to hospice 
or palliative care less than three days before death indicates poor quality care.146  Support for the 
validity of this measure comes from literature reviews; focus groups of patients, caregivers, and 
providers; expert panel review; and quantitative analysis of the indicator in Medicare claims 
data.  This measure was normed in a Medicare-SEER database, and using the highest performing 
decile of this measure, the data implied that in high performing HCSAs, fewer than 8% of dying 
patients would be admitted to hospice in the last three days of life.  When a sample of 150 charts 
at Dana-Farber were abstracted as the gold standard against which the sensitivity and specificity 
of the measure was determined, this measure was determined to have a sensitivity of 0.97, 
specificity of 1.00, and accuracy of 0.97.  As a measure of variability, investigators determined 
the 5th/95th percentile ratio (2.39) (range: 1.99-2.95).  The Georgia Cancer Coalition has 
operationalized a closely related measure as cancer patients who receive hospice care for at least 
seven days.  They propose to report this measure separately for inpatient and outpatient settings 
and to operationalize it using SEER Medicare data; the denominator is “the number of adults 
with cancer (ICD-10 codes C00-C97, ICD-9 140-208).”55  With the exception of the data from 
the Dana-Farber experience, no reliability or validity information is available.  This item is not 
known to be in current use as a measure. 
 
Measure - Site of Death.150  This measure was developed by investigators at the Dana-Farber 
Cancer Institute146 and is also being used as an indicator by CCNS77 and as a measure by Cancer 
Care Ontario.119,120  In the case of the Dana-Farber measure, the numerator is “number of cancer 
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patients who die in the hospital.”  The denominator is “all deceased cancer patients.”  This item 
focuses on high rates of hospital cancer deaths (greater than 17%)150 as indicating poor quality 
care.  Support for this item comes from literature reviews; focus groups of patients, caregivers, 
and providers; expert panel review; and quantitative analysis of the indicator in Medicare claims 
data.  The British Gold Standards Framework of dying has embraced a similar metric.  This 
measure was normed in a Medicare-SEER database, and using the highest performing decile of 
this measure, the data implied that high performing HCSAs would have fewer than 17% 
inpatient deaths among cancer patients.  When a sample of 150 charts at Dana-Farber were 
abstracted as the gold standard against which the sensitivity and specificity of the measure was 
determined, this measure was determined to have a sensitivity of 0.95, specificity of 1.00, and 
accuracy of 0.97.  As a measure of variability, investigators determined the 5th/95th percentile 
ratio (2.49) (range: 2.05-3.12).  Cancer Care Ontario is currently using this measure to evaluate 
provincial cancer care.  About 56% of patients died in the hospital in Ontario, and rates varied 
between approximately 45% and 60% province-wide.  Patients who died in the hospital were less 
likely to receive home care in the last six months, palliative care assessments, or physician house 
calls in the last two weeks of life.119  The same item is currently being operationalized as a set of 
comprehensive administrative data-based indicators for CCNS. 
 
Measure - Safe Dying in Hospice.  This measure was developed by investigators at the 
NHPCO.63  The numerator is “the number of deceased hospice patient’s caregivers with 
documentation in the patient’s medical record who were contacted and surveyed as to the quality 
of care provided by the hospice using the following question: “If you cared for the patient at 
home, did hospice increase your confidence to safely care for your loved one as death 
approached?”  The denominator is “all caregivers of hospice patients.”  This indicator is based 
on the assumption that caregivers who lack confidence or unsafe environments will aggravate 
dying or may hasten death.  The “high risk, high volume, problem prone” home care 
environments are those in which there may be variable, uncertain, or absent caregiver 
competencies.  Family caregivers, who may be uneducated in health care delivery, stressed by 
the anticipation of a loved one’s anticipated death, and fatigued by the labor associated with care 
of a physically dependent person, are given significant responsibility for the care of the patient.  
For the 116 agencies that voluntarily reported this information in 2002, the mean and median 
values were 98% for caregivers reporting safe dying experience.54,79 
 
Indicator - Care Consistency With Documented Care Preferences.  The numerator for this 
ACOVE measure is “the number of vulnerable elders whose specific treatment preferences were 
followed.  The denominator is “all vulnerable elderly patients in any health care setting with 
specific treatment preferences documented in their medical record.”59  The assumption is that the 
patient’s preferences and designated surrogate will be elucidated and documented within the 
patient’s medical record, usually within a specified timeframe that depends on the site within the 
hospital, or there will be documentation as to why surrogate and preferences were not able to be 
obtained.  Thus, the documentation in patients’ records of their preferences would provide the 
standard by which care consistency would be evaluated.  Both patients and health care providers 
believe that end-of-life discussions are important and should be held while the patient is still able 
to meaningfully and actively participate in decision making.  However, studies have shown that 
these conversations are not common.141  Moreover, research assessing the effectiveness of 
written advance directives in the care of seriously ill, hospitalized patients shows that even if the 
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patient has completed an advance directive, and it is accessible in the patient’s chart, physician-
patient communication or decision making about resuscitation was not substantially enhanced.  
Current practice patterns indicate that increasing the frequency of advance directives is unlikely 
to be a substantial element in improving the care of seriously ill patients.151  Recent efforts to 
improve end-of-life care have focused on the application of documented preferences, as there is a 
strong theoretical basis and expert consensus that patient preferences should drive care.  Danis 
and colleagues (1991)124 showed a high correlation between documented care preferences and 
life-sustaining treatments.  However, similar work has not been performed in the outpatient or 
hospital settings.  No trials have studied whether documentation improves the concordance of 
care with values and preferences.  This indicator was not tested in ACOVE’s community-based 
sample and is not in current use. 
 
Potential Indicators and Measurement Gaps 
We reviewed a number of sets of proposed potential indicators, clinical practice guidelines, 
and quality improvement studies that did not meet the standards set for inclusion of relevant 
indicators.  Overall, guidelines did not rise to the level of indicators because of the lack of 
specification of various elements required for this review: patient population, denominator, 
conceptual clarity, or data source information.  We identified fourteen potential indicators.  
These potential indicators overlapped with those identified in the indicator table and also 
addressed a number of gaps in the indicator literature, including the special population of 
children with cancer.152-155 
Although many of the issues in advance care planning in adults are similar to those in 
children, indicators for children may need to differ in some respects (Potential Indicators #1; #7, 
#8, #10, #11, #12).  Potential indicators identified for children are derived from the Initiative for 
Pediatric Palliative Care (IPPC) Quality Domains of Children Living with Life-Threatening 
Conditions152 (Potential Indicator #1, #11, #12, #13), the Society of Industrial and Organization 
Psychology (SIOP) Working Committee on Psychosocial Issues in Pediatric Oncology154 
(Potential Indicator #7), the American Academy of Pediatrics Committee on Bioethics and 
Committee on Hospital Care155 (Potential Indicator #8), and a literature review on key 
components of quality pediatric end-of-life care153 (Potential Indicator #11).  These potential 
indicators overlap with those identified for adults but address children’s needs in light of their 
developmental level, and include assessment of needs, documentation of advance directives, 
support of the child and family, and continuity-of-care plans across provider sites. 
Another potential indicator focused on adults in the ICU135 (Potential Indicator #2).  This 
indicator was derived from the American College of Physicians intervention literature and 
specified the components of the clinical identification of end-of-life ICU patients and the 
components of end-of-life care planning.   
A number of potential indicators were identified from palliative care guidelines (Indicator #3, 
#4, #5, #14)69,131,156 and focused on end-of-life palliative care for hospitalized patients.  These 
indicators were derived from the National Consensus Project for Quality Palliative Care Clinical 
Practice Guidelines69,131 and the Palliative Care Australia Standards for Palliative Care 
Provision.156  Continuity of patient information across settings was addressed in Potential 
Indicator #6148 and was derived from the intervention literature.   
The use and withdrawal of feeding tubes in institutionalized patients (hospital, nursing home) 
is addressed in Potential Indicator #9.157  
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A final potential indicator was identified from the National Consensus Project69,131 (Indicator 
#14) and focused on the treatment of the body in a culturally sensitive and respectful manner 
after a patient has died.  
Cancer Care Ontario119 is using several measures related to waiting times for chemotherapy 
and radiotherapy that could be adapted for supportive or palliative care with appropriate 
denominator adjustments. 
 
Measure That Crosses All Domains  
Follow-up.  We identified one composite measure that crosses all domains. 
 
Measure - Family Evaluation of Hospice Care (FEHC).  The FEHC is a 61-item survey 
administered after the death of a hospice patient to assess family members’ perceptions of care 
provided by the hospice.  The survey is based on the After-Death Bereaved Family Interview, 
which was developed based on a systematic review of the measurement literature relative to end-
of-life care, consensus conferences, and focus groups.158  Please refer to the Evidence Table in 
Appendix F5*.  The numerator is “the percentage of respondents reporting opportunity for 
improvement in attention to family needs for support, attending to family needs for information, 
provision of desired physical comfort and emotional support, and mean overall satisfaction.”  
The denominator is “family members of hospice decedents.”  Although there are individual 
questions that relate to pain, depression, dyspnea, advance care planning, and other domains, and 
might be used for independent performance measurement, the FEHC is intended to be 
administered as a complete instrument or as modules and is therefore described here as a 
composite measure.  The measure is intended for a mixed-hospice population.  Hospices submit 
data voluntarily to NHPCO.  In the first half of 2004, 352 hospices submitted data on 29,292 
patients: 51% had cancer, 93% were white, 3% were African-American, and 3% were 
Hispanic.158  For pain, 6% of family members reported unmet need (25th and 75th percentiles 
among hospices with more than30 observations, 4% and 8%); for dyspnea, 5% (3% and 7%); 
and for emotional support, 9% (5% and 13%).  Some questions related to advance care planning 
as well, such as satisfaction questions about respecting patient wishes and dying on one’s own 
terms, but these values are reported only as a composite with other questions.  Validity and 
reliability information are not available for this measure, although it is derived from other 
measures that have undergone extensive psychometric testing.  Finally, little variation was found 
among hospices on this survey.  However, these results are from early adopters; thus, it is 
possible that more variation would have been found if the survey had been administered among 
all hospices.  It continues to be in voluntary use by hospices and NHPCO. 
 
Summary 
We identified a number of measures and many indicators addressing the domains of pain, 
dyspnea, depression, and advance care planning within supportive and palliative cancer care.  
Many of these measures or indicators were developed and evaluated in populations that included 
cancer patients, although few were developed for quality assessment or improvement of cancer 
                                                 
* Appendixes cited in this report are provided electronically at  
http://www.ahrq.gov/downloads/pub/evidence/pdf/eolcanqm/eolcanqm.pdf 
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care exclusively, and even fewer have proven their usefulness in application.  Existing measures 
and indicators address both processes and outcomes of care.  Canadian health care systems have 
been among the early adopters in initiating supportive and palliative cancer measurement, 
although ongoing US measurement efforts include the Georgia Cancer Coalition, and the VHA 
health care system, which are actively implementing measurement systems for cancer care and 
palliative care respectively.  Some of these measures are mature enough for widespread 
application in quality improvement, but few have met all the criteria for public reporting and 
accountability. 
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Chapter 4. Discussion 
We identified a remarkable number of measures or indicators that address aspects of pain, 
dyspnea, depression, and advance care planning.  However, in all domains, we found very few 
items that had been developed for and tested specifically in a cancer population and none for 
pediatric care.  We also found few that were developed for or had been tested across the full 
trajectory of cancer care.  Early stage indicators or measures were particularly lacking.  With 
regard to settings of care, the fewest measures were found for outpatient care, even though 
patients receive most of their care in that setting.  For all symptom domains, the evidence base 
for measurement is certainly strongest in the area of assessment, with relative shortcomings in 
treatment and follow-up.  Our systematic review should have also uncovered evidence that these 
measures promote quality assessment and improvement, but there has been little investment in 
implementing these measures.  For example, although a few carefully conducted trials have been 
conducted for control of pain in seriously ill or cancer patients, only one has used quality 
indicators as the mechanism for quality improvement,62 and the generalizability of other studies 
to routine practice and to a cancer population159,160 is unclear, although these studies were 
effective in reducing the severity of pain in a population and do include potential indicators.  
An important limitation of our report is that, for the topics of pain and depression, we did not 
search for indicators for conditions other than cancer.  The ability to use indicators or measures 
developed generically for these conditions and apply them to patients with cancer rests on the 
assumptions that the physiologic processes of pain and depression are essentially similar across 
disease conditions and that there are no particular measurement challenges in translating them 
from one population to another.  This assumption requires certain caveats, such as the short time 
frames available for treatment in palliative care when these indicators or measures are applied to 
late-phase disease, and the fact that generic indicators or measures may not address short-term 
interventions.  While these are empirically testable propositions, health care systems instituting 
measures for these conditions should be aware that they may not want to limit themselves to the 
disease-specific indicator or measures we have identified.  NQF in particular has reviewed a 
large number of mental health indicators that may be readily applied to palliative conditions. 
 
Future Research 
Field Testing in Relevant Populations 
The lack of reported experience with these tools may not be surprising, as the measures or 
indicators we identified were largely developed in the last five years, reflecting the newness of 
the field of supportive cancer care.21  In addition, the science of quality improvement in 
particular has suffered from confusion about optimal methodological approaches.161  It is 
encouraging that some of the measures or indicators that we identified have been recently 
implemented or will be implemented in the near future for monitoring and improving population 
care (e.g., in Georgia, Ontario, Nova Scotia, and in the VHA system), which should offer 
opportunities for nurturing a fundamental knowledge base to foster improving the delivery of 
supportive or palliative cancer care.  An especially important endeavor to foster progress in 
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measurement would be to apply the better- developed general measure and indicator sets (e.g., 
ACOVE) to supportive or palliative care populations with cancer.  
An important objective of future testing is to obtain more robust information about the 
performance characteristics of the strongest measures.  Even given limitations, many of them 
may be useful now for institutional-level quality assessment and improvement activities. 
However, most of these measures lack even basic published information about reliability and 
validity.  Before they are deployed at higher levels of the health care system, information about 
their ability to discriminate quality performance and responsiveness to change will be required.  
In addition, testing in a variety of settings and institutions may also be needed.  Differences in 
instrumentation, data source, and data collection protocols may significantly affect the 
performance and feasibility of measures, and research on these methodological issues and how 
they affect palliative care evaluation is needed.  Furthermore, health care systems must consider 
the cost and feasibility of data collection and must be assured that measures are low risk for 
perverse incentives and that they can provide timely feedback on performance so that 
measurement can contribute to operational decisionmaking.  
 
The Need for Measures To Address Impaired Self-Report 
None of the indicators address how to evaluate symptoms among individuals with impaired 
self-report, which can be due to either temporary (e.g., delirium) or durable factors (e.g., 
dementia, brain metastasis).  There is no doubt that delirium is common among cancer patients, 
although its incidence and prevalence are not well studied.  Some recent reports noted a 
prevalence of 18-50% among patients with cancer in general, 162-164 and observed rates are even 
higher in certain treatment settings such as the intensive care unit or in the nursing home, where 
almost 60% of the population is also living with dementia.  The clinical needs of these 
populations are undoubtedly profound; a recent description of the clinical profile of cancer 
patients in US nursing homes reveals that, of the 190,976 cases, 51% of cases surviving more 
than one assessment had persistent pain, 25% of all cases were using oxygen, only 45% had 
DNR orders, and only 29% of those who were defined as “terminally ill” received hospice 
services.165  A major effort to expand basic research in this area and ultimately address it through 
quality measurement would benefit many people at the end of life.166,167 
Considering the example of pain, health professionals’ estimates of patient’s pain correlate 
poorly with patient self-reports, and discrepancies between patients and physicians in perceptions 
of pain severity are predictive of inadequate management.8  Without regular screening for pain, 
many patients with significant pain do not have pain documented in the medical record and do 
not receive analgesia.85  Patient vulnerability makes data collection challenging even among 
patients capable of self-report, yet many patients who need palliative care are incapable of self-
report at least part of the time, often at times when they are also at great risk of pain.  Research 
that addresses methodological challenges of obtaining patient reports and methods that allow 
monitoring of pain without self-report are an urgent need.  All of the pain quality improvement 
interventions identified in this review that succeeded in reducing population pain intensity in 
different settings also included increasing the frequency of pain assessment as a key component 
of the intervention.62,159,160  
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The Lack of Pediatric Measures 
A related and obvious shortcoming we noted is the complete absence of pediatric measures 
or indicators.  As in the case of many adults, care assessment in young children is challenged by 
their inability to self report.  Cancer represents the second leading cause of death among children 
ages 5-15 in the United States.168  However, profound challenges and serious deficiencies in the 
care of pediatric cancer cases have been noted.169,170  It is insufficient to propose that adult 
measures or indicators could simply be adopted for pediatric care, as the kinds of disease, 
challenges of symptom reporting and intervention, and basic approach to care differ so 
significantly between pediatric and adult oncology care.  Many but not all of the adult measures 
have potentially useful analogues in the pediatric population,171 but substantial basic research 
will be needed to translate such efforts into useful pediatric tools.  A comprehensive review in 
2003 found only 22 research studies and 6 guideline statements in the area,153 and most of this 
limited literature addresses pain, to the exclusion of other symptoms or experiences.152  In 
addition, a systematic review of measure and indicator sets relevant to pediatrics found no 
measures or indicators for end-of-life care.34,172-175 
 
Defining the “End-of-Life” 
The lack of consensus on definitions of “end-of-life” presents what has been called the 
“denominator” problem.  Of central importance is the continuing challenge of establishing a 
consistent and accepted definition of end-of-life that is not confined to that of the “imminently” 
dying.  The correct definition of the end-of-life may well depend upon what use is to be made of 
the definition.  For the measures reviewed, many of the indicators explicitly define end-of-life 
retrospectively (e.g., last six months of life).  While appropriate for evaluating “aggressive 
treatment” in the last days before death, this definition does not provide guidance on important 
clinical services such as pain prevention or the timing of advance care planning.  In addition, 
retrospective analyses may introduce a number of biases, since the timing of death is often not 
predictable.  Prospective indicators, such as the quality of the discussion about whether the 
patient wants chemotherapy, would account for patient preferences.  The ACOVE indicators 
come closer to a prospective method by identifying “vulnerable community-dwelling elders” for 
which the identification and documentation of life-sustaining treatment decisions may be most 
appropriate.  Prospective analyses for cancer will require methodological work to define which 
cancer patients (certain types that are usually fatal, those at advanced stage) should be in the 
denominator for measures of the aggressiveness of care. 
 
The Publication Gap for Quality Measurement 
An important finding of our report was that much of the evidence on the measures that we 
identified was unpublished.  Additional information that might inform the evidence base for 
these measures, (i.e., from local quality assessment and improvement efforts) probably exists but 
is likely unpublished and compiled by non-academic organizations.  Further, much of the actual 
experience with measures and measurement probably exists in an anecdotal rather than archival 
form.  We found that a strategy that consisted of an Internet search coupled with networking 
widely with organizations and individuals in the fields of oncology and supportive or palliative 
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care was relatively effective for identifying such information.  Future systematic reviews should 
be aware of this important issue and make an explicit effort to capture this unpublished 
information.  Methods for systematically compiling and analyzing this type of data might help to 
improve the evidence base for quality measurement.  Methods or other strategies to better 
promote the use of candidate measures in quality improvement work or to otherwise link 
measurement development work to quality improvement projects in cancer, such as the Veterans 
Administration Collaborative,160 might help to provide the information on measure 
responsiveness that is needed.   
 
Strengthening Quality Measurement of Depression in Cancer 
Given the strength of the literature on measurement in mental health in general and the 
recognized importance of depression in the care of cancer patients, surprisingly few indicators 
have been evaluated for depression in advanced cancer.  This lack of indicators is striking 
because indicators for mental health are well represented within available measure sets in 
general.  Indicators developed for other settings may be appropriate but have not been tested in 
this population.  Furthermore, depression is widely recognized to be an important influence on 
the experience of cancer.  Certainly, many of the drugs used to treat depression are relevant 
within the scope of cancer care, especially for earlier stage disease.  More fundamental clinical 
research is needed to address late stage disease – such as the optimal approach to screening and 
the usefulness of short-term treatment, which has not, for the most part, been addressed by this 
literature.21  Further research on similarities between measurements in cancer populations and 
those in non-cancer populations might allow elements of this work to be used as supporting 
evidence for particular measures.  This effort may be particularly important for areas where there 
is significant non-cancer-related evidence, such as in patients with cognitive impairment. 
 
Building an Evidence Base To Compare Population Subgroups 
We found insufficient evidence to comment on important differences by population.  This 
finding is not surprising, as the tools for examining these differences are limited by the lack of 
basic knowledge.21  However, an important priority for future research is evaluating measures in 
important sub-populations (i.e., by race/ethnicity, age, language, and gender).  With regard to 
pain, members of minority groups with cancer have higher rates of inadequate pain assessment 
and treatment than others.86, 87  A recent nonsystematic review of the topic of cancer pain found 
that differences in pain management persist for both assessment and treatment, across multiple 
settings and types of pain.88  Older cancer patients8 and cancer patients in nursing homes87 are 
also less likely to receive adequate pain treatment.  This issue was addressed in some of the 
guidelines we reviewed (e.g., the Oncology Nursing Society Position in Cancer Pain 
Management)82 but has not been operationalized into indicators.  It is important to define 
subgroups of cancer by stage of illness and to understand the performance of indicators among 
major subgroups.  
Durable improvement in symptom assessment will require measures that are capable of being 
implemented with other routine metrics of performance in important care settings.  For example, 
improvements in pain management often decay over time.  In one study to increase daily pain 
assessment, performance on the indicator was 82% after an educational intervention but 
decreased to 59% over a seven-month period.9  Evaluations of the use of pain assessment in 
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clinical settings have shown good feasibility with minimal burden for staff.9  However, in one 
study with a high prevalence of unreported pain, training of home health aides to document pain 
scores resulted in a large increase in screening; however, physician documentation increased by 
only 5- to 8%.85  In addition, although most of the indicators or measures that we identified were 
focused on the inpatient setting, much routine cancer care occurs in the ambulatory setting, and 
we found fewer indicators or measures to address outpatient performance.  
 
Conclusions 
Over time, measures should become available for an increasing number of areas of clinical 
performance in supportive or palliative cancer care.  Research is needed to ensure that valid and 
reliable measures are available to address the full spectrum of palliative domains, including the 
most important symptoms that patients face: spiritual well-being and caregiver burdens, 
including bereavement.  Measures are needed for the major settings where patients receive care 
(i.e., the outpatient setting) as well as those that follow patients across care venues.  More 
patient-centered measures that address the actual processes important to high quality symptom 
control and care planning are needed.  Especially in terms of treatment, current indicators do not 
fully reflect progress in adult supportive or palliative care, particularly with regard to pain, 
dyspnea, and depression care.21  However, a thoughtful application of existing measurement will 
ensure that some palliative measures are useful now for most (adult) cancer patients.   
Unlike other tools for quality evaluation where incentives are relatively strong in the private 
sector for improved quality management (e.g., those for prevention or treatment of hypertension 
or diabetes), the adoption of quality metrics for supportive and palliative care is particularly 
dependent on federal endorsement.  Almost all elder care is the ultimate responsibility of the 
federal government through Medicare, Medicaid, or the VA systems.  The absence of supportive 
or palliative measures within the recent National Healthcare Quality Report is particularly 
notable in that regard.176  Strong federal leadership of both research and the application of 
measurement in clinical care will be needed to make progress in this important area.  However, 
the number of measures and indicators that we have identified and the recency of progress in this 
area suggest that now is a promising time to initiate these efforts within our health care system. 
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Appendix C. Literature Search Strategies 
SEARCH METHODOLOGIES – END OF LIFE CANCER MEASUREMENT 
 CINAHL   
 
DATABASE SEARCHED & TIME PERIOD COVERED:  
CINAHL – 1995-2005 
 
OTHER LIMITERS: 
  ENGLISH 
  HUMAN 
 
SEARCH STRATEGY #1 (PAIN NOT PALLIATIVE) 
 
(neoplasm$ or cancer$ or tumour$ or tumor$ or carcinoma$ or adenocarcinoma$ or 
malignan$).mp. [mp=title, cinahl subject headings, abstract, instrumentation]  
 
AND 
 
(guideline$ or audit$ or outcome$ or peer review$ or professional review$ or evaluat$ or 
benchmark$ or utilization review$ or consensus or perform$ or quality).mp.  
 
AND 
 
((quality or perform$) and (measur$ or indicator$ or assess$)).mp.  
 
AND 
 
pain.mp.  
 
NUMBER OF ITEMS RETRIEVED : 414    
   
------------------------------------------------------------------------------------------- 
       
SEARCH STRATEGY #2 (DEPRESSION): 
 
(neoplasm$ or cancer$ or tumour$ or tumor$ or carcinoma$ or adenocarcinoma$ or 
malignan$).mp.  
AND 
 
(guideline$ or audit$ or outcome$ or peer review$ or professional review$ or evaluat$ or 
benchmark$ or utilization review$ or consensus or perform$ or quality).mp. 
   
AND 
 
((quality or perform$) and (measur$ or indicator$ or assess$)).mp.  
 
AND 
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(depression or depressive or sadness).mp.  
 
NUMBER OF ITEMS RETRIEVED: 215 
 
----------------------------------------------------------------------------------------- 
 
DATABASE SEARCHED & TIME PERIOD COVERED:  
CINAHL – 1995-2005 
 
OTHER LIMITERS: 
  ENGLISH 
  HUMAN 
 
SEARCH STRATEGY #3 (DYSPNEA) 
 
(dyspnea or shortness of breath or difficulty breathing or breathless$).mp. 
 
AND 
 
(guideline$ or audit$ or outcome$ or peer review$ or professional review$ or evaluat$ or 
benchmark$ or utilization review$ or consensus).mp. 
 
AND 
 
((quality or perform$) and (measur$ or indicator$ or assess$)).mp. 
 
NUMBER OF ITEMS RETRIEVED : 278  (78 were duplicates) 
 
------------------------------------------------------------------------------------------------------------------ 
   
 DATABASE SEARCHED & TIME PERIOD COVERED:  
CINAHL – 1995-2005 
 
OTHER LIMITERS: 
  ENGLISH 
  HUMAN 
 
SEARCH STRATEGY #4 (ADVANCE DIRECTIVES) 
 
(advance directive$ or withdraw$ care or living will or resuscitat$).mp. 
 
AND 
 
(guideline$ or audit$ or outcome$ or peer review$ or professional review$ or evaluat$ or 
benchmark$ or utilization review$ or consensus).mp. 
 
AND 
 
((quality or perform$) and (measur$ or indicator$ or assess$)).mp. 
 
NUMBER OF ITEMS RETRIEVED : 182 
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SEARCH METHODOLOGIES – END OF LIFE CANCER MEASUREMENT 
REVISIONS – DYSPNEA & ADVANCE DIRECTIVES “NOT” CANCER 
 
 
DATABASE SEARCHED & TIME PERIOD COVERED:  
PUBMED  – 1995-2005 
 
OTHER LIMITERS: 
  ENGLISH 
  HUMAN 
 
SEARCH STRATEGY #1 (DYSPNEA) 
 
guideline*[tiab] OR quality of health care OR guideline adherence OR medical audit OR nursing audit OR 
outcome and process assessment, health care OR commission on professional and hospital activities OR 
peer review, health care OR professional review organizations OR program evaluation OR benchmarking 
OR quality assurance, health care OR guidelines[mh] OR practice guidelines OR total quality 
management OR quality indicators, health care OR utilization review OR practice guideline[pt] OR 
consensus development conference[pt] OR (communication AND physician* AND (patient* OR 
consumer*)) 
 
AND 
 
(quality OR perform*) AND (measur* OR indicator* OR assess*) 
 
AND 
 
dyspnea OR shortness of breath OR difficulty breathing OR breathless* 
 
NOT 
 
case report* 
 
NUMBER OF ITEMS RETRIEVED : 887   
 
 
DATABASE SEARCHED & TIME PERIOD COVERED:  
PUBMED  – 1995-2005 
 
OTHER LIMITERS: 
  ENGLISH 
  HUMAN 
 
SEARCH STRATEGY #2 (ADVANCE DIRECTIVES) 
 
guideline*{tiab} OR quality of health care OR guideline adherence OR medical audit OR nursing audit OR 
outcome and process assessment, health care OR commission on professional and hospital activities OR 
peer review, health care OR professional review organizations OR program evaluation OR benchmarking 
OR quality assurance, health care OR guidelines[mh] OR practice guidelines OR total quality 
management OR quality indicators, health care OR utilization review OR practice guideline[pt] OR 
consensus development conference[pt] OR (communication AND physician* AND (patient* OR 
consumer*)) 
C-4 
AND 
 
(quality OR perform*) AND (measur* OR indicator* OR assess*) 
 
AND 
 
advance care OR advance directive* OR withdrawal of care OR living will OR "do not resuscitate" 
 
NOT 
 
case report* 
 
NUMBER OF ITEMS RETRIEVED : 486  
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SEARCH METHODOLOGIES – END OF LIFE CANCER MEASUREMENT 
PAIN NOT PALLIATIVE/DEPRESSION – PUBMED 
 
 
SEARCH STRATEGY #1 (PAIN NOT PALLIATIVE): 
 
DATABASE SEARCHED & TIME PERIOD COVERED:  
   PUBMED 1995-2005 
 
OTHER LIMITERS: 
  ENGLISH 
  HUMAN 
  NOT CASE REPORTS 
 
SEARCH STRATEGY: 
 
neoplasms[mh] OR neoplasm*[tiab] OR cancer* OR tumour* OR tumor* OR carcinoma* OR 
adenocarcinoma* OR malignan* 
 
AND 
 
pain[mh] OR pain[ti] 
 
AND 
 
quality of health care OR guideline adherence OR medical audit OR nursing audit OR outcome 
and process assessment, health care OR commission on professional and hospital activities OR 
peer review, health care OR professional review organizations OR program evaluation OR 
benchmarking OR quality assurance, health care OR guidelines[mh] OR practice guidelines OR 
total quality management OR quality indicators, health care OR utilization review OR practice 
guideline[pt] OR consensus development conference[pt] OR (communication AND physician* 
AND (patient* OR consumer*)) 
 
AND 
 
(quality OR perform*) AND (measur* OR indicator* OR assess*) 
 
NOT 
 
case report* 
 
NUMBER OF ITEMS RETRIEVED: 691 
 
------------------------------------------------------------------------------------------------------------------ 
 
SEARCH STRATEGY #2 (DEPRESSION): 
 
DATABASE SEARCHED & TIME PERIOD COVERED:  
   PUBMED 1995-2005 
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OTHER LIMITERS: 
  ENGLISH 
  HUMAN 
  NOT CASE REPORTS 
 
SEARCH STRATEGY: 
 
neoplasms[mh] OR neoplasm*[tiab] OR cancer* OR tumour* OR tumor* OR carcinoma* OR 
adenocarcinoma* OR malignan* 
 
AND 
 
depressive disorders OR depression OR sadness 
 
AND 
 
quality of health care OR guideline adherence OR medical audit OR nursing audit OR outcome 
and process assessment, health care OR commission on professional and hospital activities OR 
peer review, health care OR professional review organizations OR program evaluation OR 
benchmarking OR quality assurance, health care OR guidelines[mh] OR practice guidelines OR 
total quality management OR quality indicators, health care OR utilization review OR practice 
guideline[pt] OR consensus development conference[pt] OR (communication AND physician* 
AND (patient* OR consumer*)) 
 
AND 
 
(quality OR perform*) AND (measur* OR indicator* OR assess*) 
 
NOT 
 
case report* 
 
NUMBER OF ITEMS RETRIEVED: 468 
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SEARCH METHODOLOGY – END OF LIFE CANCER MEASUREMENT - DEPRESSION 
PSYCINFO 
 
DATABASE SEARCHED & TIME PERIOD COVERED:  
PSYCINFO – 1995-2005 
 
OTHER LIMITERS: 
  ENGLISH 
  HUMAN 
 
SEARCH STRATEGY  
 
(kw: neoplasm* OR kw: cancer* OR kw: tumour* OR kw: tumor* OR kw: carcinoma* OR kw: 
adenocarcinoma* OR kw: malignan*) 
 
AND 
 
(kw: guideline* OR kw: audit OR kw: outcome* OR (kw: peer and kw: review) OR (kw: 
professional and kw: review) OR kw: evaluat* OR kw: benchmark* OR (kw: utilization and kw: 
review) OR kw: consensus) 
 
AND 
 
((kw: quality OR kw: perform*) AND (kw: measur* OR kw: indicator* OR kw: assess*)) 
 
AND 
 
((kw: depressive and kw: disorders) OR kw: depression OR kw: sadness) 
 
NUMBER OF ITEMS RETRIEVED: 86 
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SEARCH METHODOLOGIES – END OF LIFE CANCER MEASUREMENT 
                                                         PSYCINFO 
 
DATABASE SEARCHED & TIME PERIOD COVERED:  
PSYCINFO – 1995-2005 
 
OTHER LIMITERS: 
  ENGLISH 
 
SEARCH STRATEGY #1 (PAIN NOT PALLIATIVE): 
 
(kw: neoplasm* OR kw: cancer* OR kw: tumour* OR kw: tumor* OR kw: carcinoma* OR kw: 
adenocarcinoma* OR kw: malignan*) 
 
AND 
 
(kw: guideline* OR kw: audit OR kw: outcome* OR (kw: peer and kw: review) OR (kw: 
professional and kw: review) OR kw: evaluat* OR kw: benchmark* OR (kw: utilization and kw: 
review) OR kw: consensus) 
 
AND 
 
((kw: quality OR kw: perform*) AND (kw: measur* OR kw: indicator* OR kw: assess*)) 
 
AND 
 
Kw: pain 
 
NUMBER OF ITEMS RETRIEVED: 92 
 
------------------------------------------------------------------------------------ 
 
SEARCH STRATEGY #2 (DEPRESSION): 
 
DATABASE SEARCHED & TIME PERIOD COVERED:  
PSYCINFO – 1995-2005 
 
OTHER LIMITERS: 
  ENGLISH 
 
(kw: neoplasm* OR kw: cancer* OR kw: tumour* OR kw: tumor* OR kw: carcinoma* OR kw: 
adenocarcinoma* OR kw: malignan*) 
 
AND 
 
(kw: guideline* OR kw: audit OR kw: outcome* OR (kw: peer and kw: review) OR (kw: 
professional and kw: review) OR kw: evaluat* OR kw: benchmark* OR (kw: utilization and kw: 
review) OR kw: consensus) 
 
AND 
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((kw: quality OR kw: perform*) AND (kw: measur* OR kw: indicator* OR kw: assess*)) 
 
AND 
 
((kw: depressive and kw: disorders) OR kw: depression OR kw: sadness) 
 
NUMBER OF ITEMS RETRIEVED: 86 
 
------------------------------------------------------------------------------------------- 
 
SEARCH STRATEGY #3 (DYSPNEA): 
 
DATABASE SEARCHED & TIME PERIOD COVERED:  
PSYCINFO- 1995-2005 
 
OTHER LIMITERS: 
  ENGLISH 
 
SEARCH STRATEGY: 
 
(kw: dyspnea OR (kw: shortness and kw: breath) OR (kw: difficulty and kw: breathing) OR kw: 
breathless*) 
 
AND 
 
(kw: guideline* OR kw: audit OR kw: outcome* OR (kw: peer and kw: review) OR (kw: 
professional and kw: review) OR kw: evaluat* OR kw: benchmark* OR (kw: utilization and kw: 
review) OR kw: consensus) 
 
AND 
 
((kw: quality OR kw: perform*) AND (kw: measur* OR kw: indicator* OR kw: assess*)) 
 
 
NUMBER OF ITEMS RETRIEVED: 25 
 
-------------------------------------------------------------------------------------------------------- 
 
SEARCH STRATEGY #4 (ADVANCE DIRECTIVES): 
 
DATABASE SEARCHED & TIME PERIOD COVERED:  
PSYCINFO- 1995-2005 
 
OTHER LIMITERS: 
  ENGLISH 
 
SEARCH STRATEGY: 
 
((kw: advance and kw: care) OR (kw: advance and kw: directive*) OR (kw: withdrawal and kw: 
care) OR (kw: living and kw: will) OR kw: do w1 resuscitate) 
 
C-10 
AND 
 
(kw: guideline* OR kw: audit OR kw: outcome* OR (kw: peer and kw: review) OR (kw: 
professional and kw: review) OR kw: evaluat* OR kw: benchmark* OR (kw: utilization and kw: 
review) OR kw: consensus) 
 
AND 
 
((kw: quality OR kw: perform*) AND (kw: measur* OR kw: indicator* OR kw: assess*)) 
 
NUMBER OF ITEMS RETRIEVED: 66 
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Project – Measure Developer Contact Form 
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Appendix E. Cancer Measure Review Article Screener 
 
Appendix F1. Quality Measures and Indicators for Supportive Cancer Care: Pain 
 
Assessment 
 
F1-1 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease Patient Characteristics Setting 
Data Source, 
Reliability, and Validity 
1 QA Tools 
RAND1 
McGlynn, E.A.2 
Asch, S.M.3 
(Measure) Regular 
assessment of Pain. 
All patients with metastatic 
cancer to bone. 
Patients with the presence or 
absence of pain noted at least 
every 6 months. 
Mixed cancer McGlynn, E. A.: 
  Adult 
  White 
  Other (Non-White) 
   60% Male 
  Average age is 45.5 
  Age ranges from 18 to 97 
Asch, S. M.: 
  100% Male 
  Average age is 63.0 
McGlynn, E. A.: 
Community 
Asch, S. M.: 
  Community 
  (including  
  veteran sample) 
 
McGlynn, E. A.: 
  Chart 
  Reliability reported 
Asch, S. M.: 
  Chart 
2 UHC 
Maxwell, T.4 
(Measure) Routine inpatient 
pain assessment. 
Adults > or = 18 years of age, 
with admission for CHF 
(DRG 127), Cancer (DRG 82, 
203, 172, 274, 346, 10) HIV 
(DRG 489) OR respiratory 
(DRG 475, 483) AND length 
of stay > 4 days, 2 prior 
admissions for any cause in 
preceding 12 months in the 
hospital. 
Pain assessment within 48 
hours of admission on chart 
review. 
CHF 
Mixed cancer 
HIV 
Mixed 
respiratory 
diseases 
Adult 
Average age is 58.4 
Lower boundary 
for age is 18 
Hospital (non-ICU)
Hospital (ICU) 
Chart 
Reliability / Validity not 
reported 
3 UHC 
Maxwell, T.4 
(Measure) Routine inpatient 
pain assessment with a 
numeric scale. 
Adults > or = 18 years of age, 
with admission for CHF 
(DRG 127), Cancer (DRG 82, 
203, 172, 274, 346, 10) HIV 
(DRG 489) OR respiratory 
(DRG 475, 483) AND length 
of stay > 4 days, 2 prior 
admissions for any cause in 
preceding 12 months in the 
hospital , AND reported pain 
within the 1st 48 hours of 
admission. 
Persons assessed with a 
numeric pain scale. 
CHF 
Mixed cancer 
HIV 
Mixed 
respiratory 
diseases 
Adult 
Average age is 58.4 
Lower boundary 
for age is 18 
Hospital (non-ICU)
Hospital (ICU) 
Chart 
Reliability / Validity not 
reported 
 
 
Assessment 
 
F1-2 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease Patient Characteristics Setting 
Data Source, 
Reliability, and Validity 
4 VHA 
VHA Updated March 
20055 
Pronovost, P.J.6 
Erdek, M.A.7 
(Measure) Regular ICU pain 
assessment. 
4 hour periods during which 
the patients physically present 
in the ICU, including the 
initial period if at least present 
for 2 hours. 
Total number of 4-hour 
intervals (within the first 24 
hours following ICU 
admission) for which pain was 
assessed and documented, 
using an appropriate rating 
scale. 
Mixed ICU 
Population 
Not Reported Hospital (ICU) Data source not reported 
Reliability / Validity not 
reported 
5 QOPI 
Neuss, M.N.8  
(Measure) Assessing pain in 
patients close to death. 
Recently deceased patients 
from oncology practices. 
Medical records where there 
is an explicit practioner's 
notation quantifying their 
physical pain or lack thereof 
on their last visit to the office 
prior to death. 
Mixed cancer Not Reported Ambulatory / 
outpatient care 
Chart 
Reliability / Validity not 
reported 
6 ACOVE End of Life 
Wenger, N.S.9 
Saliba, D.10 
(Indicator) Routine pain 
assessment in expected dying. 
IF a VE who was conscious 
during the last 3 days and died 
an expected death THEN the 
medical record should contain 
documentation about pain or 
lack of pain during the last 3 
days of life. 
Vulnerable elders who are 
conscious during the last 3 
days of life. 
Number of vulnerable elders 
with documentation of pain or 
lack of pain during the last 3 
days of life. 
Not Reported Wenger, N. S.: 
  Adult 
   36% Male 
  Average age is 81.0 
Wenger, N. S.: 
  Not Reported 
Saliba, D.: 
  Nursing home 
 
Patient interview / survey 
Chart 
Reliability / Validity not 
reported 
 
7 Cancer Care Georgia 
National Cancer Policy 
Board (NCPB)11 
(Indicator) Routine 
assessment of pain. 
Number of cancer patient 
encounters. 
Number of cancer patient 
encounters where patient 
where patient was assessed for 
pain. 
Mixed cancer Not Reported Not Reported Data source not reported 
Reliability / Validity not 
reported 
 
 
 
 
Treatment 
 
F1-3 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease Patient Characteristics Setting 
Data Source, 
Reliability, and Validity 
8 QA Tools 
RAND1 
McGlynn, E.A.2 
Asch, S.M.3 
(Measure) Responsive pain 
treatment. 
All cancer patients whose pain 
is uncontrolled. 
Patients offered a change in 
pain management within 
24hours of the pain 
complaint. 
Mixed cancer McGlynn, E. A.: 
  Adult 
  White 
  Other (Non-White) 
   60% Male 
  Average age is 45.5 
  Age ranges from 18 to 97 
Asch, S. M.: 
  100% Male 
  Average age is 63.0 
McGlynn, E. A.: 
Community 
Asch, S. M.: 
  Community 
  (including  
  veteran sample) 
McGlynn, E. A.: 
  Chart 
  Reliability reported 
Asch, S. M.: 
  Chart 
9 UHC 
Maxwell, T.4 
(Measure) Regular 
prophylaxis of opiate-induced 
constipation. 
Adults > or = 18 years of age, 
with admission for CHF (DRG 
127), Cancer (DRG 82, 203, 
172, 274, 346, 10) HIV (DRG 
489) OR respiratory (DRG 475, 
483) AND length of stay > 4 
days, 2 prior admissions for 
any cause in preceding 12 
months in the hospital , AND 
treated with narcotics. 
Proportion with a bowel 
regimen ordered within 24 
hours of the opioid ordered 
and not contraindicated. 
CHF 
Mixed cancer 
HIV 
Mixed 
respiratory 
diseases 
Average age is 58.4 
Lower boundary 
for age is 18 
Hospital (non-
ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not 
reported 
10 Wu, J.S.12 
 
(Indicator) Minimizing 
radiotherapy burden. 
All adult patients with single of 
multiple radiographically 
confirmed bone metastases of 
any histology corresponding to 
painful areas in previously 
nonirradiated areas without 
pathologic fractures or spinal 
cord/cauda equina 
compression. It does not apply 
to the management of 
malignant primary bone tumor. 
For patients receiving 
radiotherapy where the 
objective / intent is pain relief. 
% of those patients receiving 
single dose therapy as a single 
8Gy treatment, prescribed to 
the appropriate target volume. 
Mixed cancer Adult Not Reported Data source not reported 
Reliability / Validity not 
reported 
 
 
Treatment 
 
F1-4 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease Patient Characteristics Setting 
Data Source, 
Reliability, and Validity 
11 Cancer Care Nova Scotia 
Grunfeld, E.13 
(Indicator) Effective 
treatment for painful bony 
metastasis. 
Patients with uncontrolled bone 
pain. 
Patients who are offered 
within one week of the 
notation of pain: - radiation 
therapy to the sites of pain. 
Mixed cancer All patients in the 
population with cancer 
Not Reported Cancer registry, 
administrative claim data, 
hospital discharge abstract 
Reliability / Validity not 
reported 
 
 
Follow-up 
 
F1-5 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease Patient Characteristics Setting 
Data Source, 
Reliability, and Validity 
12 NHPCO 
National Hospice and 
Palliative Care 
Organization (NHPCO)14 
Connor, S.R.15  
Ryndes, T.16 
(Measure) Timely treatment 
of pain in hospice. 
Patients admitted to hospice who 
answer 'yes' when asked "Are you 
uncomfortable because of pain?". 
The proportion of patients 
between 48 and 120 hours 
after admission who report 
'yes' when asked "Was your 
pain brought to an 
acceptable level within 48 
hours of your admission to 
the hospice program?". 
Mixed hospice 
population 
NHPCO: 
  Adult 
Connor, S. R.: 
  Adult 
  White 
  African American 
  Hispanic 
  Asian 
  Native American / Eskimo 
  44% Male 
Hospice Patient interview / survey 
Reliability / Validity not 
reported 
13 VHA 
Updated March 20055 
Pronovost, P.J.6 
Erdek, M.A.7 
(Measure) Effective 
treatment of pain in the ICU. 
Total number of 4-hour intervals 
(within the first 24 hours 
following ICU admission) with 
numerical pain values of 1 to 10, 
for patients with an ICU length of 
stay >=24 hours. 
Total number of 4-hour 
intervals (within the first 24 
hours following ICU 
admission) for which the 
documented pain score was 
<3. 
Mixed ICU 
Population 
Not Reported Hospital (ICU) Data source not reported 
Reliability / Validity not 
reported 
14 Cancer Care Ontario17 (Measure) Satisfaction with 
pain treatment. 
Outpatient cancer patients 
reporting mild to severe pain. 
Patients where the response 
to the question "Do you 
think staff did everything 
they could to control your 
pain or discomfort?" was (1) 
yes, completely; (2) yes, 
somewhat; or (3) no. 
Mixed cancer Not Reported Ambulatory / 
outpatient care 
Patient interview / survey 
Reliability / Validity not 
reported 
15 UHC 
Maxwell, T.4 
(Measure) Timely treatment  
of inpatient pain. 
Adults > or = 18 years of age, 
with admission for CHF (DRG 
127), Cancer (DRG 82, 203, 172, 
274, 346, 10) HIV (DRG 489) OR 
respiratory (DRG 475, 483) AND 
length of stay > 4 days, 2 prior 
admissions for any cause in 
preceding 12 months in the 
hospital , AND reported pain 
within the 1st 48 hours of 
admission. 
Persons with pain relief or 
reduction within 48 hours of 
admission < or = 3 on 0-10 
scale. 
CHF 
Mixed cancer 
HIV 
Mixed 
respiratory 
diseases 
Adult 
Average age is 58.4 
Lower boundary 
for age is 18 
Hospital (non-
ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not 
reported 
 
 
Follow-up 
 
F1-6 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease Patient Characteristics Setting 
Data Source, 
Reliability, and Validity 
16 Cancer Care Georgia 
National Cancer Policy 
Board (NCPB)11 
(Indicator) Effective 
treatment of pain. 
Number of cancer patients who 
are not comatose. 
Number of cancer patients 
who report being in more 
than minor pain. 
Mixed cancer Not Reported Not Reported Data source not reported 
Reliability / Validity not 
reported 
 
 
 
Potential Indicators 
Assessment 
 
F1-7 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator 
17 Erdek, M.A.7 Physician documentation of 
pain assessment. 
 
All patients with 
cancer. 
Patients where a pain 
assessment is 
documented in the 
physician note. 
18 Green, C.R.18 Disparities in pain 
assessment. 
All patients with 
cancer who are 
assessed for pain. 
Non-white patients with 
cancer who are assessed 
for pain. 
19 Ferrell, B.R.19  
 
Assessment in patients who 
cannot verbalize their pain. 
Cancer patients who 
have difficulty 
verbalizing their pain. 
Patients who are 
assessed for pain. 
20 Carr, D.B.20 
 
Assessment for depression 
in patients with pain. 
 
All cancer patients 
with pain. 
Patients assessed for 
depression. 
 
 
Potential Indicators 
Treatment 
 
F1-8 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator 
21 Allard, P.21 
Gordon, D.B.22 
Education about pain 
management. 
 
Cancer patients with 
pain. 
Patients who are 
educated about pain 
management. 
22 Marinangeli, F.23 
Gordon, D.B.22 
Use of opioids for sever, 
persistent pain. 
Cancer patients with 
severe, persistent pain. 
Patients who are treated 
with opioids. 
23 NIH State-of-the-Science 
Statement24 
Use of long-acting pain 
medications. 
 
All adults with cancer 
who have persistent 
pain and are prescribed 
opioids. 
Adults who are 
prescribed long acting 
opioids. 
24 World Health Organization 
(WHO)25 
Procedure-related pain in 
children. 
All children with 
cancer receiving 
painful procedures. 
Children who receive 
appropriate preparation 
and/or anesthesia. 
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Appendix F2. Quality Measures and Indicators for Supportive Cancer Care: Dyspnea 
 
Assessment 
 
F2-1 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
1 UHC 
Maxwell, T.1 
(Measure)  Regular 
assessment of dyspnea. 
Adults > or = 18 years of age, 
with admission for CHF (DRG 
127), Cancer (DRG 82, 203, 
172, 274, 346, 10) HIV (DRG 
489) OR respiratory (DRG 475, 
483) AND length of stay > 4 
days AND 2 prior admissions 
for any cause in preceding 12 
months in the hospital. 
Dyspnea assessment 
within 48 hours of 
admission. 
CHF 
Mixed cancer 
HIV 
Mixed respiratory diseases 
Adult 
Average age is 
58.4 
Lower boundary 
for age is 18 
Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
 
 
 
Treatment 
 
F2-2 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
2 ACOVE End of Life 
Wenger, N.S.2 
 
(Indicator) Effective dyspnea treatment in 
expected dying. 
IF a noncomatose vulnerable elder is not 
expected to survive and a mechanical 
ventilator is withdrawn or intubation is 
withheld, THEN the patient should receive 
(or have orders available for) an opiate of 
benzodiazepine or barbiturate infusion to 
reduce dyspnea, and the chart should 
document whether the patient has dyspnea. 
Noncomatose vulnerable 
elders who are not expected to 
survive and a mechanical 
ventilator is withdrawn or 
intubation is withheld. 
Patient received or had 
ordered an opiate or 
benzodiazepine or barbiturate 
infusion to reduce dyspnea and 
the chart documented whether 
the patient has dyspnea. 
Not Reported Adult All settings Chart 
Reliability / Validity not reported 
3 ACOVE End of Life 
Wenger, N.S.2 
 
(Indicator) Regular treatment and follow-up 
of dyspnea in expected dying. 
IF a vulnerable elder who had dyspnea in the 
last 7 days of life died an expected death, 
THEN the chart should document how the 
dyspnea was treated and follow-up should be 
documented about the dyspnea. 
Vulnerable elders who had 
dyspnea in the last 7 days of 
life and died expected deaths. 
Chart documents how dyspnea 
was treated and follow-up 
about the dyspnea. 
Not Reported Adult All settings Chart 
Reliability / Validity not reported 
4 QA Tools 
Golomb, B.3 
McGlynn, E.A.4 
Asch, S.M.5 
 
(Indicator) Treatment of dyspnea caused by 
hypoxia. 
Patients with dyspnea and 
baseline room air oxygen 
saturation < 88% at rest. 
Therapy with home oxygen 
was used. 
COPD Adult Not Reported Chart 
Reliability / Validity not reported 
 
 
 
Follow-up 
 
F2-3 
 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
5 UHC 
Maxwell, T.1 
 
(Measure) Timely 
treatment of inpatient 
dyspnea. 
Adults > or = 18 years of 
age, with admission for CHF 
(DRG 127), Cancer (DRG 
82, 203, 172, 274, 346, 10) 
HIV (DRG 489) OR 
respiratory (DRG 475, 483) 
AND length of stay > 4 
days, 2 prior admissions for 
any cause in preceding 12 
months in the hospital , 
AND reported dyspnea 
within the 1st 48 hours of 
admission. 
Dyspnea relief or 
reduction within 48 
hours of admission. 
CHF 
Mixed cancer 
HIV 
Mixed respiratory diseases 
Adult 
Average age is 58.4 
Lower boundary for age is 18 
Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
 
 
Potential Indicators 
Assessment 
 
F2-4 
 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
6 Dudgeon, D.J.6 
Kvale, P.A.7 
Dyspnea. Mechanisms, 
assessment, and 
management: a consensus 
statement. American 
Thoracic Society8 
Ferguson, G.T.9 
 
The optimal treatment for breathlessness is correction 
of the cause. 
In all patients with lung cancer, potentially 
correctable causes of dyspnea, such as localized 
obstruction of a major airway, a large pleural 
effusion, or an exacerbation of coexisting COPD, 
should be sought initially. 
Diagnostic testing … to identify the specific nature of 
the disorder … is the cornerstone of the assessment of 
dyspnea and leads to a correct diagnosis in many, but 
not all, cases.  Correction or amelioration of the 
disorder follows and generally reduces the intensity of 
dyspnea, increases the comfort with which patients 
perform activities, and increases their capacity to 
exercise. 
Spirometry … is recommended for patients with 
respiratory symptoms such as chronic cough, episodic 
wheezing, and exertional dyspnea in order to detect 
airways obstruction. 
Patients with dyspnea. Evaluation was 
performed to search for 
correctable conditions as 
causative for dyspnea. 
Mixed cancer 
Lung cancer 
COPD 
Adult 
 
Not Reported Data source not reported 
Reliability / Validity not reported 
 
 
 
Potential Indicators 
Treatment 
 
F2-5 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
7 Kvale, P.A.7 
 
Patients with malignant pleural effusions that cause 
dyspnea initially should be drained by thoracentesis. 
Patients with NSCLC and better performance status and 
recurrent malignant pleural effusions, and whose lungs 
re-expand with initial thoracentesis or thoracoscopy, 
should be followed up by pleurodesis. 
In patients with SCLC, the treatment of choice for 
malignant effusions is systemic chemotherapy. 
Patients with cancer and 
dyspnea caused by 
malignant pleural 
effusion. 
Therapy with 
thorocentesis and 
appropriate subsequent 
therapy (pleurodesis, 
chemotherapy, or other) 
Lung cancer 
Mixed cancer 
Adult Not Reported Data source not reported 
Reliability / Validity not reported 
8 Kvale, P.A.7 
 
For patients with central airway obstruction, 
bronchoscopy should be done to determine the type of 
airway obstruction (extraluminal tumor compression of 
the major airways, intraluminal tumor growth, or both). 
In patients with central airway obstruction, rapid relief 
of dyspnea can be accomplished via bronchoscopy with 
removal of intraluminal tumor (laser, electrocautery, 
APC) and/or by inserting a stent.  
Patients with cancer and 
dyspnea caused by 
central airway 
obstruction. 
Diagnostic 
bronchoscopy and 
bronchoscopic therapy 
(laser, electrocautery, 
stent,  argon plasma 
coagulation, 
cryotherapy, 
brachytherapy, and/or 
photodynamic therapy) 
was offered or received. 
Mixed cancer Adult Not Reported Data source not reported 
Reliability / Validity not reported 
9 Kvale, P.A.7 
 
For all lung cancer patients with dyspnea, 
nonpharmacologic, noninterventional treatments 
including patient education and intervention by allied 
health personnel should be used to help control dyspnea, 
including breathing control, activity pacing, relaxation 
techniques, fans, and psychosocial support. 
Patients with cancer and 
dyspnea. 
Therapy with 
nonpharmacologic and 
noninterventional 
approaches (including 
breathing control, 
activity pacing, 
relaxation techniques, 
fans, and psychosocial 
support), including 
patient education, was 
received. 
Mixed cancer Adult Not Reported Data source not reported 
Reliability / Validity not reported 
 
 
Potential Indicators 
Treatment 
 
F2-6 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
10 Socinski, M.A.10 
Pfister, D.G.11 
Data from case series and randomized trials show that 
chemotherapy can have a palliative effect on disease-
related symptoms [especially dyspnea, cough, and chest 
pain] and can improve QOL compared to BSC in stage 
IV NSCLC patients who are deemed suitable for 
treatment.  
Brachytherapy, photodynamic therapy, and the laser … 
have been found to produce effective palliation of 
symptomatic endobronchial disease, with palliation of 
cough, hemoptysis, and dyspnea. 
Patients with 
appropriate 
malignancies and 
dyspnea. 
Palliative chemotherapy 
or radiotherapy 
(external beam, 
brachytherapy, and 
photodynamic therapy) 
was offered or received 
for patients who are 
deemed suitable for 
treatment. 
Mixed cancer Not Reported Not Reported Data source not reported 
Reliability / Validity not reported 
11 Kvale, P.A.7 
Dyspnea. Mechanisms, 
assessment, and 
management: a consensus 
statement. American 
Thoracic Society8 
Jennings, A.L.12 
Booth, S.13 
 
For all lung cancer patients with dyspnea, 
pharmacologic approaches for the management of 
dyspnea may include oxygen, bronchodilators, 
corticosteroids, antibiotics, and opioids.  
It is reasonable to recommend a trial of anxiolytic 
therapy on an individual basis, particularly in those with 
morbid anxiety or respiratory panic attacks. 
Bronchodilators have been shown … to improve 
dyspnea [in those with obstructive lung disease]. 
This review shows statistically strong evidence for a 
small and probably clinically significant effect of oral or 
parenteral opioids in the treatment of breathlessness. 
Opiates acutely relieve dyspnea and improve exercise 
performance …; despite safety concerns, these drugs do 
have a place in the management of patients in the 
terminal phase of their illness. 
Oxygen therapy may be one part of the palliative or 
supportive care of patients with cancer. 
Patients with cancer and 
dyspnea. 
Therapy with 
pharmacologic 
approaches (including  
oxygen, 
bronchodilators, 
corticosteroids, 
antibiotics, anxiolytics, 
and opiates) were 
offered or received in 
appropriate conditions 
as part of the palliative 
management. 
Lung cancer 
Mixed cancer 
CHF 
COPD 
Infection 
Adult Not Reported Data source not reported 
Reliability / Validity not reported 
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Appendix F3. Quality Measures and Indicators for Supportive Cancer Care:  Depression 
 
Assessment 
 
F3-1 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
1 UHC 
Maxwell, T.1 
 
(Measure) Regular 
assessment for 
psychosocial well-being. 
Adults > or = 18 years of 
age, with admission for 
CHF (DRG 127), Cancer 
(DRG 82, 203, 172, 274, 
346, 10) HIV (DRG 489) 
OR respiratory (DRG 475, 
483) AND length of stay > 
4 days, 2 prior admissions 
for any cause in preceding 
12 months in the hospital. 
Formal psychosocial 
assessment up to 1 year 
prior to admission during 
a previous hospitalization 
OR within 4 days of 
index admission. 
CHF 
Mixed cancer 
HIV 
Mixed respiratory diseases 
Adult 
Average age is 58.4 
Lower boundary  for 
age is 18 
Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
2 ACOVE End of Life 
Wenger, N.S.2 
Saliba, D.3 
 
(Indicator) Regular 
spiritual assessment in 
expected dying. 
IF a vulnerable elder who 
was conscious during the 
last 3 days of life died an 
expected death, THEN the 
medical record should 
contain documentation 
about spirituality or how 
the patient was dealing 
with death or religious 
feelings. 
Vulnerable elder who was 
conscious during the last 3 
days of life. 
Vulnerable elder with 
documentation of 
spiritual assessment in the 
medical record. 
Not Reported Not Reported All settings Patient interview / survey 
Chart 
Reliability / Validity not reported 
 
 
 
 
Treatment 
 
 
F3-2 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
3 ACOVE  
Wenger, N.S.2 
Saliba, D.3 
Nakajima, G.A.4 
 
(Measure) Regular 
assessment or treatment of 
depression in newly 
diagnosed cancer. 
Vulnerable elders presenting 
with onset or discovery 
malignancy (excluding skin 
cancer) and other conditions*. 
Patients asked about or treated 
for depression, or referred to a 
mental health professional 
within two months of diagnosis 
of a condition. 
Saliba, D.: 
Mixed nursing home  
population for 11 
diagnoses,   not cancer 
Adult 
 
All settings Patient interview / survey 
Chart 
Reliability / Validity not reported 
4 ACOVE  
Wenger, N.S.2 
Saliba, D.3 
Nakajima, G.A.4 
 
(Measure) Routine 
assessment or treatment of 
depression in symptomatic 
patients. 
Vulnerable elders presenting 
with new onset of one the 
following symptoms:  sad mood, 
feeling down;  insomnia or 
difficulties with sleep;  apathy or 
loss of interest in pleasurable 
activities; complaints of memory 
loss;  unexplained weight loss of 
greater than 5% in the past 
month or 10% over one year; or 
unexplained fatigue or low 
energy. 
Patients asked about or treated 
for depression, or referred to a 
mental health professional 
within two weeks of 
presentation. 
Saliba, D.: 
Mixed nursing home  
population for 11 
diagnoses,   not cancer 
Adult 
 
All settings Patient interview / survey 
Chart 
Reliability / Validity not reported 
 
* Other conditions include stroke, myocardial infarction, dementia, chronic pain, alcohol or substance abuse or dependence, anxiety disorder, or personality disorder.
 
 
Potential Indicators 
Assessment 
 
F3-3 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
5 ACOVE End of Life 
Nakajima, G.A.4 
 
IF a vulnerable elder has 
thoughts of suicide THEN the 
medical record should 
document, on the same date, that 
the patient either has no 
immediate plan for suicide, or 
that the patient was referred for 
evaluation for psychiatric 
hospitalization. 
Vulnerable elders with 
thoughts of suicide. 
Patients where medical record 
documents, on the same date, that the 
patient either has no immediate plan 
for suicide, or that the patient was 
referred for evaluation for psychiatric 
hospitalization. 
Not Reported Adult 
 
All settings Chart 
Reliability / Validity not reported 
6 ACOVE End of Life 
Nakajima, G.A.4 
 
IF a vulnerable elder receives a 
diagnosis of a new depression 
episode THEN the medical 
record should document at least 
three of the nine Diagnostic and 
Statistical Manual (DSM) IV 
target symptoms for major 
depression within the first month 
of diagnosis. 
Vulnerable elders with 
diagnosis of a new 
depression episode. 
Patients where the medical record 
documents at least three of the nine 
DSM-IV target symptoms for major 
depression within the first month of 
diagnosis. 
Not Reported Adult 
 
All settings Chart 
Reliability / Validity not reported 
7 ACOVE End of Life 
Nakajima, G.A.4 
 
IF a vulnerable elder receives a 
diagnosis of a new depression 
episode THEN the medical 
record should document, on the 
day of diagnosis, the presence or 
absence of suicidal ideation. 
Vulnerable elders with 
diagnosis of a new 
depression episode. 
Patients where the medical record 
document on the day of diagnosis the 
presence or absence of suicidal 
ideation and psychosis (consisting of, 
at a minimum, auditory hallucinations 
or delusions). 
Not Reported Adult 
 
All settings Chart 
Reliability / Validity not reported 
 
 
Potential Indicators 
Treatment 
 
F3-4 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
8 ACOVE End of Life 
Nakajima, G.A.4 
 
IF a vulnerable elder is being 
treated for  depression with 
antidepressants THEN the 
antidepressants should be 
prescribed at appropriate starting 
doses, and they should have an 
appropriate titration schedule to 
a therapeutic dose, therapeutic 
blood level, or remission of 
symptoms by 12 weeks. 
Vulnerable elders being 
treated for depression with 
antidepressants. 
Patients with antidepressants 
prescribed at appropriate starting 
doses, and with an appropriate 
titration schedule to a therapeutic 
dose, therapeutic blood level, or 
remission of symptoms by 12 weeks. 
Not Reported Adult 
 
All settings Chart 
Reliability / Validity not reported 
9 ACOVE End of Life 
Nakajima, G.A.4 
 
IF a vulnerable elder has no 
meaningful symptom response 
after 6 weeks of treatment 
THEN one of the following 
should be initiated by the eighth 
week of treatment: Optimization 
of medication (i.e., alter dose of 
initial medication; change to or 
add a different  medication); 
psychiatric referral (if initial 
treatment was medication); or 
medication trial (if initial 
treatment was psychotherapy 
alone). 
Vulnerable elders with 
depression and no 
meaningful symptom 
response after 6 weeks of 
treatment. 
Patients with one of the following 
treatment options initiated by the 8th 
week of treatment:  medication dose 
should be optimized or the patient 
should be referred to a psychiatrist (if 
initial treatment was medication); or 
medication should be initiated or 
referral to a psychiatrist should be 
offered (if initial treatment was 
psychotherapy alone). 
Not Reported Adult 
 
All settings Chart 
Reliability / Validity not reported 
 
 
 
Potential Indicators 
Follow-up 
 
F3-5 
 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
10 ACOVE End of Life 
Nakajima, G.A.4 
 
IF a vulnerable elder responds 
only partially after 12 weeks of 
treatment THEN at least one of 
the following treatment options 
should be instituted by the 16th 
week of treatment: switch to a 
different medication class or add 
a second medication to the first 
(if initial treatment includes 
medication); add psychotherapy 
(if the initial treatment was 
medication); a trial of 
medication (if initial treatment 
was psychotherapy without 
medication), consider 
electroconvulsive therapy, or 
referral to a psychiatrist. 
Vulnerable elders 
responding only partially 
after 12 weeks of 
treatment. 
Patients with one of the following 
treatment options instituted by the 
16th week of treatment:  switch to a 
different medication class or add a 
second medication to the first (if 
initial treatment includes medication); 
add psychotherapy (if the initial 
treatment was medication);  try 
medication (if initial treatment was 
psychotherapy without medication);  
consider ECT;  or refer to a 
psychiatrist. 
Not Reported Adult 
 
All settings Chart 
Reliability / Validity not reported 
11 ACOVE End of Life 
Nakajima, G.A.4 
 
IF a vulnerable elder has 
responded to antidepressant 
medication THEN he or she 
should be continued on the drug 
at the same dosage for at least 6 
months, and at least one 
physician documentation about 
depression should occur during 
that time period 
Vulnerable elders  
responding to 
antidepressant medication. 
Patients continued on the drug at the 
same dose for at least six months, and 
making at least one clinician contact 
(office visit or phone) during that time 
period. 
Not Reported Adult 
 
All settings Chart 
Reliability / Validity not reported 
12 ACOVE End of Life 
Nakajima, G.A.4 
 
IF a vulnerable elder is 
diagnosed with depression 
THEN antidepressant treatment, 
psychotherapy, or 
electroconvulsive therapy should 
be offered within 2 weeks after 
diagnosis unless there is 
documentation within that period 
that the patient has improved, or 
unless the patient has substance 
abuse or dependence, in which 
case treatment could wait until 8 
weeks after the patient is in a 
drug- or alcohol-free state. 
Vulnerable elders with 
diagnosis of a new 
depression episode. 
Patients with antidepressant treatment, 
psychotherapy, or electroconvulsive 
therapy (ECT) be offered within two 
weeks after diagnosis unless there is 
documentation within that period that 
the patient has improved, or unless the 
patient has substance abuse or 
dependence, in which case treatment 
may wait until eight weeks after the 
patient is in a drug or alcohol free 
state. 
Not Reported Adult 
 
All settings Chart 
Reliability / Validity not reported 
 
 
 
Potential Indicators 
Follow-up 
 
F3-6 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
13 ACOVE End of Life 
Nakajima, G.A.4 
 
IF a vulnerable elder is started 
on an antidepressant medication 
THEN the following 
medications should not be used 
as first- or second-line therapy: 
tertiary amine tricyclics 
(amitriptyline, imipramine, 
doxepin, clomipramine, 
trimipramine); monoamine 
oxiase inhibitors (MAOIs) 
(unless atypical depression is 
present); benzodiazepines; or 
stimulants (except 
methylphenidate). 
Vulnerable elders being 
treated for depression with 
antidepressants. 
Patients where the following 
medications are not used as first- or 
second-line therapy:  tertiary amine 
tricyclics, monoamine oxidase 
inhibitors (unless atypical depression 
is present), benzodiazepines, or 
stimulants (except methylphenidate). 
Not Reported Adult 
 
All settings Chart 
Reliability / Validity not reported 
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Appendix F4. Quality Measures and Indicators for Supportive Cancer Care: 
Advanced Care Planning 
 
Assessment 
 
F4-1 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
1 
 
 
ACOVE End of Life 
Wenger, N.S.1 
Wenger, N.S.2 
 
(Measure) Regular 
identification of a surrogate 
in the outpatient setting. 
All vulnerable elders should 
have in their outpatient chart 
one of the following: 1) an 
advance directive indicating 
the patient's surrogate/proxy 
decision-maker, 2) 
documentation of a 
discussion about who would 
be a surrogate decision 
maker or a search for a 
surrogate, or 3) indication 
that there is no identified 
surrogate upon entry to 
facility or transfer to new 
unit or site. 
All vulnerable elderly 
patients in an 
outpatient setting. 
Number of vulnerable elderly 
patient's with documentation in their 
medical record of their proxy or 
surrogate decision-maker's name and 
contact information, or of a 
discussion with patient of who would 
be surrogate, or documentation of a 
search for a surrogate, or an 
indication that there is no identified 
surrogate. 
Mixed disease Adult 
 36% Male 
Average age is 81.0 
Home care 
Hospice 
Ambulatory / outpatient care
Hospital (non-ICU) 
Hospital (ICU) 
Home 
Community 
Patient interview / survey 
Chart 
Reliability / Validity not reported 
2 
 
ACOVE End of Life 
Wenger, N.S.1 
Wenger, N.S.2 
 
(Measure) Regular 
identification of a surrogate 
among hospital admissions 
with impaired cognition. 
IF a vulnerable elder with 
dementia, coma, or altered 
mental status is admitted to 
the hospital, THEN within 
48 hours of admission the 
medical record should 1) 
contain an advance directive 
indicating the patient's 
surrogate decision maker, 2) 
document a discussion about 
who would be a surrogate 
decision maker or a 
discussion about a search for 
a surrogate, or 3) indicate 
that there is no identified 
surrogate. 
All vulnerable elders 
with dementia, coma, 
or altered mental 
status admitted to the 
hospital. 
Number of vulnerable elders with 
dementia, coma, or altered mental 
status admitted to a hospital with 
documentation within 48 hours of 
admission of 1) an advance directive 
indicating the patient's surrogate 
decision maker, 2) a discussion about 
who would be a surrogate decision 
maker or a discussion about a search 
for a surrogate, or 3) indicate that 
there is no identified surrogate. 
Mixed disease Adult 
 36% Male 
Average age is 81.0 
Ambulatory / outpatient care 
Hospital (non-ICU) 
Hospital (ICU) 
Patient interview / survey 
Chart 
Reliability / Validity not reported 
 
 
Assessment 
 
F4-2 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
3 
 
ACOVE End-of Life 
Wenger, N.S.1 
Wenger, N.S.2 
 
(Measure) Regular 
assessment of preferences 
among inpatients with 
dementia. 
IF a vulnerable elder has a 
diagnosis of severe dementia 
is admitted to the hospital 
and survives 48 hours, 
THEN within 48 hours of 
admission, the medical 
record should document that 
the patient's the patient's 
prior preferences for care 
have been considered or that 
these preferences for care 
could not be elicited or are 
unknown. 
All vulnerable elders 
with severe dementia 
admitted to a hospital 
and surviving 48 
hours. 
Number of vulnerable elders with 
severe dementia admitted to a 
hospital and surviving 48 hours with 
documentation that the patient's prior 
preferences for care have been 
considered or that these preferences 
could not be elicited or are unknown.
Mixed disease Adult 
 36% Male 
Average age is 81.0 
Hospice 
Ambulatory / outpatient care
Hospital (non-ICU) 
Hospital (ICU) 
Home 
Patient interview / survey 
Chart 
Reliability / Validity not reported 
4 
 
ACOVE End of Life 
Wenger, N.S.1 
Wenger, N.S.2 
 
(Measure) Regular 
assessment of preferences in 
an ICU. 
IF a vulnerable elder is 
admitted directly to the 
intensive care unit from an 
outpatient or ER setting and 
survives 48 hours, THEN 
within 48 hours of 
admission, the medical 
record should document that 
the patient's preferences for 
care have been considered or 
that these preferences could 
not be elicited or are 
unknown. 
All vulnerable elderly 
patients admitted 
directly to the ICU 
from an outpatient or 
ER setting and 
surviving 48 hours. 
Number of vulnerable elders 
admitted directly to the intensive 
care unit from an outpatient or ER 
setting and surviving 48 hours with 
documentation in the medical record 
that the patient's preferences for care 
have been considered or that these 
preferences could not be elicited or 
are unknown within 48 hours of 
admission. 
Mixed disease Adult 
 36% Male 
Average age is 81.0 
Hospice 
Ambulatory / outpatient care
Hospital (non-ICU) 
Hospital (ICU) 
Patient interview / survey 
Chart 
Reliability / Validity not reported 
 
 
Assessment 
 
F4-3 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
5 
 
Ryndes, T.3 
National Hospice and 
Palliative Care 
Organization (NHPCO)4 
 
(Measure) Regular 
assessment of preferences in 
hospice. 
 
All patients admitted 
to hospice. 
Number of hospice patients with 
documentation in their medical 
record that they were assessed upon 
admission including physical, 
functional, emotional and spiritual 
needs and preferences with full 
autonomy to make decisions about 
how the remainder of their life is to 
be spent; any living will or advance 
directive information, and/or an 
assigned power of attorney for health 
care. 
Mixed disease Adult Home Chart 
Construct validity 
Discriminant validity 
Other validity 
Reliability / Validity not reported 
6 
 
ACOVE End of Life 
Wenger, N.S.1 
Wenger, N.S.2 
 
(Measure) Regular patient 
participation in decisions to 
limit treatment. 
IF a vulnerable elder with 
decision-making capacity 
has orders written in the 
hospital or the nursing home 
to withhold or withdraw a 
particular treatment (e.g., a 
do-not-resuscitate order or 
an order not to initiate 
dialysis), THEN the medical 
record should document 1) 
patient participation in the 
decision or 2) why the 
patient did not participate in 
the decision. 
All vulnerable elderly 
patients in the 
hospital or nursing 
home with written 
orders to withdraw or 
withhold a LST. 
Number of vulnerable elderly 
patients with decision-making 
capacity with written orders to 
withhold or withdraw a particular 
LST with documentation in the 
medical record of 1) patient 
participation in the decision or 2) 
why the patient did not participate in 
the decision. 
Mixed disease Adult 
 36% Male 
Average age is 81.0 
Hospital (non-ICU) 
Hospital (ICU) 
Patient interview / survey 
Chart 
7 
 
UHC 
Maxwell, T.5 
 
(Measure) Regular family 
meetings among 
hospitalized patients. 
 
All adults admitted to 
the hospital. 
Number of adults admitted to the 
hospital with documentation in the 
medical record that the health care 
team conducted a patient/family 
meeting within 1 week of admission 
that included discussion of the 
patient's treatment preferences and/or 
a plan for discharge disposition. 
Mixed disease Adult Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
8 
 
UHC 
Maxwell, T.5 
 
(Measure) Timely and 
effective discharge planning. 
All adults admitted to 
the hospital. 
Number of adults admitted to the 
hospital with documentation in the 
medical record of a plan for 
discharge disposition within 4 days 
of admission. 
Mixed disease Adult Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
 
 
Assessment 
 
F4-4 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
9 
 
VHA Update March 20056 
 
 
(Indicator) Regular 
identification of a surrogate 
in the ICU. 
 
Total number of 
patients with an ICU 
length of stay > 24 
hours. 
Number  of ICU patients with 
documentation in the chart of status 
of identification of a health care 
proxy (or other appropriate surrogate 
decision-maker) including one or 
more of the following: 1) 
documentation that the patient has a 
health care proxy, 2) documentation 
that the patient declined to appoint a 
health care proxy, 3) documentation 
that the care team discussed health 
care proxy appointment with the 
patient and/or family, 4) 
documentation that the patient has an 
appropriate surrogate decision-maker 
other than a health care proxy. 
Not Reported Adult Hospital (ICU) Chart 
Reliability / Validity not reported 
10 
 
VHA Update March 20056  
 
(Indicator) Regular 
assessment of advance 
directives for ICU patients. 
Total number of 
patients with an ICU 
length of stay > than 
24 hours. 
Number  of patients admitted to the 
ICU with documentation of the 
patient's advance directive (written 
or oral instructions from the patient 
specifying the type of medical 
treatment that is desired if the patient 
becomes incapacitated, including a 
living will, durable power of attorney 
(note state-specific status) or any 
document that state law recognizes 
as an "advance directive") entered in 
the medical record within 24 hours 
following admission. 
Not Reported Adult Hospital (ICU) Chart 
Reliability / Validity not reported 
11 
 
VHA Update March 20056 
 
(Indicator) Regular 
assessment of specific 
resuscitation preferences in 
the ICU. 
Total number of 
patients with an ICU 
length of stay > than 
24 hours. 
Number of patients admitted to the 
ICU with resuscitation status 
including one or more of the 
following: 1) documentation of a 
directive to attempt resuscitation in 
the event of an arrest, 2) 
documentation of a directive to 
forego attempts to resuscitate in the 
event of an arrest, 3) documentation 
that the care team discussed 
resuscitation status with the patient 
and/or family) documented in the 
medical record within 24 hours of 
admission. 
Not Reported Adult Hospital (ICU) Chart 
Reliability / Validity not reported 
 
 
Assessment 
 
F4-5 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
12 
 
VHA Update March 20056 
 
 
(Indicator) Regular 
clinician-patient-family 
communication in the ICU. 
Total number of 
patients with an ICU 
length of stay > than 
120 hours. 
Number of patients admitted to the 
ICU who survive > than 5 days (120 
hours) with documentation in the 
medical record that an 
interdisciplinary team meeting (with 
at least the attending physician 
(primary care or ICU attending) and 
a nurse) and the patient and/or family 
was conducted within 120 hours of 
ICU admission and involved a 
discussion addressing each of the 
following topics: 1) the patient's 
condition (diagnosis and prognosis), 
2) goals of treatment; 3) the patient's 
and family's needs and preferences, 
4) the patient's and family's 
understanding of the patient's 
condition and goals of treatment at 
the conclusion of the meeting. 
Not Reported Adult Hospital (ICU) Chart 
Reliability / Validity not reported 
 
 
 
 
 
 
 
Application 
 
F4-6 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
13 
 
ACOVE End of Life 
Wenger, N.S.1 
Wenger, N.S.2 
 
(Measure) Documentation 
of care preferences across 
venues. 
IF a vulnerable elder has an 
advance directive in the 
outpatient, inpatient, or 
nursing home medical 
record or the patient reports 
the existence of an existing 
advance directive in an 
interview, and the patient 
receives care in a second 
venue, THEN 1) the existing 
advance directive should be 
present in the patient's 
medical record in the second 
venue or 2) documentation 
should acknowledge its 
existence, its contents, and 
the reason that it is not in the 
current medical record. 
All vulnerable elderly 
patients with existing 
advance directives in 
another setting 
admitted to an 
outpatient, inpatient, 
or nursing home 
setting. 
Number  of vulnerable elderly 
patients admitted to the outpatient, 
inpatient, or nursing home and 
reporting the existence of an advance 
directive in another setting with 
documentation in their medical 
record of 1) the existing advance 
directive or 2) documentation 
acknowledging the existing advance 
directive, it contents, and the reason 
that it is not included in the medical 
record. 
Mixed disease Adult 
 36% Male 
Average age is 81.0 
Home care 
Hospice 
Ambulatory / outpatient care
Hospital (non-ICU) 
Hospital (ICU) 
Home 
Community 
Patient interview / survey 
Chart 
Reliability / Validity not reported 
14 
 
ACOVE End of Life 
Wenger, N.S.1 
Wenger, N.S.2 
 
(Measure) Documentation 
of specific life sustaining 
preferences. 
IF a vulnerable elder 
indicates (during an 
interview) that he/she would 
rather die than live 
permanently comatose, 
ventilated, or tube fed, 
THEN 1) the chart should 
document a discussion of 
life-sustaining treatment 
preferences, 2) the chart 
should contain an advance 
directive, or 3) the patient 
should indicate (during the 
interview) that he/she 
discussed these topics with 
the physician or does not 
wish to discuss the topics. 
All vulnerable elders 
in any setting. 
Number of vulnerable elders in any 
setting indicating that he/she would 
rather die than live permanently 
comatose, ventilated, or tube fed 
with one of the following 
documented in their medical record:  
1) a discussion of life-sustaining 
treatment preferences, 2) an advance 
directive, or 3) that the patient 
discussed this topic with the 
physician or does not wish to discuss 
this topic. 
Mixed disease Adult 
 36% Male 
Average age is 81.0 
Home care 
Hospice 
Ambulatory / outpatient care
Hospital (non-ICU) 
Hospital (ICU) 
Home 
Community 
Patient interview / survey 
Chart 
Reliability / Validity not reported 
 
 
 
 
Follow-up 
 
F4-7 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
15 
 
ACOVE End of Life 
Wenger, N.S.1 
Wenger, N.S.2 
 
(Measure) Consistency of 
preferences with use of 
ventilatory support. 
IF a vulnerable elder 
requires mechanical 
ventilation during a 
hospitalization (except 
short-term and post 
operative mechanical 
ventilation), THEN within 
48 hours of the initiation of 
mechanical ventilation the 
medical record should 
document the goals of care 
for the patient and the 
patient's preference for 
mechanical ventilation or 
why this information is 
unavailable. 
All hospitalized 
vulnerable elders 
requiring mechanical 
ventilation (except 
short-term and post 
operative mechanical 
ventilation). 
Number of hospitalized vulnerable 
elders requiring mechanical 
ventilation (except short-term and 
post operative mechanical 
ventilation) with documentation in 
the patient record of the goals of care 
and the patient's decision for 
mechanical ventilation or why this 
information is unavailable. 
Mixed disease Adult 
 36% Male 
Average age is 81.0 
Hospital (non-ICU) 
Hospital (ICU) 
Patient interview / survey 
Chart 
Reliability / Validity not reported 
16 
 
Earle, C.C.7 
Earle, C.C.8 
Grunfeld, E.9 
(Measure) Late life hospital 
use. 
 
All deceased cancer 
patients. 
Number of dying cancer patients 
with > 1 hospital admission in the 
last month of life. 
Mixed cancer Adult 
Grunfeld, E.: 
All patients in the 
population with 
cancer 
Hospital (non-ICU) 
Hospital (ICU) 
Administrative 
Chart 
Other 
Grunfeld, E.: 
Cancer registry, administrative 
claim data, hospital discharge 
abstract 
17 
 
Earle, C.C.7 
Earle, C.C.8 
Grunfeld, E.9 
(Measure) Late life ICU 
use. 
 
All deceased cancer 
patients. 
Number of dying cancer patients 
with 1 ICU admission in the last 
month of life. 
Mixed cancer Adult 
Grunfeld, E.: 
All patients in the 
population with 
cancer 
Hospice Administrative 
Chart 
Other 
Grunfeld, E.: 
Cancer registry, administrative 
claim data, hospital discharge 
abstract 
 
 
Follow-up 
 
F4-8 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
18 
 
Dana Farber Cancer Center 
Earle, C.C.7 
Earle, C.C.8 
Grunfeld, E.9 
Cancer Care Ontario10 
(Measure) Late life rate of 
emergency care. 
 
All deceased cancer 
patients. 
Number of dying cancer patients 
with > 1 emergency room visit in the 
last month of life. 
Mixed cancer Adult 
Grunfeld, E.: 
All patients in the 
population with 
cancer 
Hospital (non-ICU) 
Hospital (ICU) 
Administrative 
Chart 
Other 
Reliability / Validity not reported 
Grunfeld, E.: 
Cancer registry, administrative 
claim data, hospital discharge 
abstract 
19 
 
Earle, C.C.7 
Earle, C.C.8 
Grunfeld, E.9 
 
(Measure) New 
chemotherapy regimen in 
last 30 days of life. 
 
All deceased cancer 
patients. 
Number of dying cancer patients 
started on a new chemotherapy 
regimen in the last 30 days of life,. 
Mixed cancer Adult 
Grunfeld, E.: 
All patients in the 
population with 
cancer 
Ambulatory / outpatient care
Hospital (non-ICU) 
Hospital (ICU) 
Administrative 
Chart 
Other 
Reliability / Validity not reported 
Grunfeld, E.: 
Cancer registry, administrative 
claim data, hospital discharge 
abstract 
20 
 
Earle, C.C.7 
Earle, C.C.8 
Grunfeld, E.9 
Cancer Care Ontario11 
(Measure) Chemotherapy in 
last 14 days of life. 
 
All deceased cancer 
patients. 
Number of dying cancer patients 
receiving chemotherapy in the last 
14 days of life. 
Mixed cancer Adult 
Grunfeld, E.: 
All patients in the 
population with 
cancer 
Hospital (non-ICU) 
Hospital (ICU) 
Administrative 
Chart 
Other 
Reliability / Validity not reported 
Grunfeld, E.: 
Cancer registry, administrative 
claim data, hospital discharge 
abstract 
 
 
Follow-up 
 
F4-9 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
21 
 
Earle, C.C.7 
Earle, C.C.8 
Grunfeld, E.9 
Cancer Care Ontario11 
National Cancer Policy 
Board (NCPB)9 
(Measure) Admission to 
hospice. 
 
All deceased cancer 
patients. 
Number of cancer patients who die 
in the hospital. 
Mixed cancer Adult 
Grunfeld, E.: 
All patients in the 
population with 
cancer 
Hospice Administrative 
Chart 
Other 
Reliability / Validity not reported 
Grunfeld, E.: 
Cancer registry, administrative 
claim data, hospital discharge 
abstract 
22 
 
Earle, C.C.7 
Earle, C.C.8 
Grunfeld, E.9 
National Cancer Policy 
Board (NCPB)9 
(Measure) Late referral to 
hospice. 
All deceased cancer 
patients. 
IF a dying cancer patients referred to 
hospice or palliative care < 3 days 
before death. 
Mixed cancer Adult 
Grunfeld, E.: 
All patients in the 
population with 
cancer 
Hospice Administrative 
Chart 
Other 
Reliability / Validity not reported 
Grunfeld, E.: 
Cancer registry, administrative 
claim data, hospital discharge 
abstract 
23 
 
Earle, C.C.7 
Earle, C.C.8 
Grunfeld, E.9 
Cancer Care Ontario10 
Cancer Care Ontario11 
(Measure) Site of death. 
 
All deceased cancer 
patients. 
Number of cancer patients who die 
in the hospital. 
Mixed cancer Adult 
Grunfeld, E.: 
All patients in the 
population with 
cancer 
Hospital (non-ICU) 
Hospital (ICU) 
Administrative 
Chart 
Other 
Reliability / Validity not reported 
Grunfeld, E.: 
Cancer registry, administrative 
claim data, hospital discharge 
abstract 
 
 
Follow-up 
 
F4-10 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
24 
 
Ryndes, T.3 
National Hospice and 
Palliative Care 
Organization (NHPCO)4 
Connor, S.12 
(Measure) Safe dying in 
hospice. 
All Caregiver's of 
Hospice patients who 
died while in hospice.
Number of deceased hospice 
patient's caregivers with 
documentation in the patient's 
medical record who were contacted 
and surveyed as to the quality of care 
provided by the hospice using the 
following question: If you cared for 
the patient at home, did hospice 
increase your confidence to safely 
care for your loved one as death 
approached?. 
Mixed disease Adult Home Chart 
Construct validity reported 
Discriminant validity reported 
25 
 
ACOVE End of Life 
Wenger, N.S.2 
 
(Indicator) Care consistency 
with documented care 
preferences. 
If a vulnerable elder has 
specific treatment 
preferences (e.g., a do-not-
resuscitate order, no tube 
feeding, or no hospital 
transfer) documented in a 
medical record, THEN these 
treatment preferences should 
be followed. 
All vulnerable elderly 
patients in any health 
care setting with 
specific treatment 
preferences 
documented in their 
medical record. 
Number  of vulnerable elders with 
specific treatment preferences 
documented in their medical record 
with those treatment preferences 
having been followed. 
Mixed disease Adult Hospice 
Ambulatory / outpatient care
Hospital (non-ICU) 
Hospital (ICU) 
Chart 
 
 
 
Potential Indicators 
Assessment 
 
F4-11 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
1 Dokken, D.L.13 
 
IF a child with life threatening 
illness is admitted to any health 
care setting, THEN the needs of 
each child are supported through 
periodic assessment and 
reassessment of the child's physical, 
social, emotional, developmental, 
spiritual, and educational strengths 
and needs in light of the child's 
developmental level and diagnosis 
and, based on the assessed needs, 
development and implementation 
of interventions involving experts 
in relevant areas (e.g., child life, 
chaplancy, physical and 
occupational therapy, psychology, 
etc.) should be conducted. 
All Children With 
Life Threatening 
Illness Admitted to 
Any Health Care 
Setting. 
Number  of children with life 
threatening illness admitted to 
any health care setting with 
documentation in the medical 
record that the needs of each 
child were periodically assessed 
(including child's physical, 
social, emotional, 
developmental, spiritual, and 
educational strengths and needs 
in light of the child's 
developmental level and 
diagnosis) and, based on the 
assessed needs, there is evidence 
of the development and 
implementation of interventions 
involving experts in relevant 
areas (e.g., child life, chaplaincy, 
physical and occupational 
therapy, psychology, etc.). 
Not Reported Children Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
 
 
 
Potential Indicators 
Application 
 
F4-12 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
2 Lilly, C.M.14 
 
IF an ICU patient has a poor 
prognosis (e.g., a condition 
associated with a high probability 
of death, who had a predicted 
length of ICU stay longer than 5 
days, a predicted mortality of 
greater than 25% as estimated by 
the attending physician, or a change 
in functional status that is 
potentially irreversible and 
sufficient to preclude eventual 
return to home) or a deteriorating 
condition (a progressive worsening 
of a patient's condition that 
predisposes the patient to death), 
THEN the attending physician 
should assess the patient's medical 
condition, review the case with the 
patient's primary care physician and 
agree on a recommended care plan, 
review any known advance 
directives, and conduct a family 
meeting with the patient's family 
(including health care proxy), 
where possible, the patient, the 
patient's nurse, and the hospital 
house officer in order to 1) review 
the medical facts and options for 
treatment, 2) to discuss the patient's 
perspectives on death and dying, 
chronic dependence, loss of 
function, and the acceptability of 
the risks and discomforts of critical 
care; 3) to agree on a care plan; and 
4) to agree on criteria by which the 
success or failure of this care plan 
would be judged using defined 
"clinical events" as milestones 
indicating that the care plan had 
been effective or not and the time 
frame for their occurrence. 
All ICU patients. umber of ICU patients with a 
poor prognosis (e.g., a condition 
associated with a high 
probability of death, who had a 
predicted length of ICU stay 
longer than 5 days, a predicted 
mortality of greater than 25% as 
estimated by the attending 
physician, or a change in 
functional status that is 
potentially irreversible and 
sufficient to preclude eventual 
return to home) or a 
deteriorating condition (a 
progressive worsening of a 
patient's condition that 
predisposes the patient to death) 
with documentation in the 
medical record that the attending 
physician assessed the patient's 
medical condition, reviewed the 
case with the patient's primary 
care physician, reviewed any 
known advance directives, and 
conducted a family meeting with 
the patient's family (including 
health care proxy). 
Mixed disease Adult 
White 
African American 
Hispanic 
 59% Male 
Average age is 59.0 
Age ranges 
from 45 to 75 
Hospital (ICU) Data Collection specified 
Reliability / Validity not reported 
 
 
Potential Indicators 
Application 
 
F4-13 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
3 National Comprehensive 
Cancer Network (NCCN)15 
 
All cancer patients with advanced, 
symptomatic, progressive disease 
and/or those with a life expectancy 
of <12 months, or with serious 
comorbid conditions, or the patient 
or family requests palliative care 
should receive a palliative care 
assessment, including symptoms, 
advance care planning discussion 
(living will, power of attorney, 
DNR orders, hospice preference), 
resource management/social 
support (caregivers, family, 
financial, community, cultural, 
spiritual, religious), and the 
benefits and risks of anticancer 
therapy to identify patient and 
family goals and expectations, 
referral for complex palliative care, 
discuss palliative care options 
(including hospice), elicit personal 
values and preferences of patient 
and family for end of life care, 
encourage communication of 
wishes between patient and family, 
and encourage the designation of a 
health care proxy. 
All cancer patients 
with advanced, 
symptomatic, 
progressive 
disease and/or 
those with a life 
expectancy of <12 
months, or with 
serious comorbid 
conditions, or the 
patient or family 
requests palliative 
care. 
Number of cancer patients with 
advanced, symptomatic, 
progressive disease and/or those 
with a life expectancy of <12 
months, or with serious 
comorbid conditions, or the 
patient or family requests 
palliative care with 
documentation in the chart that 
they received a palliative care 
assessment (including symptoms 
and advance care planning 
discussions of living will, power 
of attorney, DNR orders, hospice 
preference, resource 
management/social support 
concerning caregivers, family, 
financial, community, cultural, 
spiritual, religious needs, and the 
benefits and risks of anticancer 
therapy) to identify patient and 
family goals and expectations, 
wishes for referral for complex 
palliative care, discussion of 
palliative care options (including 
hospice), documentation of the 
personal values and preferences 
of the patient and family for end 
of life care, communication of 
wishes between patient and 
family, and encourage the 
designation of a health care 
proxy. 
Mixed cancer Adult Hospice 
Ambulatory/outpatient care 
Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
 
 
Potential Indicators 
Application 
 
F4-14 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
4 Clinical practice guidelines 
for quality palliative care16 
Standards and Quality 
Committee17 
 
A plan of care for dying patients 
should be developed for the patient 
based on 1) a comprehensive 
interdisciplinary medical, psycho-
social, spiritual/existential, cultural 
assessment of the patient and 
family; 2) the identified and 
expressed values, goals, and needs 
of the patient and family developed 
with professional guidance and 
support for decision making; the 
plan is regularly reviewed and is 
responsive to the patient's changing 
illness and the family's changing 
needs; 4) where identified, the 
patient/family should be referred to 
external specialist services; and 5) 
the services provided by the 
Palliative Care Team are consistent 
with the care plan and the patient's 
and family wishes. 
All patients 
admitted to any 
health care setting 
and determined to 
need palliative 
care. 
Number of dying patients 
admitted to any health care 
setting and needing palliative 
care with documentation in the 
patient's medical record of: 1) a 
comprehensive interdisciplinary 
medical, psycho-social, 
spiritual/existential, cultural 
assessment of the patient and 
family; 2) documentation that 
the expressed values, goals, and 
needs of the patient and family 
were developed with 
professional guidance and 
support for decision making; 3) 
the plan was regularly reviewed 
and was responsive to the 
patient's changing illness and the 
family's changing needs; 4) the 
patient/family were referred to 
external specialist services when 
appropriate; and 5) the services 
provided by the Palliative Care 
Team were consistent with the 
care plan and the patient's and 
family wishes. 
Not Reported Adult Home care 
Hospice 
Ambulatory/outpatient care 
Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
 
 
Potential Indicators 
Application 
 
F4-15 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
5 Standards and Quality 
Committee17 
 
All patients, in any health care 
setting, determined to be dying or 
whose death is expected, THEN the 
patient and family should have their 
psychological, emotional, social, 
cultural, and spiritual needs 
assessed on an ongoing basis by an 
interdisciplinary health care team, 
and where psychological, 
emotional, and/or spiritual needs 
are identified or expressed, should 
be referred to internal and external 
specialist services, including 
bereavement services and these 
assessments and referral/receipt of 
supportive services should be 
documented in the patient's medical 
record or why these needs were not 
assessed and/or addressed. 
All patients, in any 
health care setting, 
who died with an 
expected death. 
Number of deceased patients, in 
any health care setting, who died 
an expected death with 
documentation in the patient's 
medical record of ongoing 
assessment of the patient and 
family's psychological, 
emotional, social, cultural, and 
spiritual needs by an 
interdisciplinary health care 
team, and where psychological, 
emotional, and/or spiritual needs 
are identified or expressed, 
documentation of referral to 
internal and external specialist 
services, including bereavement 
services, and receipt of 
supportive services or why these 
needs were not assessed and/or 
addressed. 
Mixed disease Adult Other Data Collection specified 
Reliability / Validity not reported 
6 Clarke, E.B.18 
 
IF a vulnerable elder's care, in any 
health care setting, will be 
transferred to another health care 
provider (individual, team, setting), 
THEN the current provider should 
maximize continuity of care across 
clinicians, consultants, and settings 
by orienting new clinicians 
regarding the patient and family 
health care preferences and plan of 
care and prepare patient and family 
for a change of clinician(s) and 
introduce new clinicians. 
All vulnerable 
elders, in any 
health care setting, 
who were 
transferred to new 
clinician(s) or 
settings. 
% of vulnerable elder's care, in 
any health care setting, who 
were transferred to another 
health care provider (individual, 
team, setting), with 
documentation in the patient's 
medical record that the current 
provider oriented new clinicians 
regarding the patient and 
family's treatment preferences 
and plan of care, prepared the 
patient and family for a change 
of clinician(s), and introduced 
new clinicians to the patient and 
family. 
Mixed disease Adult Hospital (ICU) Chart 
Reliability / Validity not reported 
7 Masera, G.19 
American Academy of 
Pediatrics. Committee on 
Bioethics and Committee 
on Hospital Care. Palliative 
care for children20 
 
IF a child with life threatening 
illness is admitted to any health 
care setting, THEN a discussion of 
an advance directive discussion 
should be conducted within 48 
hours of admission to ensure that 
treatments that have become 
burdensome are not used. 
All children with 
life threatening 
illness admitted to 
any health care 
setting. 
% of children with life 
threatening illness admitted to 
any health care setting with 
documentation in the medical 
record of a discussion with the 
child's parents of advance 
directives with LST decisions 
documented within 48 hours of 
admission. 
Mixed cancer Adult/Children Home care 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
 
 
Potential Indicators 
Application 
 
F4-16 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
8 Masera, G.19 
American Academy of 
Pediatrics. Committee on 
Bioethics and Committee 
on Hospital Care. Palliative 
care for children20 
 
IF a child with cancer cannot be 
successfully treated by presently 
available therapies, and the child 
needs specific treatments identified 
to be palliative and not curative for 
mental or physical distress, THEN 
the focus of care should be on key 
issues, including communication, 
social, psychological, emotional 
support, symptom control, etc. and 
a advance directive discussion 
should be conducted with the 
child's parents within 48 hours of 
admission. 
All children with 
life threatening 
illness admitted to 
any health care 
setting. 
% of children with cancer that 
cannot be successfully treated by 
presently available therapies 
needing specific treatments 
identified to be palliative and not 
curative for mental or physical 
distress with documentation in 
their medical record that the 
focus of care is on key issues, 
including communication, 
social, psychological, emotional 
support, symptom control, etc. 
and a advance directive 
discussion should be conducted 
with the child's parents within 48 
hours of admission. 
Mixed cancer Children Home care 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
9 Mitchell, S.L.21 
 
IF a patient entering any health care 
facility is determined to have 
dementia and has a feeding tube 
inserted and there is no 
accompanying documentation of 
the patient's advance directive or 
treatment preferences, THEN the 
medical record should document 
that the health care team has 
conferred with the patient's family 
members and/or proxy regarding 
sustaining or withdrawing the 
feeding tube (including a 
discussion of the evidence 
regarding the lack of benefit, 
improved survival, or prevention of 
aspiration of feeding tubes) within 
48 hours of admission. 
Total number of 
patients entering 
any health care 
facility with 
dementia, a 
feeding tube, and 
no accompanying 
documentation of 
the patient's 
advance directive 
or treatment 
preferences with 
LOS > 24 hours. 
Number  of patients entering any 
health care facility with 
dementia, a feeding tube, and no 
accompanying documentation of 
the patient's advance directive or 
treatment preferences with 
documentation in the medical 
record that the health care team 
conferred with the patient's 
family members and/or proxy 
regarding sustaining or 
withdrawing the feeding tube 
(including a discussion of the 
evidence regarding the lack of 
benefit, improved survival, or 
prevention of aspiration of 
feeding tubes) within 48 hours of 
admission. 
Mixed disease Adult 
Lower boundary 
for age is 65 
Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
 
 
Potential Indicators 
Application 
 
F4-17 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
10 Dokken, D.L.13 
 
IF a child with life threatening 
illness is admitted to any health 
care facility, THEN the child and 
his/her family should be regarded 
as the unit of care and 1) any 
concerns raised by the family about 
the child's condition should be 
acknowledged and addressed in a 
timely and respectful manner, 2) 
the family's cultural values, beliefs, 
views about quality of life and 
customary modes of interaction 
among family and community 
should be respected by health care 
providers, 3) the family is present 
with the child and involved in 
his/her care to the extent they 
desire and degree feasible based on 
the child's condition and health care 
setting, and 4) the impact of the 
child's illness on the parental 
relationship, siblings, and family 
coping strategies and finances 
should be routinely assessed, and a 
range of practical (including 
financial), emotional, and spiritual 
supports should be made available 
to meet family-identified needs by 
the health care institution and/or 
through the community. 
All children with a 
life threatening 
illness admitted to 
any health care 
facility. 
Number of children with life 
threatening illness is admitted to 
any health care facility with 
documentation in the patient's 
medical record that the child and 
his/her family were regarded as 
the unit of care and 1) any 
concerns raised by the family 
about the child's condition were 
acknowledged and addressed in 
a timely and respectful manner 
by the health care team, 2) the 
family's cultural values, beliefs, 
views about quality of life and 
customary modes of interaction 
among family and community 
were respected by health care 
providers, 3) the family was 
present with the child and 
involved in his/her care to the 
extent they desired and degree 
feasible based on the child's 
condition and health care setting, 
and 4) the impact of the child's 
illness on the parental 
relationship, siblings, and family 
coping strategies and finances 
was routinely assessed and a 
range of practical (including 
financial), emotional, and 
spiritual supports were made 
available to meet family-
identified needs by the health 
care institution and/or through 
the community. 
Not Reported Children Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
 
 
Potential Indicators 
Application 
 
F4-18 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
11 Widger, K.A.22 
 
Key components of quality care for 
children include information 
transmission, preparation for death 
and care at death, bereavement 
care, interpersonal aspects and 
competence of health professionals, 
clarity and honesty of 
communication, parent role, 
support for the family, pain and 
symptom management, decision 
making, psychosocial and spiritual 
needs of the child, availability and 
accessibility of services, 
coordination and integration of 
services, respite care for families, 
and financial support. 
All children with a 
life threatening 
illness admitted to 
any health care 
facility. 
Number of children with a life-
threatening illness admitted to 
any health care facility with 
documentation in the patient's 
medical record that the key 
components of quality terminal 
care for children with cancer and 
their families. 
Mixed cancer Children Not Reported Not Reported 
 
 
Potential Indicators 
Application 
 
F4-19 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
12 Dokken, D.L.13 
 
IF a child with life threatening 
illness is admitted to any health 
care setting, THEN each child 
should have a designated 
individual, a physician or other 
health care providers, identified as 
responsible for coordinating the 
child's overall care and who should 
1)should be involved in care 
planning and decision-making with 
the child, family, and other health 
care providers, 2) is responsible for 
ongoing communication among the 
designated health care provider, the 
child and family, and the child's 
other health care providers, and the 
health care setting should develop 
and implement a process for the 
child and family to articulate 
concerns about the choice of 
designated health care provider and 
to explore the possibility of 
changing providers. 
All children with a 
life threatening 
illness admitted to 
any health care 
facility. 
Number of children with life 
threatening illness admitted to 
any health care setting with 
documentation in the medical 
record that a designated 
individual, a physician or other 
health care providers, was 
identified and was identified as 
being responsible for the 
coordinating the child's overall 
care and who was involved in 
care planning and decision-
making with the child, family, 
and other health care providers, 
2) was identified to the child and 
family as responsible for 
ongoing communication among 
the designated health care 
provider, the child and family, 
and the child's other health care 
providers, and there is 
documentation in the medical 
record that the child and family 
were informed about the health 
care setting's process for the 
child and family to articulate 
concerns about the choice of 
designated health care provider 
and to the method established for 
the child and family to change 
designated providers if they 
chose to do so. 
Not Reported Children Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
 
 
 
 
Potential Indicators 
Application 
 
F4-20 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description / 
Original Source Wording Numerator Denominator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
13 Dokken, D.L.13 
 
IF a child with life threatening illness 
is admitted to any health care setting, 
THEN each child should have a 
comprehensive and appropriate 
written plan of care documented in 
their medical record and should be 
developed with the child's (to the 
extent appropriate), the family, and 
their health care providers 
involvement and that is 1) periodically 
reviewed, 2) that outlines the roles of 
family caregivers and the relationships 
between them, and 3) that includes 
discharging and receiving health care 
providers, within and across care 
settings, and 4) that is communicated 
in a timely manner across all care 
settings. 
Number of children with life 
threatening illness admitted to any 
health care setting with 
documentation in their medical 
record of a comprehensive and 
appropriate written plan of care 
developed with the child's (to the 
extent appropriate), the family, and 
their health care providers 
involvement that is 1) periodically 
reviewed, 2) that outlines the roles of 
family caregivers and the 
relationships between them, and that 
is communicated in a timely manner 
across all care settings, including 
discharging and receiving health care 
providers and within and across care 
settings. 
All children 
with a life 
threatening 
illness admitted 
to any health 
care facility. 
Not Reported Children Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
14 National Comprehensive 
Cancer Network (NCCN)15 
All families and next of kin of cancer 
patients who have died SHOULD 
receive culturally sensitive and 
respectful after death care, including 
respectful treatment of the patient's 
body, family time with the body, 
address concerns about organ donation 
or autopsy, facilitate funeral 
arrangements, inform insurance 
companies, and the offer and referral 
of family/next of kin to grief and 
bereavement services. 
Number of families and next of kin 
of cancer patients who died with 
documentation of receiving 
culturally sensitive and respectful 
after death care, including respectful 
treatment of the patient's body, 
family time with the body, address 
concerns about organ donation or 
autopsy, facilitate funeral 
arrangements, inform insurance 
companies, and the offer and referral 
of family/next of kin to grief and 
bereavement services. 
All families and 
next of kin of 
patients who 
died in any 
health care 
setting. 
Mixed cancer Adult Home care 
Hospice 
Ambulatory/outpatient care
Hospital (non-ICU) 
Hospital (ICU) 
Chart 
Reliability / Validity not reported 
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Appendix F5. Quality Measures for Cancer Palliation: Measures That Cross  
All Domains 
 
Pain, Depression, Dyspnea, and Advance Care Planning 
 
F5-1 
No. 
Measure or Indicator Set/ 
Reference / Year 
Description of  
measure or indicator Denominator Numerator Disease 
Patient  
Characteristics Setting 
Data Source, 
Reliability, and Validity 
1 Connor, S. R.1 
 
(Measure) Family 
evaluation of hospice care 
Family members of 
hospice decedents 
Percentage of respondents reporting 
opportunity for improvement in 
attention to family needs for support, 
attending to family needs for 
information, provision of desired 
physical comfort and emotional 
support; and mean overall 
satisfaction 
Mixed hospice 
population 
Adult/Children 
White 
African American 
Hispanic 
Asian 
Hospice Family interview / survey 
Reliability / Validity not reported 
F5-2 
Reference List 
1.  Connor SR, Teno J, Spence C, Smith N. Family  
evaluation of hospice care: results from voluntary  
submission of data over website. 
 
 
 
Appendix G.  Peer Reviewer Comments 
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Item Name Institution Role 
Page Section Comment  Response 
1 
Adalsteinn 
Brown, AB, 
D.Phil 
University of 
Toronto Reviewer 2 Introduction 
When we review performance measures with complex continuing 
(chronic) care hospitals and rehabilitation hospitals in Ontario they 
often ask us to think about measures of caregiver burden and health 
status. When I read your comments about depression on page 2 and 
how both patients and care-givers maintain hope, I thought it might be 
important to point out that measures of how care-givers are doing 
might be important (at least as predictors of patients’ capacities) but 
that they would be difficult to incorporate into the assessment, 
treatment, and follow-up paradigm and might be also be subject to a 
lot of exclusions in measurement. 
We agree that measures of 
caregiver burden are important 
elements of palliative cancer care 
not addressed within the scope of 
the current task order. However, 
we have been reminded to stress 
the need to consider these in 
future work in the Discussion. 
2 
Adalsteinn 
Brown, AB, 
D.Phil 
University of 
Toronto Reviewer     
We have just completed an assessment of recall or reliability in 
complex continuing care hospital patients in relation to their ability to  
report on their perceptions of care. It was awful. But the important 
thing out of the study was the fact that repeated assessment, in this 
case by a trained interviewer, actually caused some of the patients 
anxiety as they worried that they “hadn’t gotten it right the first time” or 
wouldn’t be able to answer the same again. I think it might be useful to 
point out some of the issues associated with repeated measurement 
that might happen in some surveying programs in chronically ill 
patients. 
Your comment raises the caution 
that application of measures that 
require patient report will have to 
be tested carefully as there are 
unique challenges given the frailty 
of the population. We have now 
emphasized this in our 
Discussion. 
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3 
Adalsteinn 
Brown, AB, 
D.Phil 
University of 
Toronto Reviewer 30 
CCO- 
Measure 
CCO patient satisfaction survey. All the NRC surveys go through a 
very primitive form of psychometric validation (alpha) before they go 
into widespread use. I don’t know whether you believe the Picker 
surveys are reflexive surveys or not, but you might want to note that 
there has been some validation. Also, we have used a cut-off of 100 
responses for a long time in Ontario for virtually all our other surveys 
(for no better reason that than the confidence intervals were 
reasonable at that point). I wouldn’t be surprised that CCO (you note 
300 surveys) goes that route shortly as well. We will be publishing two 
papers on oncology satisfaction shortly (one has been accepted at 
Annals of Oncology and the other is under revision) but I do not 
believe they will be of much use to you. Let me know if you want to 
see them confidentially regardless. 
We have now noted this in the 
text discussion of the measure- 
thank you.  
6 
Ellen Stovall, 
PhD/ Mark 
Gorman 
National 
Coalition for 
Cancer 
Survivorship 
(NCCS) 
Reviewer   Stage of Illness 
Evidence discussed is derived from end of life, hospice or a narrowly 
defined "palliative" stage of a cancer patient's illness. Numerous IOM 
evidence-based findings point out, cancer patients need 
comprehensive symptom management at all phases of their treatment 
beginning with their diagnosis and continuing throughout the 
remainder of their lives.  
We raise this concern in the 
introduction, although it is true 
that many measures do not speak 
to earlier stages of illness 
explicitly. We have emphasized 
this shortcoming in the 
Discussion. 
7 
Ellen Stovall, 
PhD/ Mark 
Gorman 
National 
Coalition for 
Cancer 
Survivorship 
(NCCS) 
Reviewer   Settings of Care 
Many measures discussed in this report are derived from an inpatient 
setting and some are derived from the highly specialized setting of an 
ICU. A majority of US cancer patients are treated in ambulatory 
settings, and most of those are treated completely outside a hospital 
setting in private community oncology practices. Therefore, there is a 
need for development of measures and indicators relevant to physician 
office settings where most of cancer care is provided. 
We now raise this issue in the 
Discussion. 
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8 
Ellen Stovall, 
PhD/ Mark 
Gorman 
National 
Coalition for 
Cancer 
Survivorship 
(NCCS) 
Reviewer   Sources 
One source of data that does not appear, namely information from the 
60 NCI designated cancer centers. Most if not all of these centers 
have formal guidelines pertaining to at least some of the domains dealt 
with in this report.  
While we reviewed the NCCN 
guidelines, these 
recommendations unfortunately 
did not meet our standard of 
being able to be operationalized. 
9 
Ellen Stovall, 
PhD/ Mark 
Gorman 
National 
Coalition for 
Cancer 
Survivorship 
(NCCS) 
Reviewer   Task Order 
Processes vs. Outcomes: Task order for this study directed a focus on 
processes, from the patient's perspective outcomes are more 
important. While it is useful that the study has included some outcome 
measures for "completeness," assigning such secondary importance to 
outcomes measures represents a misplacement of priorities. 
Particularly in the domains of symptom management, which so 
dramatically impact a cancer patient's quality of life, having good 
measures of whether particular interventions are resulting in better 
patient outcomes is vital. 
We agree that the process-
outcome link is a critical 
assumption. We have not 
commented directly on that issue 
here, although you have reminded 
us to raise it in our conceptual 
discussion.  
10 
Ellen Stovall, 
PhD/ Mark 
Gorman 
National 
Coalition for 
Cancer 
Survivorship 
(NCCS) 
Reviewer   Overall 
Progress in setting quality measures fro cancer will need to focus on 
both process and patient outcomes, be based on the real world 
settings where most of cancer care is provided, and be applicable to 
all stages of patient's treatment.  
We acknowledge that evaluation 
of process measurement 
implementation should include 
validation of the effects on patient 
and caregiver outcomes. 
11 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer 10 Methods 
Search strategy: what was the rationale for starting the search in 
1995?  Some justification is warranted. 
Our prior experience with the 
topic of palliative care and quality 
indicators suggested that relevant 
literature would be found in the 
past decade. Empirically, 
Shekelle et.al., have found that 
the lifetime of guidelines in 
general is ~3 years. 
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12 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer 16 Results 
re statement on ORYX, JCAHO, NCQA – should you at least include 
them in Table 1? 
We decided not to include them 
since we did not abstract these 
measures or indicators.  
13 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer 18 Table 1 
Description of CCNS qualitative phase – the most important 
component of this phase is the focus groups with patients with 
metastatic cancer and bereaved caregivers, and the modified Delphi 
process with health care providers (oncologists, palliative care 
physicians, cancer nurses, social workers, community family 
physicians) to determine their views on the 19 quality indicators being 
measured in the quantitative component of the study.  You may want 
to add this to your description of the qualitative phase of this project.  
(NB: These have now all been conducted and analysis is nearing 
completion.) 
Thank you - we have amended 
this description. 
14 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer 28 Pain 
re: treatment for painful bony metastases.  We have now examined 
this indicator both in terms of its acceptability to stakeholders (i.e., 
through the Delphi with health care providers) and through attempting 
to calculate it using administrative datasets.  Based on these two 
processes, it is now clear that we will not adopt this as a useful QI 
despite the evidence that it is an effective treatment.  The primary 
difficulty is that we are not able to measure when the pain is no longer 
controlled by medications and requires radiotherapy.  The one week 
window was considered appropriate by the stakeholder group but they 
did not agree with our denominator for the same reason given above. 
Thank you - we have amended 
information about this indicator. 
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15 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer 46-50 ACP 
the measures included here (those used by Dana Farber and CCNS) 
do not appropriately fit under ACP since they do not measure when 
these aspects of care are in keeping with the patients’/caregivers’ 
preferences.  In fact, in our Delphi process the principal objection was 
that measuring these indictors in isolation of knowledge of patients’ 
preferences does not necessarily reflect good quality of care. 
You have pointed out an 
important limitation of these 
indicators and we have noted it. 
At the same time, it is not clear 
that they should not be included 
for completeness sake.  We felt 
that it was reasonable to consider 
treatments or healthcare 
utilization under care planning 
since much of the literature on 
care planning focuses on 
utilization outcomes and their 
avoidance (e.g., resuscitation)  or 
facilitation (e.g., hospice use) 
through care planning. Indeed, 
others might have made a 
reasonable decision to exclude 
them.  
16 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer 
54, 
Para1 ACP 
I think this is a very important point.  Where are these indictors being 
used to actually improve quality of care? 
We agree that this is important. 
Unfortunately, we found little 
evidence related to actual current 
use of these indicators. Where we 
did find such information it is 
discussed in the Results.  
17 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer 
Appe
ndix Reviewer list 
Please note the correction to your reviewer list: Dr. Grunfeld, MD, 
DPhil Done 
18 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer   Depression 
Consideration might be given to include an indicator for 
screening/treatment of depression in caregivers See response to Item #1 
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19 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer   Title 
I find the title not sufficiently specific.  Suggest either end-of-life cancer 
measures (as originally termed) or measures of cancer symptom 
management. 
We changed the title to reflect the 
task order. 
20 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer     
In some instances you discuss the issue of benchmarking which 
essentially aims to define how one concludes whether an 
institution/organization/region is doing a good job.  When is it enough, 
when is it too much, or too little?  A general discussion about this point 
and potential approaches to benchmarking would enhance the 
usefulness of the report. 
Unless it is used in reference to a 
specific project or title, we have 
eliminated use of the term 
'benchmarking'  since our report is 
spherically addressing quality 
performance and we find more 
specific terminology more helpful, 
in general. 
21 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer   Suggestions 
Perhaps a table summarizing those indicators you conclude are most 
helpful could be added. 
While it was out of scope for us to 
make specific recommendations 
about preferred measures or 
indicators, we did try to provide 
similar information about their 
attributes for the comparability of 
readers. 
22 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer   
Evidence 
Tables 
Tables – description of CCNS indictors: For all indicators - Patient 
characteristics should read “all patients in the population with cancer”.  
The data sources are: cancer registry, administrative claims data, 
hospital discharge abstracts. 
We have amended these 
descriptions. 
23 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer   Chapter 4 
The major gap is raised by your statement in the first paragraph of 
Chapter 4: where is the evidence that quality measures are actually 
being used to measure and promote quality of care.  Two possible 
examples are the National Comprehensive Cancer Network (Weeks et 
al) which uses a measurement and feedback system with the goal of 
improving adherence to guidelines (as a process measure of quality of 
care); and the Cancer Care Ontario quality initiative (your references 
54, 113 and 114).. 
We highlight these examples in 
the Discussion. 
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24 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer   
Measureme
nt tools and 
data capture 
methods.   
 
The principal point of QIs is that they are measurable.  The report does 
not specifically discuss the issue of measurement instruments (for 
example, is asking the patient if they have pain equal in value to using 
a validated pain assessment tool?) or data capture methods (chart 
abstraction vs prospective data capture using validate instruments vs 
administrative datasets).  There is a general discussion within the text 
of some of the QIs but no overarching discussion.  The validity, 
reliability and feasibility of measuring QIs will vary with each of the 
different data capture techniques and their useful is contingent on how 
the data is captured and how accessible it is to use.  Just to give one 
example, the QI ‘effective treatment of pain’ (p.81).  The denominator 
for this indicator is “number of cancer patients who are not comatose”.  
The rationale for this definition is self-evident.  However, precisely how 
an institution would capture the information is questionable.  
Institutions may be able to know precisely how many cancer patients 
they see in a given period of time.  They are much less likely to be 
able to subtract from the denominator the number that are comatose 
(or, at least not without a detailed chart review). Hence the value of the 
intended precision of this QI is reduced by the difficulty of actually 
capturing the data. 
We have amended the Discussion 
to include these limitations of the 
descriptions. Unfortunately, a 
higher level of description was not 
possible for these indicators - 
either because it was unpublished 
and / or it was not provided by 
developers. 
25 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer   
Scope of the 
report 
The questions posed in the task order indicate that the scope of the 
report is at any point of the cancer trajectory (i.e., not just end-of-life). 
This is a very wide scope.  However, the review seems to focus on 
end-of-life/palliative care (EOL/PC).  For example the majority of the 
indicator sets you have identified relate to EOL/PC.  This raises some 
confusion in my mind whether the broader scope is being adequately 
addressed or whether, in fact, it is the narrower scope that is really 
intended for the report.  If EOL/PC really is the focus, it should be 
specified clearly (for example, in the title of the report).  If it is intended 
to be the entire cancer trajectory then the other periods (e.g., 
diagnosis, treatment, and survivorship) have not be adequately 
addressed or a statement should be made that no quality indicators 
(QIs) were identified for these periods. 
See response to Item #6 
G-8 
        
Item Name Institution Role 
Page Section Comment  Response 
26 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer     
While a comprehensive discussion about measurement is probably 
beyond the scope of the task order,  you do touch on it in a general 
way on pages 54-55.  I think the usefulness of the report would be 
enhanced by a slightly more detailed discussion about measurement 
within each of the domains.  
We have expanded on generic 
challenges related to 
measurement as suggested. 
27 
Eva 
Grunfeld, 
MD, Dphil 
Cancer Care 
Nova Scotia Reviewer   Suggestions 
You identify many of the indicators as ‘not in current use’.  A separate 
table listing those indicators that are currently being used would be 
helpful 
For brevity's sake, we decided not 
to provide an additional table, 
although we have provided this 
information in the report. 
28 
Joanne 
Wolfe, MD, 
MPH 
Harvard 
University-
Pediatrics  
Reviewer 11 Methods 
With regard to the Grey Literature - Internet Search the following sites 
could have also been included: 
American Society of Pediatric Hematology/Oncology  www.aspho.org  
The Association for Children with Life-Threatening or Terminal 
Conditions and 
Their Families (ACT) www.act.org.uk 
Children's Oncology Group  http://www.childrensoncologygroup.org/ 
Children's Hospice International www.chionline.org/ 
http://www.apon.org/files/public/last_acts_precepts.pdf 
http://www.aps-spr.org 
We did review the APON 
guidelines but they did not meet 
our definitions as indicators or 
measures. We requested a 
reviewer from ASPHO but there 
was no response from several 
inquiries with the organization. 
We acknowledge that we did not 
access some of the other 
sources, although we should have 
identified published information 
about indicators or measures 
promulgated by these 
organizations.  
29 
Joanne 
Wolfe, MD, 
MPH 
Harvard 
University-
Pediatrics  
Reviewer 
13, 
para  
4 
Methods I suspect you intended to include "Canada" inside parentheses. Corrected  
30 
Joanne 
Wolfe, MD, 
MPH 
Harvard 
University-
Pediatrics  
Reviewer   Gaps/articles 
Consider including the attached article (Beal A. Quality Measures for 
Children's Health Care.  Pediatrics 2004;113(1) 199-209 
We reviewed this article, however, 
it did not meet our criteria 
(disease not cancer) 
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31 
Judi L. 
Person, 
MPH 
National 
Hospice and 
Palliative 
Care 
Organization 
Reviewer 3 Summary/ Conclusion 
The sentence: "Palliative care is a term that is sometimes used 
interchangeably, except that it is focused on living with the more 
advanced stages of illness.  " I would question this description of 
palliative care- is a component of care from diagnosis and increasing 
in focus.  
We agree that these distinctions 
and definitions are inexact, and 
therefore we have not attempted 
to define them more precisely. 
32 
Judi L. 
Person, 
MPH 
National 
Hospice and 
Palliative 
Care 
Organization 
Reviewer 19 Table 1 VHA- Spell out VHA, no reference found VHA is the actual name of the system. 
33 
Judi L. 
Person, 
MPH 
National 
Hospice and 
Palliative 
Care 
Organization 
Reviewer 30 First paragraph 
"...PE.1.4; and the National Consensus Project for Quality 
Palliative…" add Project Corrected 
34 
Judi L. 
Person, 
MPH 
National 
Hospice and 
Palliative 
Care 
Organization 
Reviewer 32 
Under 
Treatment, 
second 
paragraph, 
last 
sentence 
"…the reviewers concluded that improved adherence with long-acting 
drugs in clinical practice improved outcomes." is an incomplete 
sentence 
The sentence beginning with 
"Although…" is complete. 
35 
Judi L. 
Person, 
MPH 
National 
Hospice and 
Palliative 
Care 
Organization 
Reviewer 35 Dyspnea QA Tools 
end of paragraph, " …Association of Palliative Medicine." Reference 
country here- could be confused with AAHPM. 
It is true, but these are distinct 
organizations. 
36 
Judi L. 
Person, 
MPH 
National 
Hospice and 
Palliative 
Care 
Organization 
Reviewer 36 
Dyspnea- 
PI- 
Assessment 
ACCP, spell out somewhere, found on page 37 but should also be 
reference here, should also be listed on page 11.  Corrected 
37 
Judi L. 
Person, 
MPH 
National 
Hospice and 
Palliative 
Care 
Organization 
Reviewer 48 
ACP- 
Chemo in 
last 14 days 
measure 
"A high proportion (> 10%) of cancer patients receiving chemotherapy 
in the last 14 days of life indicates poor quality care.  This is the 
indicator? 
Yes, that is the implications of the 
measure according to the 
developers. 
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38 
Judi L. 
Person, 
MPH 
National 
Hospice and 
Palliative 
Care 
Organization 
Reviewer 50 
ACP-  safe 
dying in 
hospice 
measure 
"This indicator is based on the assumption that caregivers who lack 
confidence or…"  consider adding this to your sentence.  
This is also an indicator of caregiver competence. 
Corrected  
39 
Judi L. 
Person, 
MPH 
National 
Hospice and 
Palliative 
Care 
Organization 
Reviewer 52 ACP - PI 
What about POLST (Physicians Order for Life Sustaining Treatment) 
In use in Oregon and West Virginia, close to being used in NY. 
Nationwide rollout in 2006+. Probably should have some mention. 
The team is familiar with the 
POLST, but not its use as an 
indicator or measure.  
40 
Judi L. 
Person, 
MPH 
National 
Hospice and 
Palliative 
Care 
Organization 
Reviewer   Reviewer list Organization incorrect, change to National Hospice and Palliative Care Organization. Also, Kaiser is spelled incorrectly.  Done 
43 
Lindsey 
Bramwell, 
MPH, RN, 
CDR, 
USPHS 
CMS (Fed 
Reviewer) Reviewer   
Symptom 
Managemen
t 
Symptom management measures for pain, dyspnea, and depression 
disappoint in their failure to adequately examine patients freed from 
these symptoms, as well as the other processes of care such as 
assessment, treatment, and follow-up.   
We agree and have modified our 
discussion of the limitations of the 
measures to point out that 
indicators or measures of follow-
up are particularly lacking. 
44 
Lindsey 
Bramwell, 
MPH, RN, 
CDR, 
USPHS 
CMS (Fed 
Reviewer) Reviewer   General 
The Report identifies gaps in the research--- the majority of the 
measures and indicators which are mentioned in this report have not 
specified the reliability and/or validity of these measures and have only 
been tested, not implemented.   
Thank you. 
45 
Lindsey 
Bramwell, 
MPH, RN, 
CDR, 
USPHS 
CMS (Fed 
Reviewer) Reviewer   
Dyspnea 
Measures 
Your innovative approach of using dyspnea measures developed for 
chronic obstructive pulmonary disease in view of the lack of specific 
cancer population dyspnea research is to be commended.  You have 
identified the need for new Cancer Care measurement research, but in 
the meanwhile, you have promoted the concept  of cross-cutting 
measures which apply to multiple diseases to move towards 
broadening the applicability and aligning Cancer Care measures with 
measurement research projects and guidelines.  
Thank you. 
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46 
Anna M. 
Lythgoe, 
RN, MSN 
VHACO Reviewer     
The review of the literature for quality indicators related to cancer care 
was broad enough to capture relevant information but stringent 
enough to focus on particular areas of interest:  pain, depression, 
dyspnea, and advance care planning/patient as decision-maker.   
It was surprising that there were not more quality of care indicators 
related to cancer care noted in the literature.   
Thank you. 
47 
Anna M. 
Lythgoe, 
RN, MSN 
VHACO Reviewer 8   
Symptom management included assessment of “frequency, severity, 
and bother or functional impact” (pg 8).  Recently reviewed studies for 
development of home care indicators indicate patients feel that loss of 
independence/function is critical to their perceptions of the quality of 
their lives.  Clinical review of functional impact of symptoms (pain, 
depression, dyspnea) would potentially improve symptom assessment 
and impact of treatment for those with cancer.   
The VHA “pain management workgroup” is currently discussing how to 
measure improvement in function as pain management improves.  It 
would seem that this would also be relevant for the cancer patient.   
We agree that it is relevant, 
although no indicators account for 
functional status at the present 
time in measuring clinical 
improvement. 
48 
Anna M. 
Lythgoe, 
RN, MSN 
VHACO Reviewer     
Potential indicators discussed that could be used to address the gaps 
in the literature were fairly global as currently stated.  However, with 
refinement, they may be well utilized to drive ongoing assessment and 
treatment of symptoms related to cancer care.  Many could be readily 
operationalized (almost) as written (e.g. physician documentation of 
pain assessment, patient education regarding pain management, 
routine assessment for dyspnea) while others may require clinical 
evidence to support change in practice (e.g. use of long acting opiates 
with as-needed opiates, indicators supporting specific interventional 
modalities).  In summary, the suggested indicators based on the 
literature reviewed were more hopeful than the indicators currently in 
place. 
We agree that there are many 
gaps in current knowledge not 
addressed by the available 
measure or indicator sets. 
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49 
Anna M. 
Lythgoe, 
RN, MSN 
VHACO Reviewer     
Mention is made of the burden of cancer on patients and caregivers 
(pg 1) but the caregivers are not addressed in the review.  The 
significant fiscal impact of (unpaid) family caregivers on the healthcare 
system begs their inclusion in the quality of care review.  Also, the 
clinical responsibility to ensure that the family caregiver has the 
education, support, and resources needed to successfully provide this 
care is heavy and must be addressed at some level. 
We agree, and it is unfortunate 
that caregiver concerns were out 
of the scope of this report. 
50 
Anna M. 
Lythgoe, 
RN, MSN 
VHACO Reviewer     
Table 2 (Processes potentially relevant to symptom care and advance 
care planning) – Assessment – Advance Care Planning:  If a family 
caregiver will be providing care, assessing his/her ability and 
willingness to provide care, educational needs, support systems, and 
identifying the limitations of their abilities may need to be assessed. 
Thank you.  This issue is 
addressed in the actual indicators 
under NHPCO client and 
caregiver assessment for unmet 
needs and care preferences.  No 
need to add to potential 
indicators, except perhaps as a 
supplemental citation and 
reference. 
53 
Phil Madvig, 
MD(Paul 
Feigenbaum 
and Jann 
Dorman) 
Kaiser 
Permanente Reviewer     
For those metrics where the denominator is a population associated 
with an institution or delivery system, e.g., "all deceased cancer 
patients" at Dana Farber there may be a concern that the metric would 
be driven by the unique characteristics of the institutional population in 
addition to the practice patterns applied to the numerator population. 
 For example, the patient population attracted to an academic medical 
center with a reputation for clinical trials may be different than the 
patient population at a regional medical center.  How would these 2 
institutions compare their performance on a single metric? 
We agree and have broadened 
our discussion of limitations to 
suggest that the populations 
tested may need to account for or 
examine differences in 
institutional bias with this 
difference in mind. 
54 
Phil Madvig, 
MD 
(Paul 
Feigenbaum 
and Jann 
Dorman) 
Kaiser 
Permanente Reviewer     
The listings of measures and indicators appeared relatively complete 
to us.  We are not aware of additional sources of measures or 
indicators which you have not included.  
Thank you. 
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55 
Phil Madvig, 
MD 
(Paul 
Feigenbaum 
and Jann 
Dorman) 
Kaiser 
Permanente Reviewer   Comment 
We face several challenges in developing quality metrics at Kaiser 
Permanente.  We need metrics that are:  
*Feasible to collect on a scale basis.  Metrics which are dependent 
upon chart review present tremendous resource challenges to 
measure in a large population.    
*Low risk for perverse incentives.  For example, the percentage of 
patients referred to hospice in the last 3 days of life can be decreased 
by not referring patients to hospice in the last 3 days of life.    
*Timely.  We need performance feedback that can be used to manage 
operations.  The metric must be reported within a time frame that is 
meaningful to make operational improvements.   
These dimensions represent the major gaps and priorities we face.    
This is helpful and we have 
highlighted these needs in our 
Discussion. 
56 
Phil Madvig, 
MD 
(Paul 
Feigenbaum 
and Jann 
Dorman) 
Kaiser 
Permanente Reviewer   ACP 
We question if the logic of the conceptual framework for the processes 
of care used for symptom management holds up for advance care 
planning.  As an example, you have labeled the second step in the 
conceptual framework "application", but refer to "application of 
preferences..." in the third step for ACP.  Given the well known 
challenges in operationalizing advance care planning on a scale basis, 
an accurate framework for the processes of advance care planning 
would be a great asset in understanding how to be successful. 
We agree that this is somewhat 
awkward, and we have changed  
'application' to 'implementation' . 
59 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 2 Last paragraph 
"...varies significantly among elderly cancer patients.." only among 
elderly, or all cancer patients? 
The citations for this statement 
are from the work of Fisher et.al. 
in the Medicare population. We 
are unaware of analyses that 
have addressed this directly in 
younger populations, although we 
would not be surprised if variation 
were found here as well. 
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60 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 2 Last paragraph 
"Cancer treatment at any stage commonly requires potentially difficult 
interventions such as chemotherapy or surgery." Not sure what 
"difficult means. 
We have clarified this language. 
61 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 2 Last paragraph 
"Now, quality practice endorses advance care planning for a number of 
reasons: to allow patients to shape care to their preferences, to avoid 
imposition of [unwanted?] treatment in urgent situations, to relieve 
patient and family anxiety…" 
Corrected  
62 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 3 Summary/ Conclusion 
"...that is sometimes used interchangeably, except that it is 
focused…" Interchangeably with what? Supportive care? Clarified 
63 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 5 Overview  Staff conducted an extensive grey literature and Web search..." Will the readers know what "grey literature" is? 
This is a standard systematic 
review term, but we have added 
some descriptive language to 
clarify it for readers unfamiliar with 
it. 
64 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 6 Third paragraph 
"Concerns were related relative to the feasibility of conducting a 
systematic review of distress."  Consider "Concerns were expressed 
relative to the feasibility of conducting a systematic review of distress." 
Clarified 
65 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 9 Last paragraph 
"Elements of care planning include prediction of the clinical 
situation,.." Not sure what this means? Prognostication? Yes. Clarified  
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66 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 10 
Table 2, first 
row under 
Symptom 
Managemen
t 
"...preferences for evaluation and treatment;…" Does this include 
patients desired level of relief? 
Yes, among other considerations. 
Clarified in Table 2. 
67 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 17 Table 1, Dana Farber 
The Dana-Farber Cancer Center at Harvard University has pursued an 
effort to develop a set of administrative data-based indicators for 
palliative cancer care as part of its recent research agenda.- Are these 
intended as quality measures, or for some other purpose? 
We are not certain if there are 
other intended uses besides 
quality assessment, although they 
have been reported as quality 
measures. 
68 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 19 Table 1, GCC 
1. Pain assessment and management. 
2. Use of hospice care. 
Why only mention these 2 of the 80 measures? Are none other 
relevant to this project? 
Yes that is correct. Our discussion 
of the indicator and measure sets 
highlights how we selectively 
used these sets to identify 
indicators or measures relevant to 
this project. 
69 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 19 Table 1, CCO 
Measures relevant to palliative [cancer?] care include those that 
address: Corrected  
70 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 20 Table 1, VHA 
o Assess pain regularly 
o Manage pain optimally 
Do these not continue across the ICU stay/measurement period? Are 
they only measured at day 1? 
The VHA bundle is designed so 
that each measure is targeted to a 
day of admission.  The pain 
measures are targeted to day 1 
and are only measured for that 
period. 
71 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 21 Literature flow "…we found 389 articles from the database…"  Unique from the 4580? 
Yes, and we have clarified this 
description. 
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72 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 21 Table 1, NHPCO 
Quality measures included: 1. Comfortable dying 2. Self-determined 
life closure 3. Safe dying 4. Effective grieving 5. Family evaluation of 
hospice care Any need to define any of these? 
Corrected-We have provided a 
reference so that readers can 
explore these definitions 
themselves. 
73 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 24 Pain, Introduction- 
Two last paragraphs of the introduction, Can this be presented as a 
table instead? Somewhat difficult to follow in text? 
Corrected-We embedded a 
reference to the Evidence Tables 
which essentially present this in 
tabular form. 
74 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 25 
Measures 
and 
Indicators 
Section is somewhat difficult to follow in text but is a nice description of 
these measures. Thank you.  
75 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 25 
Measures 
and 
Indicators 
Suggest add, Measures and Indicators: Pain as the section header. 
Did I miss somewhere a statement of the structure for this section (re 
measures/indicators in italics) 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
76 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 31 
Potential 
Indicators 
and 
Measureme
nt Gaps 
Any data that physician documentation actually translates into 
improved pain management? 
This is addressed in a limited 
fashion in the Discussion. 
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77 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 31 
Potential 
Indicators 
and 
Measureme
nt Gaps 
Suggest add Potential Indicators and Measurement Gaps: Pain as 
section title 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
78 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 32 
Potential 
Indicators 
and 
Measureme
nt Gaps 
First paragraph "Disparities in pain assessment" What about age 
related differences/disparities? Are also data that geriatrics population 
(especially in [illegible]) receives inadequate pain control. 
This is addressed in a limited 
fashion in the Discussion. 
79 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 32 
Treatment-  
Measureme
nt gap 
Treatment. "Procedure-related pain in children paragraph." Should this 
one be limited to children? Is it not a relevant issue for adults? 
We agree that such an indicator 
would be reasonable to consider 
for adults by analogy and have 
suggested so. 
80 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 32 Treatment 
Treatment. Education. "The numerator is patients who are educated 
about pain management.." Does this need to be defined any more 
(e.g.. Person is printed materials) 
We agree this is ambiguous and 
this would be required as part of 
trying to operationalize these 
potential indicators. 
81 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 33 Dyspnea- Introduction 
First paragraph. Again, can this be formatted differently for ease of 
following? 
We embedded a reference to the 
Evidence Tables which essentially 
present this in tabular form. 
82 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 33 
Measures 
and 
Indicators 
Measures and Indicators: Dyspnea. Suggest adding Dysnea to 
section title 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
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83 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 34 
Treatment-  
Measureme
nt gap 
Treatment: Pain. Suggest adding Dysnea to section title 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
84 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 35 Follow-up Follow-up: Dysnea. Suggest adding Dyspnea to section title. 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
85 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 36 
Potential 
Indicators 
and 
Measureme
nt Gaps 
"Assessment for treatable causes of dyspnea"  I like the measure, but 
am concerned that there are sufficient data to support a list of defined 
"treatable" causes.  
Agree that this would require 
further clarification. The potential 
indicators are meant to suggest 
informed opinion, not definitive 
evidence in that regard.  
86 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 36 
Potential 
Indicators 
and 
Measureme
nt Gaps 
footnote 1, Nice summary and important to include Thank you. 
87 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 36 
Potential 
Indicators 
and 
Measureme
nt Gaps 
Suggest adding Dyspnea to section title 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
88 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 37 Treatment 
"Treatment for malignant pleural effusions. The numerator is patients 
who have …" 
"Bronchoscopic therapy: The numerator is patients who have had…" 
"Palliative radiation and chemotherapy. The numerator is patients who 
have received..." 
Would it be "who have been offered" to respect patients choice? 
We agree that it is correct to 
consider patients who were 
'offered' a treatment as part of an 
indicator or measure. Making this 
suggested indicator into a 
measure would require resolving 
that consideration. 
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89 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 37 Treatment Treatment: Dyspnea. Suggest adding Dyspnea to title section 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
90 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 39 
Measures 
and 
Indicators 
Suggest adding Depression to title section. 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
91 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 41 
Measures 
and 
Indicators 
Suggest adding Advance Care Planning to title section. 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
92 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 45 Application Suggest adding Advance Care Planning to title section. 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
93 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 46 Follow-up Suggest adding Advance Care Planning to title section. 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
94 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 50 First paragraph 
(Measure- site of death) paragraph. "…(greater than 4%)… Is this 
number correct? 
The paper actually states that 
high performing systems will have 
less than 4% with multiple 
hospitalizations or emergency 
room visits or are admitted to the 
ICU in the last month of life (p.11 
in Earle) and sentence clarified in 
Report. 
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95 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 51 Potential Indicators 
Not ruse what is being addressed here- is this the "gaps" section? 
Where are the actual potential indicators? Did I miss something? 
This section has been completed 
in the final draft.  
96 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 51 Potential Indicators Suggest adding Advance Care Planning to title section. 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
97 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 54 Chapter 4 
Last paragraph. " Symptom assessment requires efficient indicators 
that can become part of the dashboard of quality monitors for care 
settings. Is this a comment enough terminology? 
The language has been clarified  
98 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 55 Chapter 4 
Second Paragraph. Consider the following revision: Pediatric [cancer] 
cases represent the second leading cause of death among children 
ages 5-15 in the United States. 
Clarified  
99 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 55 
Chapter 4, 
Last 
paragraph 
there is an extra closing parenthesis after dying that need not be there. No error found in current draft. 
100 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 56 
Chapter 4, 
Second to 
last 
paragraph 
It is important to define subgroups of cancer by stage of illness and to 
understand the performance of indicators among major subgroups. 
Issues such as timeliness of care and how side effects are tolerated or 
managed may vary in importance across groups distinguished by type 
or severity of illness. This seems to be a separate issue than the 
disparities addressed above, $ 
We modified the language to unify 
these considerations. 
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101 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 56 Chapter 4 
Third paragraph, first sentence. "We found insufficient evidence to 
comment on important difference by gender, race/ethnicity…" Age, 
should geriatric population have separate consideration? 
What about language issues? If measures that require patients report 
are only available in English, are less useful? 
We agree and have added 
language as a consideration in 
the Discussion. 
102 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP 57 Chapter 4 
Last paragraph. Starting with the sentence "However, unlike other 
tools…" Should this be separate paragraph? Is really a distinct issue 
from measurement availability. 
Agree and we separated these 
issues  
103 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP     
Conceptual Issues and processes of care? Quite complete. One area 
that I did not see mentioned (expect in an ACOVE measure related to 
advance care planning) is the coordination of these symptom 
management and advance care planning areas across specialty and 
primary care. This may be beyond the scope of this project, but 
perhaps worth addressing or at least acknowledging. 
We agree that coordination is an 
important element of care that 
was not addressed within the 
scope of the current project. 
104 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP     
How complete is the listing of relevant measures or indicators? Quite 
complete. Appropriate attention is paid to the need for pediatric-
specific measures and those that address potential racial. ethnic 
disparities. I question whether specific attention needs to e paid to 
geriatric-specific issues as well. 
We agree and have added some 
language to our discussion of 
population differences in the 
Discussion to highlight the need 
for further information on this 
topic. 
105 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP     
The "take home" message being that there are sufficient measures to 
begin assessment/monitoring in these areas, but that additional 
research is necessary to fill in the gaps. 
Thanks for highlighting this 
important conclusion, and we 
have underscored it more strongly 
in our Discussion. 
106 Jean Kutner, MD, MSPH 
University of 
Colorado 
Health 
Sciences 
Center 
TEP   Overall The Evidence tables are especially well-constructed and useful Thank you. 
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107 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 32   
Proposed indicator for patient education regarding pain management - 
how would "education" be operationalized?  Would this be based upon 
physician/nurse documentation in the chart?  Or would patients' and or 
their caregivers be assessed for their knowledge? 
See response to Item #78. 
108 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 32   Why is the procedure-related pain indicator limited to children? Seems like it should apply to adults also. See response to Item #77. 
109 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 36   
Routine dyspnea assessment in cancer - the denominator "all cancer 
encounters" is too broad - many patients with a diagnosis of cancer will 
not have active disease (i.e. routine follow-up of early stage breast 
cancer treated 5 years ago).  Even limiting this indicator to "all 
encounters in patients with metastatic disease" is probably too broad.  
Perhaps "all encounters in patients with lung involvement with cancer 
or a prior complaint of dyspnea" would be a reasonable starting place 
for routine assessment of dyspnea.  What would constitute 
assessment?  Is recording of a respiratory rate in the chart 
assessment or does the clinician need to question the patient 
regarding the presence or absence of dyspnea?  
We did not intend to resolve these 
ambiguities in posing this as a 
'potential indicator' We did clarify 
language around these 
ambiguities somewhat in the 
discussion of this particular item. 
We also added further description 
of potential indicators in our 
Methods so that readers would 
understand our intent of offering 
only reasoned suggestions in this 
section of potential indicators. 
110 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 36   
Assessment for treatable causes of dyspnea - consider making this 
numerator more specific - perhaps # of patients who have had all of 
the following performed within xx weeks of the complaint of dyspnea:  
vital signs, lung exam, O2 saturation, Hb, chest imaging,  DVT/PE 
assessment (documentation of physical exam of legs or Doppler/UTZ 
lower extremities or CT angio or VQ or D-dimer).  The other challenge 
here is longitudinal assessment - what if patient has dyspnea in July 
and is evaluated and treated for pneumonia with resolution of 
symptoms and then in September has dyspnea again? 
See response to #107. 
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111 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 37   
Treatment of malignant pleural effusions.  I would urge you to consider 
being more cautious in the recommendation of pleurodesis as a quality 
indicator.  In my own experience, there tends to be overuse not 
underuse of pleurodesis - use in patients who are not symptomatic or 
where the production of malignant fluid is occurring at such a rapid 
rate that pleurodesis cannot be successful.  Many of the published 
reports tend to overstate the effectiveness observed in actual practice 
and rarely provide the rates of continued success 1-2 months later.  
I'm attaching a survey of pulmonologists regarding their views of the 
procedure which I think echoes the uncertainty regarding its 
effectiveness. 
Treatment of malignant effusions 
were taken from ACCP and are 
the state-of-the-art and most 
current recommendations - 
limitations are noted and we only 
propose this as a potential 
indicator supported by available 
data.  The limitations will need to 
be addressed in subsequent work  
112 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 37   
Broncoschopic therapy - other treatment modalities for central airway 
obstruction are not mentioned.  Brachytherapy and external beam 
radiation can often be quite effective and may be more widely 
available than bronchoscopic therapy.  In selected cancers (small cell 
lung cancer, lymphoma), chemotherapy is the most effective 
approach.  Also, steroids may provide significant relief of symptoms 
and if patients are in a terminal phase of their disease, this may be 
enough to provide them palliation until death. 
These other modalities are briefly 
mentioned proportionate to the 
available data identified in the 
systematic review.  
113 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 37   Patient education - same comment as pain indicator regarding education. See response to Item #78. 
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114 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 46   
Late life hospital use - it may be worth explaining under what 
circumstances this may or may not be a good quality measure.  It likely 
reflects structural as much if not more than process quality - without 
high quality in home care or inpatient hospices or nursing homes that 
really address the needs of the dying, hospitalization may actually 
provide patients with a more comfortable death experience and more 
support for families.  Given the daily capitation rate for hospice, current 
home hospice provides very little in the way of support - and is really 
not viable for patients who do not have informal caregivers or the 
resources to pay for round the clock care.   
In addition, there is a catch-22 that as not been fully addressed by the 
work of the proponents of this and other similar measures:  patients 
hospitalized late in life and/or who die in the hospital is asked may 
have had a preference for hospitalization at that time.  Those same 
patients may also have had a preference to die at home.  However, at 
the time of hospitalization, they may not yet accepted that death was 
imminent even if this was communicated to them.  I cannot tell you 
how many times in my own practice, I have talked with patients and or 
family of members of patients at home receiving hospice care while 
the paramedics were waiting to take them to ER (even after making a 
home visit earlier in the day...).  
The issue of the limitations posed by the retrospective "look back" of a 
number of these quality measures should also be addressed (see 
article by Bach et al.).  Research efforts should focus on developing 
quality measures that allow prospective identification of the 
denominator, for example by using performance status or some other 
predictor of death.  My own experience caring for patients at the end-
of-life has been limited to patients with breast cancer.  And, except in a 
rare case, I have been struck by how patients have lived with good 
quality of life and excellent performance status for several years before 
having quite a precipitous decline over 3-6 weeks prior to dying.  I 
imagine that different cancers have different trajectories and that for 
our quality measures to improve the care of patients we need to be 
able to account for these differences in disease trajectory -- as well as 
patient preferences - neither of which can be accomplished with these 
global "look back" measures.  
Finally, there may be cultural differences regarding preferences for 
place of death that have yet to be fully explored.        
Thank you - we agree that it is 
important to stress these 
limitations and we have added 
language to make that clear to 
readers (P41) Also, see response 
to Item # 17. 
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115 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 8 para 2 "Self report" may be jargon and not readily understood by all readers - it may be worth explaining a few more words the first time you use it. Clarified  
116 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 11 para 2 
We also searched for 'related articles' for citations that described 
measures..."  -- I found this sentence confusing. I was not sure what 
'related articles' were or how they pertained to ACOVE. 
Clarified  
117 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 12 Last paragraph 
 It might be clearer to state "We searched the database of the End of 
Life Care and Outcomes Project, a systematic review recently 
completed by this report's authors, for articles coded as 'cancer." 
Clarified  
118 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 23   Figure only mentions indicators and potential indicators not measures Corrected 
119 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 25   
Consider reminding reader of the distinction between measure and 
indicator.  Also I found the use of the parentheses in the headings 
somewhat distracting - consider using heading and subheadings: 
Measures Identified 
Regular Assessment of Pain: Quality Assessment Tools proposed 
We have changed our Chapter 
and section headings for 
smoother reading of the report. 
120 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 25    last paragraph refers to the second UHC "pain assessment indicator" but this appears to be a measure? Corrected 
121 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 26 para 3 
"As with other pain outcome measures..." - Is the proposed measure 
"regular pain assessment," which would be a process measure, or the 
score (average, final, change in?), which would be an outcome 
measure? 
More information on the 
specification of the measure is not 
available. 
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122 Jennifer Malin, MD 
UCLA 
School of 
Medicine, 
RAND 
TEP 31 para 2 Have the numerator and denominator been reversed? No error found in current draft. 
124 Joan Teno, MD, MS 
Brown 
Medical 
School 
TEP   Indicators You need to move away chart based indicators 
Agree that this is a consideration 
that should affect the use of the 
current set and implications for 
future research. We have 
stressed that chart-based and 
administrative data based 
indicators may not provide 
adequate information for quality 
assessment and improvement, 
and that these limitations should 
be understood as part of better 
population studies. Obviously, the 
merits of specific indicators and 
data sources must be understood 
individually. 
125 Joan Teno, MD, MS 
Brown 
Medical 
School 
TEP   Literature Search 
The literature searching strategy that restricted everything to cancer 
was unneeded for symptoms, pain, and cancer. They do not need to 
be cancer specific processes. There is nothing that is inherent to the 
disease trajectory that warrant a different process of care. So you 
indicators that could go forward that has been used in other research 
and quality improvement efforts.   
While we went beyond the scope 
of our task order in searching 
dyspnea and ACP, we agree this 
would have been a consideration 
had resources permitted it. We 
have tried to acknowledge this as 
a limitation and have suggested 
how that might be mitigated by 
the NQF process. 
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126 Joan Teno, MD, MS 
Brown 
Medical 
School 
TEP   Measurement Set 
My overall assessment is that the current measurement set is very 
weak and potentially, should not go forward - information on reliability 
and validity is missing. Even more important, I did not see information 
on responsiveness, discriminate validity.. all things that are very 
important prior to the use of accountability. 
We have stressed the need for 
additional evaluation in 
populations to address these 
attributes and that the use of 
measures should be concordant 
with the strength of information on 
their applicability within clinical 
settings and across systems.  
127 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP 31 Pain 
I found the comment at the end of page 31:  "improvements in pain 
assessment by non-physician staff may not lead to improved 
outcomes because the physician may not attend to the report of pain." 
I need to explore that reference source because if that statement is 
true, we are in deep trouble. Physicians rarely see patients in LTC and 
in the post-op period it is obviously non-physician clinicians who have 
the responsibility to assess and document pain.  
It is true that assessment must be 
linked to clinically meaningful 
outcomes to assure relevance to 
patients. 
128 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP 32 Pain 
there is a statement:  "the reviewers concluded that improved 
adherence with long-acting drugs in clinical practice improved 
outcomes."  Is there any rationale for this conclusion?  What outcomes 
are the reviewers referring to?   
They are referring to pain and the 
application of expert opinion. We 
have clarified the statement.  
129 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP 43 General Edits 
Data is a plural noun and yet sometimes use as a singular noun, e.g., 
line 2 page 43 ...."validity data is available."  
The final report has been 
reviewed by a medical editor. 
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130 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP   General Edits 
 Dangling participles are another issue.  I am a purist about those, but 
only mention two. On page 26, line 5:  what or who is "using an 
appropriate rating scale?"  On page 49, 10th line from bottom, who is 
"using the highest performing decile of this measure?"  I am certain 
you will catch the others as you edit. 
The final report has been 
reviewed by a medical editor. 
131 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP   Pain 
An important measure identified: how many patients being treated with 
opioids are on a bowel regimen was also identified by the JCAHO-
NCQA-AMA Task Force.  I think JACHO's field trial showed there was 
lots of room for improvement. 
In our discussion with JCAHO 
about this project, they felt that 
these were not yet ready to be 
measures since they still needed 
further development.  This 
information has been added to 
this section:  " A similar potential 
measure has also undergone 
some field testing in a population 
including cancer patients as part 
of the JCAHO-AMA-NCQA pain 
management performance 
measure development project 
{#8404}." 
132 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP   Dana Farber Guidelines 
I was very interested in measures developed at Dana Farber:  of new 
chemotherapy in the last 30 days of life, of patients receiving 
chemotherapy in the last 14 days of life, and late referral to hospice.  
Unfortunately, in our area, some of the more recently developed 
chemotherapies are being offered to patients with very advanced 
disease which results in a delay in their admission to hospice. My 
comment adds nothing to your review - it is just a reflection of our 
realities and makes me question how  implementing these measures 
could improve quality given the forces in the oncology profession that 
are pushing for more therapy. 
Agree these might be useful, 
although we have added some 
caveats about the use of 
utilization outcomes as measures 
in Discussion and introduction to 
ACP measures. 
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133 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP   General Edits 
Inconsistency in use of terms related to opioid analgesics.  Opioid 
would be preferred, but narcotic appears (e.g., page 27) as does the 
term opiate (e.g., page 32). 
We have changed all opiate(s) to 
opiod(s). 
134 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP   Numeric rating scales 
Is it intended that numeric rating scales be 1-10 (page 26)?  The 
numeric pain rating scale is 0-10. On page 33, there is reference to a 
10-point dyspnea scale.  Is it indeed a 10 point scale or an 11 point 
scale? 
Corrected   VHA lists this as a 1-
10 rating scale so that is what is 
reported here. 
135 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP   Pain 
It is interesting that none of the studies you cited used pharmacy 
department data.  If pain is the symptom of interest, one could 
measure the percentage of patients with a diagnosis of cancer and 
moderate to severe pain who are/were being treated with opioids.  
We agree that there are additional 
data sources and indicators that 
should be considered. 
136 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP   Future research 
Obviously data collection is a huge challenge. The data have to be 
easy to obtain. The advent of electronic medical records, should 
enable collection of accurate data so as to make measurement 
possible.   
We do now provide some 
additional discussion of 
measurement issues in the 
Discussion  
137 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP   Pain 
The cognitively impaired are a special assessment challenge.  We 
need to develop measures that don't rely on self reports if we are to 
assess pain in that population.  We are working on a scale based on 
items in MDS 2.0; certain behaviors suggest the presence of pain.  
Agree and we have highlighted 
the challenge of those who cannot 
self-report  in our Discussion. 
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138 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP   Pain 
The critical first step is assessment.  And as your report emphasizes, 
waiting 48 hours to do the assessment makes no sense.  I would 
prefer the JCAHO standard: ask about pain on admission: All patients 
with a diagnosis of cancer who are admitted to hospital should be 
screened for pain on admission regardless of the reason for their 
admission.  If pain is present, the intensity and quality of the pain 
should be assessed.The focus in all of the literature available is on 
assessment of pain intensity.  Quality should be assessed as well so 
as to determine whether the patient has neuropathic pain. A measure 
of the presence of neuropathic pain is critical to development of an 
effective treatment plan. Krause and Backonja (Clinical J of Pain, 
2003) have developed a short form of a neuropathic pain 
questionnaire which involves rating of numbness, tingling, increased 
pain due to touch. A comprehensive pain assessment involves asking 
questions about quality; should be possible to add two or three boxes 
to check or numbers to circle to provide data for this assessment.  We 
haven't made an effort to create appropriate forms to make this 
additional component of assessment a practical reality. 
We agree that symptom 
assessment is a complex task. 
We have added some language 
to address other aspects of 
assessment that are not covered 
in the existing indicators and 
measures to the potential pain 
indicators discussion.  
139 June Dahl, PhD 
University of 
Wisconsin-
Madison 
TEP   Sources 
The recent recommendations from the American Pain Society 
(Archives Int Med 2005; 165: 1574-1580) were published after you 
finished your intensive review.  They deal with acute  and cancer pain; 
the recommendations for acute pain reflect what was in reference #87 
of your draft.   
The updated information from this 
new article has been added in 
several places in the report to 
update reference #87, for 
example: "A related outcome 
potential measure, that patients 
should be adequately informed 
and knowledgeable about pain 
management, is included in the  
2005 American Pain Society 
Recommendations for Improving 
the Quality of Acute and Cancer 
Pain Management {#8404} based 
on an expert review of the 
measurement tools used in 20 
quality improvement studies in 
pain management.87"   
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140 
Laura 
Hanson, 
MD, MPH 
University of 
North 
Carolina at 
Chapel Hill 
TEP   
Process vs. 
Outcome 
Measures 
Consider adding to the report whether a measure is a process 
measure which primarily addresses quality of care, vs. an outcome 
measure which directly addresses the patient experience. 
These are sometimes hard to 
qualify or categorize exactly. 
There is also the concern that 
some measures may reflect 
structure (see Item # ). We agree 
that it is important to stress that 
measures should ideally reflect 
the patient experience. We have 
added additional language to 
highlight these issues in the 
Discussion. 
141 
Laura 
Hanson, 
MD, MPH 
University of 
North 
Carolina at 
Chapel Hill 
TEP     
I would encourage addition of the absence of reliable and valid 
measures for cognitively impaired patients to your lists of gaps in 
quality measurement. 
Thank you and this is discussed 
in the current version (as those 
who cannot self report). 
142 
Laura 
Hanson, 
MD, MPH 
University of 
North 
Carolina at 
Chapel Hill 
TEP     
In addition to reporting reliability and validity of individual measures, it 
would be very valuable to report on the responsiveness of these 
measures. It will not be true for all measures, but for any that have 
repeated measures over time and/or in relations to interventions, 
adding evidence that a measure has dynamic properties adds its 
relevance to clinical quality improvement.  
We agree and have highlighted 
the need for more research on 
this as an issue in the Discussion.  
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143 
Laura 
Hanson, 
MD, MPH 
University of 
North 
Carolina at 
Chapel Hill 
TEP   Pain 
The text would benefit from an introduction to measurement issues 
from pain, the best studied of all these symptoms, so that the 
measures are in a broader context of certain limitations. I would 
include the following aspects: 
Measurement systems need to specify exclusion or use of alternative 
measures for patients unable to self-rate symptoms due to cognitive 
impairment 
Effect of depression, symptom interpretation and addiction history may 
modify treatment approaches; settings may vary in the frequency with 
which these effects influence measurement 
Pain literature shows a discrepancy between pain severity scores and 
patient satisfaction with pain treatment- perhaps due to low 
expectations for relief, OR due to positive responses to attention to 
pain even when it is not fully relieved. You might want to address the 
dilemma of symptom scores as measures vs. satisfaction with care. 
We agree that it might be helpful 
to illustrate these challenges in 
the context of pain care. We have 
added some language to highlight 
these considerations in the 
conceptual discussion. 
144 
Marilyn 
Bookbinder, 
RN, PhD 
Beth Israel 
Medical 
Center 
TEP   Future research 
If benchmarks are to represent best practice and serve as the “gold 
standard” for practitioners to emulate – more rigorous research 
designs and larger homogeneous samples are needed to strengthen 
the evidence base and persuade those allocating funds  to increase 
“quality” care research dollars.  
This is a helpful point and we 
have stressed the need for testing 
of the measures in cancer 
populations in our Discussion. 
145 
Marilyn 
Bookbinder, 
RN, PhD 
Beth Israel 
Medical 
Center 
TEP   Sources 
Revised indicators for measuring outcomes of pain management have 
recently been published (Arch Intern Med. 2005 Jul 25;165(14):1574-
80) by the American Pain Society Task Force on Quality. They include 
items such as how often the patient had moderate to severe pain in 
the last 24 hours; how much interference did pain have with their 
function (able to do what they needed to do) interference with sleep, 
interference with mood.  No data has been published to date, although 
we at Beth Israel and colleagues at University of Wisconsin have data 
on selected indicators.   
We have included this in our 
review. 
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146 
Marilyn 
Bookbinder, 
RN, PhD 
Beth Israel 
Medical 
Center 
TEP   Potential Indicators 
The potential indicators lists are relevant and are an excellent 
approach to using data available (not meeting the criteria).  The 
indicators selected and approach used to target vulnerable populations  
(DRG, LOS, Adm)  is excellent and I think will give others the guidance 
and tools needed to measure and improve symptom management and 
ACP in problem- prone high risk groups. 
Thank you. 
147 
Molla 
Donaldson, 
DrPH, MS 
National 
Cancer 
Institute 
(Fed 
Reviewer) 
TEP 0 Title 
Make the title more specific as there are two other EPC reports on 
cancer measures - perhaps along the line of Cancer Quality of Care 
Measures for Supportive care and End of Life  
See Response to Item # 19 
148 
Molla 
Donaldson, 
DrPH, MS 
National 
Cancer 
Institute 
(Fed 
Reviewer) 
TEP 3 Introduction 
The term "utilization outcomes" is a little strange without explanation - I 
think of utilization as just that (e.g., admissions, length of stay, hospice 
use), so that sentence could be clarified.  
We have added additional 
discussion to explain our inclusion 
of these items and why we placed 
them in Advance Care Planning. 
We also modified the description 
in the Introduction. 
149 
Molla 
Donaldson, 
DrPH, MS 
National 
Cancer 
Institute 
(Fed 
Reviewer) 
TEP 5 Chapter 2 
Under the 1. RFTO question, you might explain that after further 
discussion distress was dropped in favor of dyspnea - something along 
those lines so that it is clear you were responsive  to the task order.  
We have clarified this under the 
task order questions. 
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150 Patricia Ganz, MD 
UCLA 
Schools of 
Medicine 
and Public 
Health 
TEP     
It looks like you have found quite a few measures, but overall, I was 
very disappointed to see that so few had been implemented or tested. 
 Have you contacted the measure developers in follow-up to see if 
they can give you any information on their use?  For that reason, I 
worry that many of the measures may look good from an academic or 
measurement perspective, but may not be ready for prime time.  I see 
this as a real limitation.  
Yes, we contacted measure 
developers for all measure sets 
except the Georgia Cancer 
Coalition. 
151 Patricia Ganz, MD 
UCLA 
Schools of 
Medicine 
and Public 
Health 
TEP     
Did you find any references to the pain thermometer scales that are 
being widely used in hospitals as required for hospital accreditation?  
We also use them in our outpatient department.  I don’t know how 
reliable and valid they are as measures, but they are now in wide use 
and seem practical.  
No, we did not. 
152 Patricia Ganz, MD 
UCLA 
Schools of 
Medicine 
and Public 
Health 
TEP     
I think Chapter 4 does a good job talking about the limitations of the 
measures and indeed the issue of obtaining self-report data from 
seriously ill patients is a real challenge.  
Thank you. 
153 Patricia Ganz, MD 
UCLA 
Schools of 
Medicine 
and Public 
Health 
TEP     In summary, I think you have done a fine job, but I have concerns about how practical a lot of these measures will be for implementation. 
We agree that further testing is of 
the highest priority before the 
potential of these measures can 
be fully realized. 
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154 Perry Fine, MD 
University of 
Utah TEP 11 
Internet 
Search 
Under the section listing "Studies or Internet documents....", the first 
bullet point omits Canadian references. Was this purposeful or an 
unintended omission? 
Unintended, now corrected  
155 Perry Fine, MD 
University of 
Utah TEP 32 
Treatment- 
Measureme
nt gap 
Might I suggest that a more broadly applicable potential indicator 
(measurement gap) would be (numerator) patients with moderate-
severe pain who receive prescriptions for opioid analgesics 
(denominator = all patients with moderate-severe pain scores). This 
might be simplified further to the % of all cancer patients in a given 
practice who are prescribed opioids, with a benchmark extrapolated 
from exigent literature on the prevalence of moderate-severe pain in 
cancer patients. 
Thank you. Our pain reviewers 
concur and we have added it to 
the list of potential indicators.  
This is also a potential indicator 
from a project including JCAHO, 
AMA, & NCQA. 
156 Perry Fine, MD 
University of 
Utah TEP 40 Depression 
I was very surprised to see that there were no potential indicators/ 
measurement gaps enumerated for depression. Is there really no basis 
to elaborate upon this section (assessment, treatment and follow-up)? 
This section has been completed 
in the final draft.  
157 Perry Fine, MD 
University of 
Utah TEP   Chapter 4 
You rightly elaborate upon the clinically significant and problematic 
area of pain assessment in non-self-reporting patients. There may be 
the opportunity to round out the pain assessment section with 
additional potential indicators from (non-cancer) dementia studies. I 
would refer you to Dr. Keela Herr, who chairs the gerontological 
nursing division in the U. of Iowa College of Nursing, whose area of 
focus is pain assessment in cognitively impaired older patients. She 
may be able to point quickly to a rich little vein of literature that was not 
easily uncovered in your search. Her email address is keela-
herr@uiowa.edu 
Corrected-Thanks you - we were 
unable to expound upon this 
information for the draft report, but 
we have cited it for readers so 
that they can avail themselves of 
it 
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158 Roger Winn, PhD 
National 
Quality 
Forum 
TEP   Overall 
I think the reviewers have done an admirable job of collecting available 
measures and analyzing them in a well conceptualized framework. I 
found the division between measures, indicators, and potential 
indicators useful and operationally sound. The analyses of the specific 
measures appears to be balanced and to target the major strengths 
and weaknesses. The conclusions of the report are justified by the 
body of evidence reported. 
Thank you. 
159 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 1 1 Mention scope: limited to pain, dyspnea, depression, advanced directives 
The scope is covered in the 
introduction 
160 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 3 para 2, line 13 toxic instead of taxing Changed to 'difficult'  
161 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 7 para 2, line 2-3 
 I think this statement is a little too strong, For example the number of 
trained social workers or psychologists might have an impact on 
depression. I think it’s more the case that it’s difficult to directly 
establish the linkages between structure and outcomes. 
Modified 
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162 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 7 para 2 
Although I think it’s implied, you might want to point out that for 
symptom-related measures, the data collection is usually a patient 
response instrument, which from a measure perspective is much 
harder than trying to capture data from administrative sources or even 
the medical record. {I see you make the point later  in the report} 
Thank you. 
163 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 16 1 I don't understand the decision not to abstract JCAHO, ORYX, or NCQA measures of relevance 
This decision was made because 
these are widely available 
measure sets and in light of 
resources, it was felt to be more 
helpful for NQF's purposes to 
enumerate less visible indicator 
and measure sets.  This decision 
was made in consultation with our 
task order officer. 
164 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 34   ACOVE effective dyspnea measure: I’m confused about the numerator: shouldn’t the denominator be all patients with dyspnea? 
No, the specifications are correct 
as described 
165 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 39   ACOVE spiritual assessment: Numerator and denominator definitions are reversed Corrected  
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166 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 41   
ACOVE surrogates for poor cognition measure: how does the measure 
operationalize “dementia and altered mental state” to determine the 
denominator? How is impairment assessed, i.e standard tests, etc? 
Similar consideration for regular assessment of inpatients with severe 
dementia (p 42).  
We have now included a 
definition. 
167 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 46   
ACOVE documentation of specific life sustaining preferences. Why is 
the denominator restricted to those who state they do not want life-
prolonging measures? Shouldn’t the preference of those who do want 
aggressive therapy also be documented? 
Since the default of providing 
these treatments is typical in 
clinical practice, documentation is 
not typically required to assure 
these interventions. Certainly, 
effective communication should 
be the standard for patients and 
families whether or not they elect 
specific treatments. However, the 
specification reflects the actual 
indicator. 
168 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 46   
ACOVE consistency of preferences and mechanical ventilation. 1) As 
stated, the numerator doesn’t seem to get at the consistency 
(concordance) issue: isn’t the measure all those who are receiving 
ventilation in the denominator and all those who stated they did not 
want it in the numerator? 2) The discussion appears to be about 
withdrawal of ventilation not its institution. 
In this case, the numerator 
reflects a discussion of 
preferences having occurred in 
patients who qualify for 
mechanical ventilation, regardless 
of whether or not they declined it. 
169 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 47   
Dana Farber hospital use and ICU use measures: both discussions 
quote the norm in terms of use of emergency visits. This applies only 
to the ER measure. 
The paper actually states that 
high performing systems will have 
less than 4% with multiple 
hospitalizations or emergency 
room visits or are admitted to the 
ICU in the last month of life (p.11 
in Earle) and sentence clarified in 
Report. 
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170 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 48   
Dana Farber new chemo measure: does it exclude acute leukemias 
(10-15%) die from drug toxicity and hospitals with large leukemia 
practices might therefore suffer from this measure. 
This information was not 
available, but we have addressed 
the concern that institutional 
variation and care mix adjustment 
needs to be strongly considered 
with these measures. See 
response to Item # 51 
171 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 49   
Dana Farber admission to hospice measure: the Earle paper gives 
reasons for the low sensitivity (24%) and this should probably be 
included. 
Agree and this is now included. 
172 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 49   
 Site of death  Dana Farber late referral to hospice: does this need to 
be a composite measure with the % hospice admission? If two 
hospitals both have 9% late admissions of all the patients who die, i.e. 
poor quality, is this the same measure of quality for hospital A  who 
has a 50% hospice admission rate and hospital B who has a (% 
admission rate (all late)? 
While this measure does not 
address it, we agree that this 
measure has to be interpreted in 
light of the total hospice referrals 
of an organization. 
173 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 50   Dana Farber site of death , line 7 should be “(greater than 17%)” not 4% Corrected  
174 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 51   Need NEJM reference for Danis. Corrected 
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175 Roger Winn, PhD 
National 
Quality 
Forum 
TEP 54 para 4 line 1: 
 I really have trouble understanding:  “Symptom assessment requires 
efficient indicators that can become part of the dashboard of quality 
monitors for care settings". What are efficient indicators?  
We have clarified this sentence. 
176 Steve Asch, MD, MPH VAGLHS TEP     No comments received. N/A 
177 
William 
Lawrence, 
MD 
AHRQ TOO 5 Task Order questions 
 I think this would read easier to start with the final key questions in the 
task order questions section (if you’d like, you can even change the 
subhead to final questions).  I’d rather the emphasis for the report 
were placed on the questions you actually answer in the report, not the 
ones that you were originally asked.  If you’d like, I think it would be 
quite reasonable to put the initial questions (unbolded) in the approach 
to the report section, if you want to detail how we arrived at the final 
questions.  At the moment, the only stand-alone key questions section 
lists questions that you only answer some of. 
We agree and have presented the 
final, modified task order 
questions in the introduction - with 
a note that they were modified. 
We decided not to include all of 
the original questions since they 
are largely duplicative and we 
thought this presentation would 
be clearer for readers. 
178 
William 
Lawrence, 
MD 
AHRQ TOO 24 Pain the mention of an XRT measure in relation to pain was a bit confusing – I presume this was palliative XRT specifically? 
Yes, XRT for symptom 
management. 
179 
William 
Lawrence, 
MD 
AHRQ TOO 25 Pain 
First measure (as general comment). “The measure is not in use” – I 
appreciate having this bit of data, but this means not in use anywhere?  
Not in use by the organization that has proposed it? 
That is correct - to our knowledge. 
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180 
William 
Lawrence, 
MD 
AHRQ TOO 37 Dyspnea 
 treatment of malignant pleural effusions.  Despite having worked in a 
cancer center, I don’t have enough clinical experience here to judge, 
so I’ll ask you – does this happen with enough frequency that you think 
it will be usable as a quality measure (i.e. will the rates be made from 
enough cases for a particular entity, be it practice, hospital, health 
plan, that the rate is stable enough to judge quality from the number)?  
This would get at the importance of the measure. 
See our response to item #113 
181 
William 
Lawrence, 
MD 
AHRQ TOO 39 Depression 
assessment of psychosocial well-being.  Is “formal assessment” 
defined?  Is a screening survey sufficient?  Must it be an assessment 
by a psychologic specialist? 
We have clarified that this 
generally meant an assessment 
by a social woker. 
182 
William 
Lawrence, 
MD 
AHRQ TOO 39 Depression 
Spiritual assessment.  Looks like you have your numerator and 
denominator backward.  Also, I presume the numerator is specifically 
those with a spiritual assessment and have died?  Otherwise, 
numerator is not a subset of the denominator. 
Corrected 
183 
William 
Lawrence, 
MD 
AHRQ TOO 40 ACP  first measure.  Watch the measure/indicator terminology – you refer to this first as a measure, then as an indicator. Corrected 
184 
William 
Lawrence, 
MD 
AHRQ TOO 40 Gaps 
 Would appreciate this section sooner or later, preferably sooner.  
While I’m thinking about it, I thought your gaps sections (at least the 
ones that exist) were excellent in both content and writing. 
Thank you,. 
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185 
William 
Lawrence, 
MD 
AHRQ TOO 41 ACP 
regular identification of surrogate.  Numerator is “vulnerable” elderly.  
How do we define vulnerable?  This section in general seems to have 
a several terms with a similar degree of vagueness. 
Vulnerable elders are 
conceptually defined as those 
persons 65 years or older who are 
at increased risk of death or 
functional decline in the next 2 
years.   Vulnerable elders are 
specifically defined as those 
scoring 3 or greater on the VE-13 
scale,  a self-report that gives 
points for age, self-reported 
general health and activity 
limitations( Saliba et al. JAGS 
49:1691-1699, 2001).  In practice 
the VE-13 identifies about 20-30% 
of community-dwelling older 
adults as vulnerable and they 
have a 4 fold increase in the odds 
of death or function decline. 
186 
William 
Lawrence, 
MD 
AHRQ TOO 42 ACP 2
nd regular identification of surrogate.  Is the numerator a subset of the 
denominator here? 
Yes, but we tried to clarify the 
description to make that clearer 
(42) 
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187 
William 
Lawrence, 
MD 
AHRQ TOO 42 ACP last measure – how do we assess that a patient had care consistent with expressed preferences? 
The assumption in the ACOVE 
measures is that the patient's 
preferences, surrogate will be 
elucidated and documented within 
the patient's medical record, 
usually within a specified 
timeframe depending on site 
within the hospital, or why 
surrogate and preferences were 
not able to be obtained.  Thus, the 
documentation in the patient's 
record of their preferences would 
provide the standard by which 
care consistency will be 
evaluated.  Clarification text 
inserted in final report. 
188 
William 
Lawrence, 
MD 
AHRQ TOO 46 ACP 
documentation of specific life sustaining preferences.  Not sure why 
the denominator is only those who don’t want therapies (although, if 
this is what the measure says, we go with it, but might deserve 
comment).  Also, numerator and denominator could be from different 
sets. 
See response to Item #162 
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189 
William 
Lawrence, 
MD 
AHRQ TOO 47 ACP 
DFCC measure set – you refer to ER visits for discussions of 
hospitalizations and ICU episodes.  Also, while I could grasp your ratio 
of the 5th percentile/95th percentile for a measure of variability of the 
measure, I think it would be helpful to put in the raw rates here also. 
Raw rates are not included in the 
paper from which these data were 
derived {#0742} or in the 
published article used as 
supporting evidence {#0142}.  
Accuracy data and the range for 
the 95% CI have been added to 
the text of the final report. 
190 
William 
Lawrence, 
MD 
AHRQ TOO 48 ACP chemotherapy in last 30 days of life.  Does this include Phase I trials?  Should it?  Is palliative chemotherapy used this late? 
This is not addressed in the 
available information we have on 
the measure. Presumably it would 
not capture Phase 1 trials, unless 
they are covered (and recorded) 
in Medicare administrative 
records. 
191 
William 
Lawrence, 
MD 
AHRQ TOO 49 ACP 
admission to hospice and others.  Is there a definition of “deceased 
cancer patients”?  Is a breast cancer survivor NED for 5 years who 
dies of a heart attack a deceased cancer patient? 
This is not addressed in the 
available information we have on 
the measure.  
192 
William 
Lawrence, 
MD 
AHRQ TOO 51 ACP potential indicators – a reference to the appendix would be nice here. 
Corrected-We embedded a 
reference to the Evidence Tables 
which essentially present this in 
tabular form. 
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193 
William 
Lawrence, 
MD 
AHRQ TOO 54 
Chapter 4, 
3rd 
paragraph 
Can we say anything from the extensive amount of data that you 
reviewed concerning the frequency with which pain is assessed and 
appropriately treated?  I realize that by virtue of the settings being 
quality measure testing settings, they might not be generalizable, but 
presumably they could at least be considered an upper bound of what 
happens in reality. 
We have added this information:  
"Some information is available on 
measure for pain assessment, but 
we identified no measures with 
this type of information for 
appropriate pain treatment.  The 
UHC measure of any pain 
assessment within 48 hours of 
admission to the hospital, which 
was met in almost 100% of 
patients and showed little 
variation among facilities, would 
not be useful for any of these 
purposes.  The more rigorous 
UHC measure, requiring 
assessment with a numeric pain 
scale(mean 76%, range 13-100%) 
and the QOPI measure for pain 
assessment on the last oncology 
visit prior to death (mean 56%, 
range, 30-90%) show more 
variation and therefore more 
promise, but would need 
evaluation for responsiveness and 
association with outcomes.   The 
VHA measure for regular pain 
assessment in the ICU shows a 
low level of initial performance in 
1 institution (42%), 
responsiveness to an intervention 
(94%), and a relationship with 
improved outcomes (a decrease 
in pain scores >=3 from 41 to 
6%).60) "   
194 
William 
Lawrence, 
MD 
AHRQ TOO 55 
Chapter 4, 
second 
paragraph 
Agree with the issue of no measures in pediatric cancer.  It might be 
worthwhile echoing this in some of the gaps sections in the prior 
paragraphs. 
We have added this additional 
language. 
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195 
William 
Lawrence, 
MD 
AHRQ TOO 56 
Chapter 4, 
1st 
paragraph 
Also agreed on the issue of the measures not providing guidance.  My 
question for you is whether this is a downside of the measure.  Ideally, 
a quality measure is linked to a leverage point that clinicians, health 
systems, or someone else should be able to impact upon both to 
change the measure but ultimately to improve outcomes.  For me as a 
clinician, it would be much easier to implement change if I have 
parameters with which to act in accordance with the quality measure 
and presumably in accordance with quality care.  If the trigger is that I 
should take action 3 weeks prior to the person dying, it is somewhat 
hard to operationalize in my practice.  I agree that the ACOVE 
measures have a better conceptual basis here, although again it would 
be helpful to understand what defines a vulnerable elder (if a definition 
has been specified in the measure). 
We do agree that this is a 
downside of some of these 
measures. 
196 
William 
Lawrence, 
MD 
AHRQ TOO 56 
Chapter 4, 
3rd 
paragraph 
The lack of information on race, gender, etc, is not particularly 
surprising, but does anyone at all publish rates on their measures by 
these categories?  If so, it would be worth mentioning. 
We found no published 
differences in rates of these 
indicators by race / ethnicity or 
gender. 
197 
William 
Lawrence, 
MD 
AHRQ TOO 
25 
and 
on 
  
Minor editorial comment – could you reference the appropriate 
appendix containing the evidence tables at the intro of the sections, 
simply to note that there is more detailed info on the discussed 
measures.  That way, if people want a formal definition of numerator, 
denominator, or want to know how data are abstracted, they’ll know 
where to look. 
Corrected-We embedded a 
reference to the Evidence Tables 
which essentially present this in 
tabular form. 
198 
William 
Lawrence, 
MD 
AHRQ TOO 
Front 
Matte
r 
  
Don’t forget abstract, executive summary, etc.  Would also appreciate 
an acknowledgement of the Federal Partners – in addition to AHRQ, 
they include NCI, CMS, and CDC. 
We have acknowledged the 
Partners in the Introduction.  
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199 
William 
Lawrence, 
MD 
AHRQ TOO   Measures 
Also, general issue on the reports of measures – at times, you put in 
rates for the measures (e.g. second measure on page 25), which is an 
issue in testing (has someone actually put the measure out in the field 
and tested it enough to be able to get a rate?).  It might be reasonable 
to consistently comment on rates, or might want to put up front that if 
you don’t comment on rates, there aren’t any (or whatever the 
conditions are for your not including these data).  Also, should they 
appear in the evidence tables? 
We have clarified this in our 
Methods. This information was 
provided only when it was 
available. 
200 
William 
Lawrence, 
MD 
AHRQ TOO   Evidence Tables 
could you spell out Advanced Care Planning in the title?  To me, ACP 
is American College of Physicians Clarified  
201 
William 
Lawrence, 
MD 
AHRQ TOO   Organization 
I liked the organization of the measures/indicators by 
Assessment/Treatment/Follow-up – that seems a very intuitive 
approach to dividing the measures. 
Thank you. 
202 
William 
Lawrence, 
MD 
AHRQ TOO   
Defining 
difference 
between 
measures 
and 
indicators 
In the results section, you divide things into measures and indicators, 
but I haven’t found where you define the difference between the two.  
Could you make this clear in text?  Similarly, you have in your 
abstraction sheets a working definition of a quality measure, which I 
didn’t see in text in the intro – might be worth adding. 
We added a sentence referring 
readers back to the Methods 
sections for the definitions. 
203 
William 
Lawrence, 
MD 
AHRQ TOO   Evidence Tables 
Incidental note after comparing page 39 text to evidence tables – it 
would be helpful if you could have the order of measures in the 
evidence table match the order in text – much easier to find a measure 
in the appendix that way. 
We have now corrected this. 
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204 
William 
Lawrence, 
MD 
AHRQ TOO   Table 1 
Table 1.  I like this table.  Having just finished commenting on the draft 
of colorectal measures report recently, they found a lot of literature 
reports on one or two measures (e.g. percent of stage III colorectal 
cancer patients receiving adjuvant chemotherapy) in a report.  In 
yours, it appears that most or all of the measures/indicators are 
individual items from much broader measure sets.  Is this true?  Don’t 
necessarily need to comment on this in the report, but I found the 
difference quite interesting 
Yes, that is true. 
205 
William 
Lawrence, 
MD 
AHRQ TOO   Evidence Tables 
While it is out of chronologic order, would suggest for the evidence 
tables that you list denominator first, then numerator, since typically 
the numerator should be a subset of the denominator.  This will a) 
save you repeating the denominator in the numerator cell in the tables, 
and b) help make it easier to spot when the numerator isn’t a subset 
(happened at least once – I’ll find it in my notes), which should at least 
raise a red flag. 
Thank you, and we have reversed 
the order of the columns in the 
final tables. 
206 Castillo, DonnaRae AHRQ     Title 
The title is not descriptive enough.  Suggest a change to “Quality 
Measures for Supportive Cancer Care” or something very similar as 
you mention in your text. 
We changed the title to reflect the 
task order. 
207 Castillo, DonnaRae AHRQ     Title page 
It is unclear who the actual authors are.  I am assuming the two PIs 
and the two directors. This needs to be clear (for reference purposes).  Done 
208 Castillo, DonnaRae AHRQ     Contents 
This needs to be restructured.  List the chapters in order, then 
References, Figures, Tables, Appendixes. (The last are merely listed 
with their titles; no page numbers for Appendixes (note it is 
“Appendixes” not Appendices] as these are only online.)  Note also 
figures and tables are not listed within chapters. 
Done 
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209 Castillo, DonnaRae AHRQ     Contents 
We normally only use the first and, if necessary, second level of 
headings. Otherwise it becomes too unwieldy (see reworking of 
Chapter 3 contents, below). 
We have corrected our chapter 
and section headings. 
210 Castillo, DonnaRae AHRQ     Contents 
Remove the line “Areas of Study” from the Contents for Chapter 3.  It 
is not in text and is superfluous.  Here is Chapter 3 using 1st and 2nd 
level heads: 
Chapter 3: Results.................................................. 
     Overview........................................................... 
     Literature Flow.................................................. 
     Pain.................................................................... 
          Introduction................................................... 
          Measures and Indicators................................ 
          Potential Indicators and Measurement Gaps.. 
    Dyspnea................................................................ 
          Introduction.................................................... 
          Measures and Indicators................................. 
          Potential Indicators and Measurement Gaps.. 
    Depression............................................................ 
          Introduction.................................................... 
          Measures and Indicators................................. 
          Potential Indicators and Measurement Gaps.. 
    Advance Care Planning........................................   
          Introduction.................................................... 
          Measures and Indicators................................. 
          Potential Indicators and Measurement Gaps.. 
    Summary............................................................... 
You may want to only use the chapter title and 1st level since the 
sections are short.  
Done 
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211 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
Report proper begins on page 1 (arabic not roman). All chapters open 
on a right hand page 
This reviewer received a different 
version of the report directly from 
AHRQ. 
212 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
First level headings (next level down from the chapter title) are 
centered Corrected 
213 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
Appendixes, tables and figures are numbered in the order they are 
cited in the text. Corrected 
214 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
Please do not leave space between paragraphs.  The indention is 
enough to mark the beginning of new paragraph. The extra leading 
wastes space. 
Corrected 
215 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
Do not use bold to emphasize a word in text; italics is sufficient and it 
should only be used when defining a term e.g., “An indicator was 
defined as a descriptive statement...”).   Italics should not be used 
repeatedly.  For example, ACOVE or Dana Farber should not be 
emphasized whenever they are noted as the measure source and so 
forth.  
Corrected  
216 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
Titles of published books listed in running text should be in italics. (See 
for example p. xxxi, 1st full paragraph and p. xv, 2nd full paragraph.)  
This includes the title of your evidence report/summary in the run-on 
sentence at the bottom of p. xv; suggest you rewrite as:  The authors 
had recently conducted a systematic review, End-of-Life Care and 
Outcomes.21 The project’s database was searched for articles coded 
as “cancer”—regardless of type—by our topics of interest.)  
Corrected. 
217 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
First word of a bulleted item is capitalized. Generally, periods end each 
bulleted item (this is mainly a Web convention for compliance and 
readability). 
Corrected 
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218 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
If quotations are necessary they should be double, not single marks 
(e.g., “living wills” on p. vi). Often, however, these marks are not 
needed. 
Corrected 
219 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
As a courtesy to the reader, spell out any acronym when it is 
introduced in the report (e.g., SCEPC on p. viii, DNR and DNI on p. 
xv).  Do not, however, spell out acronyms in every chapter or in every 
section within chapters. 
Done 
220 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
The following are printed solid: followup (used as a noun or 
adjective), contraindicated, decisionmaking Corrected 
221 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
When used as a reflexive pronoun, self is hyphenated (e.g., self-
expression, self-reported, etc.) Done 
222 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
Health care is two words (e.g. “health care measurement” or “health 
care system”) unless used as an established title (e.g., “Agency for 
Healthcare Research and Quality”). 
Corrected 
223 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
There is no space on either side of the solidus mark; i.e., 
Summary/Conclusion and 5/95 are correct (not Summary / 
Conclusion or 5 / 95). 
Corrected 
224 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
Use the ™ and ®  symbols when required; for example, Google™  
CINAHL®  PsychINFO®  HEDIS®   Corrected 
225 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
If two or more numerals are used in conjunction and at least 1 of them 
is 10 or more, make them all numerals (as in this sentence). Thus we 
would not say “In nine of 10 trials...” 
Corrected 
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226 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
The word State is initial cap when referring to a U.S. State (this is U.S. 
govt. style). Done 
227 Castillo, DonnaRae AHRQ     
General 
Format and 
Style 
It is not necessary to name books or articles if you are providing 
reference citations (see p. xxxi for example; you already cite the 
reference #71.) 
Corrected 
228 Castillo, DonnaRae AHRQ     Chapter 1 
I suggest that either here (or alternatively at the beginning of the next 
chapter), you distinguish between measure and indicator as you are 
using them.  This is not totally clear. 
We discuss this in our Methods 
chapter. 
229 Castillo, DonnaRae AHRQ     Chapter 2 
On current p. viii where you list your two key questions, I suggest you 
either put the a/b/c of question 1 with the main part of the question or 
break out the two parts of question 2 after the word “including” as “a” 
and “b” in order to be consistent in format with question 1.  In other 
words, question 2 formatted like question 1 would read:2.  What gaps 
in knowledge about quality measurement are evident from the 
currently available literature, including: a. Absence of measures or b. 
Measures lacking evidence of their scientific soundness, whether for 
the population of cancer patients as a whole or for specific 
populations. 
These were the key questions 
assigned to us. 
230 Castillo, DonnaRae AHRQ     Chapter 1 
Table 1 is mentioned at top of current p. x as a list of organizations.  I 
am assuming this is the Table 1, now in Chapter 3, that lists the 
organizations and the measures they are supplying.  thus this table 
should be moved to Chapter 2.   Table 1 and Table 2 can be placed at 
the end of this chapter so as not to interfere with the running text.  If 
this current Table 1 is not the one you reference on p. x, that table 
needs to be supplied. 
We changed the order in which 
we describe them in the text. We 
decided to leave Table 2 in the 
Results section rather than 
Methods because it reflects 
findings of the review.  
G-53 
        
Item Name Institution Role 
Page Section Comment  Response 
231 Castillo, DonnaRae AHRQ     Chapter 2 
As noted above, appendixes are numbered in the order cited.  As cited 
in the text of Chapter 2, the order should be: 
A. Technical Expert Panel and Peer Reviewers  
B. TEP Worksheet  
C. Literature Search Strategies   (NOTE:  This is one appendix, 
Appendix C, not Appendixes C; the individual databases are not C-1, 
C-2 etc.). 
D. Contact Form 
E. Article Screener 
Corrected 
232 Castillo, DonnaRae AHRQ     Chapter 2 
At the top of p. xiv, to make more typographically consistent, I suggest 
you reformat as the end of the sentence just before the bulleted items 
as follows: 
The main search strategy included an extensive list of terms intended 
to identify research publications associated with all of the following: 
· Each of the domains of interest (pain, dyspnea, depression, advance 
care planning). 
· Quality assessment or improvement. 
· Quality measurement. 
Done 
233 Castillo, DonnaRae AHRQ     Chapter 2 
The hyperlinks on pp. xiv and xv should be removed. (okay to leave 
the underlining). Corrected 
234 Castillo, DonnaRae AHRQ     Chapter 3 
Headings should be consistent in wording and format.  For example, in 
the Pain section, one of the headings is “Potential Measures & 
Measurement Gaps”; in the Dyspnea section, the equivalent heading 
reads “Potential Measures / Measurement Gaps”; and in the Advance 
Care section it is just “Potential Measures.” They should all read 
Potential Measures and Measurement Gaps  
Corrected 
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235 Castillo, DonnaRae AHRQ     Chapter 3 
As noted above, if the reference to Table 1 is to the Table 1 mentioned 
in Chapter 2, it needs to be moved and the title should reflect the 
measure source; for example:  Table 1.  Sources and attributes of 
identified measures and indicators  
We corrected the names and titles 
of Table 1 and 2 as suggested. 
236 Castillo, DonnaRae AHRQ     Chapter 3 
Run-in headings should be bold, not italics or parenthesized, and 
followed by a period.  Do not make the beginning of the sentence bold.  
For example, in the Pain section, the first paragraph under “Measures 
and Indicators” in Chapter 3, p. xxviii, begins with the following 
heading and 1st sentence:(Measure - regular assessment of pain) 
Quality Assessment Tools (QA Tools), proposed in 200062  includes 
one measure relevant to pain assessment.This is awkward and not 
according to our required style. It should read:Measure: Regular 
assessment of pain. Quality Assessment Tools (QA Tools), proposed 
in 2000,62  includes one measure relevant to pain assessment.All the 
measure or indicator names would be set up the same way. 
Corrected 
237 Castillo, DonnaRae AHRQ     Chapter 3 
Move the name of the second UHC measure on p. xxviii to make it a 
heading, for typographical consistency.  For example: 
Measure: Routine inpatient pain assessment.   (for the first measure)   
Measure: Routine inpatient pain assessment with a numeric scale.  
(for the second measure) 
This would apply also on p. xliii to the second ACOVE measure under 
Treatment of Depression. 
Corrected 
238 Castillo, DonnaRae AHRQ     Chapter 3 
Under the “Treatment” section on p. xxx, the text mentions “3 
measures and 1 indicator”; however the text in that section (see pp. 
xxx and xxxi” presents 2 measures and 2 indicators.  This discrepancy 
must be reconciled; either the intro sentence or a run-in heading is 
wrong. 
Corrected 
G-55 
        
Item Name Institution Role 
Page Section Comment  Response 
239 Castillo, DonnaRae AHRQ     Chapter 3 
Under the “Followup” section of Advance Care Planning, the intro 
sentence mentions 14 measures in 10 categories and 7 indicators in 8 
categories.  The 10 general measure categories are easily seen; the 
indicators are not.  For those measures that also that include a similar 
indicator, we should modify the run-in heading to include the notation.  
For example the measure noted as “Measure: late life hospital use” 
includes a similar indicator.  Let’s change the heading to: 
Measure/Indicator: Late life hospital use. (or alternatively, but less 
preferable, Measure and indicator: Late life hospital use.) 
Corrected 
240 Castillo, DonnaRae AHRQ     Chapter 3 
In addition, I count 8, not 7, indicators listed within this section as 
follows (page nos. in parens): 
 1) late life hospital use (p. xlix) 
 2) late life ICU use (p. l) 
 3) late life rate of emergency care (also p. l) 
 4) new chemotherapy regimen in last 30 days of life (p. li) 
 5) chemotherapy in last 14 days of life (also p. li) 
 6) admission to hospice (p. lii) 
 7) site of death (p. liii) 
The above 7 are within the “measure” paragraphs; but there is also 
 8)  care consistency with documented care preferences (p liii) 
If this is correct, please change the intro paragraph to read 8 indicators 
in 8 categories.  
Corrected 
241 Castillo, DonnaRae AHRQ     Chapter 4 This should include Discussion as part of the chapter title. Corrected 
242 Castillo, DonnaRae AHRQ     References References is the correct title of this section Corrected 
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243 Castillo, DonnaRae AHRQ     
Excluded 
Studies 
Since this is one of the last reports under the “old” style guide, it is 
appropriate to list alphabetically the excluded studies (your current 
Appendix J as listed in the Contents could fill this need here.) 
The excluded studies will be a 
separate appendix. 
244 Castillo, DonnaRae AHRQ     Appendixes 
As noted these should be reordered and numbered in the order of their 
citation in text. As of now, this is the order of their call-out in the text: 
A. Technical Expert Panel and Peer Reviewers  
B. TEP Worksheet  
C. Literature Search Strategies   (NOTE:  This is one appendix, 
Appendix C, not Appendixes C; the individual databases are not C-1, 
C-2 etc.). 
D. Contact Form 
E. Article Screener 
F. Evidence Tables 
Corrected 
245 Castillo, DonnaRae AHRQ     Appendix A:  
Please make sure you have permission from the individuals to be 
listed to include their names in the report. Permissions granted. 
246 Castillo, DonnaRae AHRQ     Appendix B:  Title should be Appendix C: Literature Search Strategies.  Corrected 
247 Castillo, DonnaRae AHRQ     
Evidence 
Tables 
 Title should be Appendix F. Evidence Tables.  Table titles should be 
where the distinctions are made.  For example:  
Evidence Table F.1.  Quality Measures and Indicators for Supportive 
Cancer Care: Pain.   
Corrected 
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248 Castillo, DonnaRae AHRQ     
Other 
Appendixes 
· Perhaps I overlooked them but I could not find any text reference to 
several appendixes (G-L) currently listed in your Contents table.  
These appendixes are not here. 
· Is the “Cambridge Ballot” necessary? 
· I have already mentioned Appendix J above which can become the 
List of Excluded Studies. 
· What is the purpose of separating observational evidence tables 
currently noted as Appendix L from the others currently noted as 
Appendix E (which will become App F)? Can these be combined? Why 
are the “Observational Studies” necessary anyway if they are not 
discussed? 
· Appendix H should be one appendix, not two, entitled Appendix H: 
Methodological Issues in Measurement or, if you prefer, Appendix H: 
Reliabiliy,Validity, and Other Measurement Issues. Include the table 
within the appendix.   
· Delete Appendix K.  Including peer review comments is unnecessary. 
This is prepublication information.  They belong in your file, not with a 
published report. 
This reviewer received a different 
version of the report /appendixes 
from AHRQ. 
 
H-1 
Appendix H. Excluded Studies 
Rejected: Duplicate Data 
 
 1.  Appendix A: panel rating sheets by condition. Kerr, E. A.; Asch, S. M.; Hamilton, E. G., and McGlynn, E. A. 
Quality of care for cardiopulmonary conditions: a review of the literature and quality indicators.  
RAND; 2000; pp. 251-84. 
Rec #: 739 
 2.  Appendix B: crosswalk table to original and final indicators. Kerr, E. A.; Asch, S. M.; Hamilton, E. G., and 
McGlynn, E. A. Quality of care for cardiopulmonary conditions: a review of the literature and quality 
indicators .  RAND; 2000; pp. 285-327. 
Rec #: 740 
H-2 
Rejected: Non-Western Location 
 
 1.  Auchus, A. P. and Chen, C. P. Asia-Pacific Consensus Statement on dementia. Alzheimer Dis Assoc Disord. 
2001 Apr-2001 Jun 30; 15(2):63-5. 
Rec #: 635 
 2.  Howland SC. Managing the Alzheimer's patient. Emerg Med Serv. 2000 Sep; 29(9):89-92. 
Rec #: 32435 
 3.   Ministry of Health, Singapore.  Cancer pain.  2003 Mar(Clnical Practice Guildelines).  
Rec #: 207 
 4.  National Comprehensive Cancer Network (NCCN). Colon cancer. Clinical Practice Guidelines in Oncology. 
2005; (2). 
Rec #: 128 
 5.  Palliative Care and Critical Care Committees. Removal of mechanical ventilation in the dying patient. 
Guidelines for Physician Staff Froedtert Hospital, Milwaukee, Wisconsin :1-4. 
Rec #: 136 
 6.  Tomita T and Kitamura T. Clinical and research measures of grief: a reconsideration. Compr Psychiatry. 2002 
Mar-2002 Apr 30; 43(2):95-102. 
Rec #: 15879 
H-3 
Rejected: No Domain of Interest 
 
 1.  American Academy of Hospice and Palliative Medicine (AAHPM). Position statements: comprehensive end-
of-life care and physician-assisted suicide [Web Page]. 1997 Jun 25; Accessed 2005 Jan 24.  
Rec #: 483 
 2.  American Academy of Hospice and Palliative Medicine (AAHPM). Position statements: statement on the 
ethics of palliative care research [Web Page]. 2002 Jan 30; Accessed 2005 Jan 24.  
Rec #: 482 
 3.  American Academy of Hospice and Palliative Medicine (AAHPM). Position statements: statement on the use 
of nutrition and hydration [Web Page]. 2001 Nov 16; Accessed 2005 Jan 24.  
Rec #: 481 
 4.  American Academy of Hospice and Palliative Medicine (AAHPM). Positions statements: statement on 
sedation at the end-of-life [Web Page]. 2002 Sep 13; Accessed 2005 Jan 24.  
Rec #: 480 
 5.  American Board of Family Practice. Carcinoma of the breast. Reference Guide. 2001. 
Rec #: 465 
 6.  Bast, R. C. Jr; Ravdin, P.; Hayes, D. F.; Bates, S.; Fritsche, H. Jr; Jessup, J. M.; Kemeny, N.; Locker, G. Y.; 
Mennel, R. G., and Somerfield, M. R. 2000 update of recommendations for the use of tumor markers 
in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical 
Oncology. J Clin Oncol. 2001 Mar 15; 19(6):1865-78. 
Rec #: 174 
 7.  Benson, A. B. 3rd; Schrag, D.; Somerfield, M. R.; Cohen, A. M.; Figueredo, A. T.; Flynn, P. J.; 
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